<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName ACSJournal-v102.dtd?><?SourceDTD.Version 1.02?><?ConverterInfo.XSLTName acs2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">ACS Nano</journal-id><journal-id journal-id-type="iso-abbrev">ACS Nano</journal-id><journal-id journal-id-type="publisher-id">nn</journal-id><journal-id journal-id-type="coden">ancac3</journal-id><journal-title-group><journal-title>ACS Nano</journal-title></journal-title-group><issn pub-type="ppub">1936-0851</issn><issn pub-type="epub">1936-086X</issn><publisher><publisher-name>American Chemical Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7376974</article-id><article-id pub-id-type="doi">10.1021/acsnano.0c04117</article-id><article-categories><subj-group><subject>Review</subject></subj-group></article-categories><title-group><article-title>Hard Nanomaterials in Time of Viral Pandemics</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="ath1"><name><surname>Reina</surname><given-names>Giacomo</given-names></name><xref rid="cor2" ref-type="other">*</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Peng</surname><given-names>Shiyuan</given-names></name></contrib><contrib contrib-type="author" id="ath3"><name><surname>Jacquemin</surname><given-names>Lucas</given-names></name></contrib><contrib contrib-type="author" id="ath4"><name><surname>Andrade</surname><given-names>Andr&#x000e9;s Felipe</given-names></name></contrib><contrib contrib-type="author" corresp="yes" id="ath5"><name><surname>Bianco</surname><given-names>Alberto</given-names></name><xref rid="cor1" ref-type="other">*</xref></contrib><aff id="aff1">CNRS, Immunology, Immunopathology and Therapeutic Chemistry, UPR 3572,
<institution>University of Strasbourg ISIS</institution>, 67000 Strasbourg,
<country>France</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email:
<email>a.bianco@ibmc-cnrs.unistra.fr</email>.</corresp><corresp id="cor2"><label>*</label>Email:<email>g.reina@ibmc-cnrs.unistra.fr</email>.</corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>07</month><year>2020</year></pub-date><elocation-id>acsnano.0c04117</elocation-id><history><date date-type="received"><day>17</day><month>05</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 American Chemical Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license license-type="open-access"><license-p>This article is made available via the PMC Open Access Subset for unrestricted RESEARCH
re-use and analyses in any form or by any means with acknowledgement of the original
source. These permissions are granted for the duration of the World Health Organization
(WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0019" id="ab-d31e132"/></p><p>The SARS-Cov-2 pandemic has spread worldwide during 2020, setting up an uncertain start
of this decade. The measures to contain infection taken by many governments have been
extremely severe by imposing home lockdown and industrial production shutdown, making
this the biggest crisis since the second world war. Additionally, the continuous
colonization of wild natural lands may touch unknown virus reservoirs, causing the
spread of epidemics. Apart from SARS-Cov-2, the recent history has seen the spread of
several viral pandemics such as H2N2 and H3N3 flu, HIV, and SARS, while MERS and Ebola
viruses are considered still in a prepandemic phase. Hard nanomaterials (HNMs) have been
recently used as antimicrobial agents, potentially being next-generation drugs to fight
viral infections. HNMs can block infection at early (disinfection, entrance inhibition)
and middle (inside the host cells) stages and are also able to mitigate the immune
response. This review is focused on the application of HNMs as antiviral agents. In
particular, mechanisms of actions, biological outputs, and limitations for each HNM will
be systematically presented and analyzed from a material chemistry point-of-view. The
antiviral activity will be discussed in the context of the different pandemic viruses.
We acknowledge that HNM antiviral research is still at its early stage, however, we
believe that this field will rapidly blossom in the next period.</p></abstract><kwd-group><kwd>nanoparticles</kwd><kwd>biomaterials</kwd><kwd>antiviral</kwd><kwd>immune system</kwd><kwd>vaccine</kwd><kwd>virucidal</kwd><kwd>surface chemistry</kwd><kwd>phototherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>nn0c04117</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>nn0c04117</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><p id="sec1">The current emergence caused by SARS-Cov-2 is dramatically changing the everyday life of
all of us. Due to the high globalization, new viruses can spread all over the world much
faster than ever, infecting the communities worldwide. The current technologies and
measurements are able to sensibly slow down the infection spread. However, their cost is
tremendously high, impacting the healthcare systems and causing the shutdown of industries
and the lockdown of the population. The impact of SARS-Cov-2 on the worldwide economy is
estimated to be a 2&#x02013;3% decline, making this the biggest crisis since the world
wars.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> A possible vaccine is hopefully expected to come in 1&#x02013;2
years, originating a buffer period pretty much uncertain for many people. Vaccination is the
only way known to accelerate the flock immunity without causing further death by this
pandemic. Contemporary history has seen the spread of other viral pandemics such as H2N2 flu
(1956&#x02013;1958), H3N3 flu (1968), HIV (peak reached between 2005 and 2012), SARS (2009),
while MERS (2012 to now) and Ebola (1975 to now) viruses are in a prepandemic phase. The
continuous colonization of wild nature lands may touch unknown virus reservoirs causing the
spread of contagious epidemics. Due to these facts, there is a clear urgency in the
development of viral treatments to avoid the risk of new pandemics.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> In
particular, the possibility to have smart antiviral tools able to efficiently disinfect
surfaces, block the viral spreading, enhance the survival of infected people, and boost
immunization are highly desirable. In particular, more investments in the next years are
expected in the antiviral research.</p><p>Hard nanomaterials (HNMs) have been extensively studied for many types of applications
including drug delivery, bioimaging, and biosensing.<sup><xref ref-type="bibr" rid="ref3">3</xref>&#x02212;<xref ref-type="bibr" rid="ref5">5</xref></sup> The use of nanomaterials in biomedical research is highly developed,
reaching in some cases clinical approval.<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> Despite that, nanomaterials
have been mainly developed for cancer therapy, while scarce attention has been spent on
their application in viral infections.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> The continuous virology research
has more and more increased into viral replication machinery, allowing the preparation and
rationalization of more sophisticated vaccine formulations and viral inhibitors. The use of
HNMs may be one of the keys to provide more effective biomedical agents with a wide spectrum
of activity in viral pandemics.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup></p><p>An increasing number of reports describe how HNMs can be successfully applied to block
viral spread. HNMs can be used at different stages of viral infection: blocking viral entry,
hampering interaction with infected host cells, and modulating immune responses. Due to
their core composition (<italic>e</italic>.<italic>g</italic>., metal oxides, noble metals),
HNMs can have an important antiviral activity inactivating some specific proteins of the
capsid or dysregulating radical homeostasis in the virus particles. Additionally, surface
functionalization can sensibly increase HNM antiviral activity, enabling the mimicking of
host cells or enhancing the targeting efficiency.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p><p>In this review, we will critically analyze different strategies for the application of HNMs
as antiviral agents. The rational and the synthetic strategies will be highlighted and
correlated to different relevant examples. Particular attention will be paid on the
mechanisms of antiviral action and on HNM applicability and efficacy. For the sake of
clarity, this review is divided into three parts, namely: blocking viral entry, antiviral
activity in host cells, and stimulation of immune system. We have focused on the different
stages of infection. In the section dedicated to blocking viral entry, the application of
HNMs for surface disinfection and inactivation of the virus prior to interaction with host
cells will be described. Subsequently, the interaction of HNMs after internalization into
host cells will be addressed, stressing their antiviral delivery features and their activity
in viral replication blockage, leading to host cell survival. Then, activation of immune
response induced by HNMs, triggering the innate and the adaptive
(<italic>e</italic>.<italic>g</italic>., nanovaccines) immunity, will be presented. The
different adopted strategies will be correlated to the nanomaterial core
(<italic>e.g.,</italic> composition, size, shape) and surface (<italic>e.g.,</italic>
chemistry, surface charge) properties. Finally, limits (<italic>e.g.,</italic> unknown
long-term toxicity), advantages (<italic>e.g.,</italic> high and wide spectrum virucidal
activity), and perspectives will be discussed with particular attention to the applications
in viral pandemics (<italic>e</italic>.<italic>g</italic>., HIV, SARS, and influenza
viruses). This review is addressed to material and biomaterials scientists who are
interested in antiviral research. We acknowledge that application of HNMs as antiviral
agents is still in the early stages; however, we believe that the research on this topic is
going to grow soon. Thus, with this contribution we genuinely hope to inspire researchers in
the preparation of smart and efficient HNM antiviral agents.</p><sec id="sec2"><title>Blocking Viral Entry</title><p>The last decades have been characterized by increasing investigation on viruses. In
particular, their surface charge, protein composition, and host cell entry mechanism have
been elucidated, allowing to formulate the first-generation wide spectrum antivirals.
Blocking the viral entry is one of the most common known antimicrobial procedure to stop
infections at the early stage. In this context, antiviral materials have been used for
surface disinfection or for epidemic limitation in humans and animals. Due to their high
surface to volume ratio, composition, and tunable surface chemistry, HNMs are now more and
more studied as powerful agents in blocking viral entry. As for other biological
interactions, the attachment and entry of viruses into host cells are mediated by
multivalent interactions between the surface of the virus and cell surface receptors.<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> Nanomaterials can display multivalency that makes them able to compete with
the host cells on virus attachment, limiting their infectivity. The mechanism of antiviral
actions relies on the inactivation of the capsid proteins. As a matter of fact, HNMs have
been used for: (1) blocking target proteins for viral entry, (2) capsid protein oxidation,
(3) mimicking cell surface, and (4) mechanical rupture of viruses (<xref rid="fig1" ref-type="fig">Figure
<xref rid="fig1" ref-type="fig">1</xref></xref>). These strategies target proteins and mechanisms of entry
common in most of the viruses, thus allowing the preparation of wide spectrum antiviral
agents. In this section, the application of different HNMs as powerful inhibitors of viral
entry will be discussed.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Illustration of the main mechanisms of blocking virus entry into host cells: capsid
denaturation, mimicking cell surface, and mechanical breaking of the virus.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0001" id="gr1" position="float"/></fig><sec id="sec2.1"><title>Noble Nanoparticles</title><p>Noble nanoparticles (NPs), made of gold and silver, are attractive as antiviral agents
for their surface functionalization versatility and their capacity to cleave disulfide
bonds. Their use in disinfection has been extensively studied for different types of
viruses. The morphology and the size of the NPs play a crucial role in their ability to
efficiently interact with the capsids and in their toxicity for the organism. These
nanomaterials are characterized by a very large specific surface area (inversely
proportional to the particle diameter). As the particle size becomes smaller and smaller,
the percentage of surface atoms increases, creating many unsaturated bonds due to lack of
neighboring atoms. As a consequence, AgNPs and AuNPs have unstable atoms with high surface
energy. This kind of structure provides a lot of contact adsorption sites and reaction
points for further modifications. These chemical features allow to easily combine surface
NP atoms with other atoms through chemical bonds.</p><p>Besides the composition of the metal core, several studies have pointed out the
importance of the control of the surface chemistry. The surface groups can: (1) stabilize
NPs in the biological media, (2) insert targeting agents, and (3) enhance the circulation
time inside the body. Antiviral efficiency can be also enhanced by the multivalency
effect, where highly branched ligands are used to locally augment the local concentration
of the targeting molecules. In this section the main strategies and results for silver
(AgNPs) and gold (AuNPs) nanoparticles in blocking viral entry will be critically
discussed.</p></sec><sec id="sec2.2"><title>Silver Nanoparticles</title><p>Many studies have shown that naked AgNPs have a good effect on the control and prevention
of a variety of viral diseases (<xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>).
However, the antiviral mechanism of nanosilver is still unclear. The antiviral action is
associated with the following mechanisms: Nanosilver can prevent the virus from entering
the host cells and inhibit the virus from binding to the cell receptor, thereby stopping
the virus from infecting the targeted cells. AgNPs may be able to bind the viral surface
protein and inhibit the interaction between the virus and the cell membrane receptors
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, left). However, it has been also
reported that AgNPs can inactivate the virus through denaturation of surface proteins
containing cysteine and methionine residues present on the viral capsid, in a similar way
reported for bacteria. For example, AgNPs smaller than 10 nm were shown to interact with
the sulfur-bearing residues of gp120 glycoprotein knobs distributed on the lipid membrane
of HIV-1 virus, preventing the virus from binding to CD4 receptor site on the host cells,
thus inhibiting the viral infection.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> By means of a viral adsorption
assay, it was shown that the AgNP mechanism of anti-HIV action is based on the inhibition
of the initial stages of the HIV-1 cycle. To demonstrate that the antiviral effect of
AgNPs is due to the particle structure rather than to silver ions present in solution, the
antiviral activity of silver sulfadiazine (AgSD) and silver nitrate (known antibacterial
silver salts) was evaluated. Both salts showed a much lower therapeutic index than AgNPs
<italic>in vitro</italic>, indicating that silver ions themselves are less
efficient.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> These results point out that the antiviral efficacy is
not only related to the dose of Ag<sup>+</sup> ions present in solution but is also
regulated by different other parameters (<italic>e.g.,</italic> size, charge, and surface
functionalization) associated with the nanosize dimension. For instance, in the case of
Herpesviridae and Paramyxoviridae viruses (both enveloped viruses with embedded
viral-encoded glycoproteins), AgNPs can effectively reduce their infectivity, by blocking
the interaction between the viral particles and the host cells with an antiviral activity
strictly dependent on the size and &#x003b6; potential of the AgNPs. As a general
observation, it was reported that smaller nanoparticles have better antiviral effect. This
effect was associated with the increase of the surface area, where smaller-sized AgNPs
could bind more efficiently to the viral particles exerting a higher antiviral
activity.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> Another study reported the impairment of Peste des petits
ruminants virus (PPRV) replication after incubating infectious viral particles with AgNPs,
which did not exhibit any virucidal effect even up to 900 &#x003bc;g/mL. This result
suggested that the anti-PPRV activity of the AgNPs is due to the inhibitory effect on
viral replication in the target cells. AgNPs do not prevent the binding of PPRV to host
cells, but inhibit the entry of viruses into these cells. AgNPs can also interact with the
surface and core of PPRV, but this interaction cannot kill the virus directly.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The same results were then confirmed on other viruses. AgNPs with a
diameter of 25 nm inhibited Vaccinia virus replication by preventing viral entry into host
cells. However, AgNPs cannot prevent the virus from adsorbing onto the cells, and this
virus is still infectious, indicating that AgNPs lack a direct virus-killing
effect.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup></p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Potential antiviral mechanism of AgNPs. (1) AgNPs interact with viral envelope and/or
viral surface proteins; (2) AgNPs interact with cell membranes and block viral
penetration; (3) AgNPs block cellular pathways of viral entry; (4) AgNPs interact with
viral genome; (5) AgNPs interact with viral factors necessary for viral replication;
and (6) AgNPs interact with cellular factors necessary for productive viral
replication. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref14">14</xref>). Copyright 2016 Taylor and Francis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0002" id="gr2" position="float"/></fig><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Antiviral AgNPs and Their Possible Mechanisms of Action</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="center" char="."/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">virus</th><th style="border:none;" align="center">shape</th><th style="border:none;" align="center" char=".">size (nm)</th><th style="border:none;" align="center" char=".">active concentration</th><th style="border:none;" align="center">mechanism of action</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left">HIV-1</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">1&#x02013;10</td><td style="border:none;" align="center" char=".">25&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">interaction with gp120</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref11">11</xref>)</td></tr><tr><td style="border:none;" align="left">HIV-1&#x000a0;III<sub>B</sub></td><td style="border:none;" align="left">&#x02013;</td><td style="border:none;" align="char" char=".">30&#x02013;50</td><td style="border:none;" align="center" char=".">440&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">interaction with gp120</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref19">19</xref>)</td></tr><tr><td style="border:none;" align="left">HSV-1,&#x000a0;HSV-2,&#x000a0;and&#x000a0;HPIV-3</td><td style="border:none;" align="left">&#x02013;</td><td style="border:none;" align="char" char=".">20&#x02013;50</td><td style="border:none;" align="center" char=".">not available</td><td style="border:none;" align="left">possible interaction directly with the viral envelope or its
protein</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref20">20</xref>)</td></tr><tr><td style="border:none;" align="left">Adenovirus&#x000a0;type&#x000a0;3</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">5&#x02013;18</td><td style="border:none;" align="center" char=".">25&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">direct destruction of virus particles and DNA structure</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref15">15</xref>)</td></tr><tr><td style="border:none;" align="left">H1N1&#x000a0;influenza&#x000a0;A&#x000a0;virus</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">5&#x02013;20</td><td style="border:none;" align="center" char=".">12.5&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">inhibition&#x000a0;of&#x000a0;respiratory&#x000a0;enzymes&#x000a0;and&#x000a0;electron&#x000a0;transport&#x000a0;components&#x000a0;and&#x000a0;interference&#x000a0;with&#x000a0;DNA&#x000a0;function</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref21">21</xref>)</td></tr><tr><td style="border:none;" align="left">HBV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">10&#x02013;50</td><td style="border:none;" align="center" char=".">5&#x000a0;&#x003bc;M</td><td style="border:none;" align="left">interaction with double-stranded DNA and/or binding with viral
particles</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref16">16</xref>)</td></tr><tr><td style="border:none;" align="left">PPRV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">5&#x02013;30</td><td style="border:none;" align="center" char=".">11.1&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">interaction with virus surface and core</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref12">12</xref>)</td></tr><tr><td style="border:none;" align="left">Vaccinia&#x000a0;virus</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="center" char=".">not available</td><td style="border:none;" align="left">preventing viral entry into host cells</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref13">13</xref>)</td></tr><tr><td style="border:none;" align="left">Monkey&#x000a0;pox&#x000a0;virus&#x000a0;(MPV)</td><td style="border:none;" align="left">&#x02013;</td><td style="border:none;" align="char" char=".">10&#x02013;80</td><td style="border:none;" align="center" char=".">12.5&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">blocking virus-host cell binding and penetration</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref22">22</xref>)</td></tr><tr><td style="border:none;" align="left">Tacaribe&#x000a0;virus&#x000a0;(TCRV)</td><td style="border:none;" align="left">&#x02013;</td><td style="border:none;" align="char" char=".">5&#x02013;10</td><td style="border:none;" align="center" char=".">25&#x000a0;&#x003bc;g/mL</td><td style="border:none;" align="left">inactivation of virus particles before entry</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref23">23</xref>)</td></tr><tr><td style="border:none;" align="left">Poliovirus</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">4&#x02013;9</td><td style="border:none;" align="center" char=".">3.1&#x000a0;ppm</td><td style="border:none;" align="left">preventing viral particles from binding to the receptors of RD
cells</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref24">24</xref>)</td></tr><tr><td rowspan="3" style="border:none;" align="left">TGEV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">&#x0003c;20</td><td rowspan="3" style="border:none;" align="center" char=".">12.5&#x000a0;&#x003bc;g/mL</td><td rowspan="3" style="border:none;" align="left">direct interaction with TGEV surface protein, such as TGEV S
glycoprotein</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref18">18</xref>)</td></tr><tr><td style="border:none;" align="left">linear</td><td style="border:none;" align="char" char=".">60000&#x02013;80000</td></tr><tr><td style="border:none;" align="left">linear</td><td style="border:none;" align="char" char=".">20000&#x02013;30000</td></tr></tbody></table></table-wrap><p>Alternatively, nanosilver can be combined with viral nucleic acids to change the capsid
structure, affect the replication of viral genetic material, and make the virus inactive.
For example, TEM analyses have shown that NPs can cause a change of the structure of the
Ad3 virus from a hexahedral shape to an irregular shape, destroying its fibers and capsid
proteins, leading to inhibition of the virus from binding to the host cells and destroying
the DNA structure, preventing adenoviral infection.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Nanosilver can
also bind directly to the double-stranded DNA of hepatitis B virus to inhibit its
replication.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup></p><p>In other studies, it has been demonstrated that silver ions released from nanosilver can
directly damage the viruses. Based in this property, an interesting application has been
proposed. AgNPs were used as a coating on polyurethane condoms, effectively inhibiting the
activity of HIV and herpes simplex virus (HSV). The hypothesized mechanism is that silver
ions are transferred directly from oxidized NPs to biological targets, such as viral
membrane proteins gp120 and gp41. In addition, a small amount of silver ion is also
released from the coated contraceptives to improve the antiviral level.<sup><xref ref-type="bibr" rid="ref17">17</xref></sup></p><p>Although the studies on naked AgNPs to reduce viral infectivity have shown their
potential as broad-spectrum antiviral agents, the understanding of the specific antiviral
action mechanism still needs to be elucidated in depth. Many studies have shown that the
antiviral performance of naked AgNPs is related to their size, and smaller nanoparticles
have better antiviral activities.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> In addition to particle size, the
antiviral action of AgNP morphology has also attracted interest to fight against
coronavirus. AgNPs and two types of silver nanowires were able to significantly cause an
inhibitory effect on coronavirus transmissible gastroenteritis (TGEV)-induced host cell
infection and TGEV replication. The mechanism is likely based on a direct interaction of
AgNPs with TGEV surface proteins (<italic>e</italic>.<italic>g</italic>., TGEV
glycoproteins) to inhibit the beginning of viral infection. It is possible that AgNPs and
Ag nanowires alter the structure of some surface proteins of TGEV and then inhibit their
recognition and adhesion to the cellular receptor pAPN.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></p><p>Although the potential of AgNPs as antiviral agents has been commonly recognized,
unfortunately, their wide biological applications are limited by the risks of
self-aggregation and environmental pollution. Silver ions can be released from the surface
of AgNPs and potentially pollute the environment, and their agglomeration into bulkier
particles or fibers may change their biological characteristics, diminishing the antiviral
effect. In several cases, it has been reported that naked AgNPs may affect human
health.<sup><xref ref-type="bibr" rid="ref25">25</xref></sup> Therefore, research and development of AgNPs whose surface
is modified or stabilized by protecting molecular layers is an urgent need to overcome
these problems (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).
Poly(<italic>N</italic>-vinyl-2-pyrrolidone) (PVP) is the most commonly used stabilizer of
AgNPs. The PVP-coated AgNPs are able to inhibit the activities of HIV-1, herpes simplex 2
virus (HSV-2), and respiratory syncytial virus (RSV).<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref26">26</xref>,<xref ref-type="bibr" rid="ref27">27</xref></sup> But compared to foamy
carbon, small-sized PVP and BSA-coated AgNPs showed poor antiviral activity to the HIV-1
virus.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> For RSV, PVP-coated AgNPs have a specific binding capacity
to the viral surface, evidencing a regular spatial arrangement and a clear interaction
with G-protein.<sup><xref ref-type="bibr" rid="ref26">26</xref></sup> In addition, to improve the stability of AgNPs, their
surface modification with antiviral drugs was proved to reduce the drug resistance caused
by the drugs administered alone. Tannic acid-modified AgNPs showed good antiviral effects
on HSV-2 infection <italic>in vitro</italic> and <italic>in vivo</italic>. The viral
infection was inhibited only when these NPs directly interacted with HSV-2 virions.
Indeed, the pretreatment of host cells with such AgNPs did inhibit the entry of HSV-2. Due
to the high affinity of tannins to proteins and sugars, tannic acid can bind glycoproteins
on the surface of viruses to make them inert, impairing glycoprotein function and
preventing viruses from attaching and entering host cells.<sup><xref ref-type="bibr" rid="ref28">28</xref></sup></p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Surface-Modified Antiviral AgNPs and Possible Mechanisms of Action</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">virus</th><th style="border:none;" align="center">shape</th><th style="border:none;" align="center" char=".">size (nm)</th><th style="border:none;" align="center">coating</th><th style="border:none;" align="center">mechanism of action</th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left">HIV-1</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">1&#x02013;10</td><td style="border:none;" align="left">foamy carbon, PVP and BSA</td><td style="border:none;" align="left">interaction with gp120</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref11">11</xref>)</td></tr><tr><td style="border:none;" align="left">RSV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">&#x02013;</td><td style="border:none;" align="left">PVP, BSA, and recombinant F protein (RF 412)</td><td style="border:none;" align="left">interaction with the G-protein on the virus surface</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref26">26</xref>)</td></tr><tr><td rowspan="4" style="border:none;" align="left">H1N1 influenza virus</td><td rowspan="4" style="border:none;" align="left">spherical</td><td rowspan="4" style="border:none;" align="char" char=".">2&#x02013;5</td><td style="border:none;" align="left">Oseltamivir</td><td rowspan="3" style="border:none;" align="left">inhibition of the activity of neuraminidase and
hemagglutinin</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref34">34</xref>)</td></tr><tr><td style="border:none;" align="left">Amantadine</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref35">35</xref>)</td></tr><tr><td style="border:none;" align="left">Zanamivir</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref36">36</xref>)</td></tr><tr><td style="border:none;" align="left">inhibition of accumulation of reactive oxygen species (ROS)</td><td style="border:none;" align="left">&#x000a0;</td><td style="border:none;" align="left">&#x000a0;</td></tr><tr><td style="border:none;" align="left">HAV, NoV and CoxB<sub>4</sub></td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">&#x02013;</td><td style="border:none;" align="left">polyphosphonium-oligochitosans</td><td style="border:none;" align="left">preventing viral attachment and penetration</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref29">29</xref>)</td></tr><tr><td style="border:none;" align="left">MPV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">10&#x02013;80</td><td style="border:none;" align="left">polysaccharide</td><td style="border:none;" align="left">blocking virus-host cell binding and penetration</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref22">22</xref>)</td></tr><tr><td style="border:none;" align="left">TCRV</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">10</td><td style="border:none;" align="left">polysaccharide</td><td style="border:none;" align="left">inactivation of virus particles prior to entry</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref23">23</xref>)</td></tr><tr><td style="border:none;" align="left">HSV-1</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">4</td><td style="border:none;" align="left">mercaptoethanesulfonate</td><td style="border:none;" align="left">competition for the binding of the virus to the cell</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref30">30</xref>)</td></tr><tr><td style="border:none;" align="left">Enterovirus 71 (EV71)</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">2&#x02013;5</td><td style="border:none;" align="left">PEI and antiviral siRNA</td><td style="border:none;" align="left">inhibition of the accumulation of ROS and activation of AKT and p53</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref37">37</xref>)</td></tr><tr><td style="border:none;" align="left">HSV-2</td><td style="border:none;" align="left">spherical</td><td style="border:none;" align="char" char=".">13, 33, 46</td><td style="border:none;" align="left">tannic acid</td><td style="border:none;" align="left">direct interaction and blocking of virus attachment, penetration and
spread</td><td style="border:none;" align="left">(<xref ref-type="bibr" rid="ref28">28</xref>)</td></tr></tbody></table></table-wrap><p>The surface modification can also exert a synergistic antiviral effect. AgNPs decorated
with polyphosphonium-oligochitosan (PQPOC) exhibited moderate to excellent antiviral
activity against HAV, NoV, and CoxB<sub>4</sub>. In addition, AgNPs could interact with
the virion glycoproteins and prevent viral attachment and penetration. PQPOC can also
serve as an effective virus inhibitor by blocking the interaction of the targeted virus
with the host through the electrostatic interaction between the cationic polymers and the
negatively charged binding sites of the virus.<sup><xref ref-type="bibr" rid="ref29">29</xref></sup></p><p>Surface-modified AgNPs can also prevent viral infection by competitive adsorption on host
cells. The process of infection of cells by herpes simplex virus type 1 (HSV-1) involves
the interaction between viral envelope glycoproteins and heparan sulfate (HS) on cell
surface. Therefore, researchers designed AgNPs capped with mercaptoethanesulfonate
(Ag-MES) to compete with the cellular HS through the sulfonate end groups, thereby
blocking the virus from entering the cells.<sup><xref ref-type="bibr" rid="ref30">30</xref></sup></p><p>A few years ago, it was shown that curcumin could prevent the replication and the budding
of RSV,<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> but the disadvantage of poor solubility and low
bioavailability limited its clinical application.<sup><xref ref-type="bibr" rid="ref32">32</xref></sup> Curcumin was used
as a reducing and capping agent to prepare stable curcumin AgNPs (cAgNPs) under
physiological conditions. cAgNPs could reduce cytopathic effects induced by RSV and showed
efficient antiviral activity against infection by directly inactivating the virus prior to
entry into the host cells. Its antiviral effect was higher than curcumin alone or
unmodified AgNPs (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).<sup><xref ref-type="bibr" rid="ref33">33</xref></sup></p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Schematic representation of the synthesis of cAgNPs (A) and a proposed inhibition
mode of cAgNPs against RSV infection (B). The inhibition mode of (B) shows that cAgNPs
can reduce the binding ability of virus with the binding centers on the surface of
cells (b) as compared to those without cAgNPs (a). Reproduced with permission from ref
(<xref ref-type="bibr" rid="ref33">33</xref>). Copyright 2016 Royal Chemistry
Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0003" id="gr3" position="float"/></fig><p>Alternatively, Zhu <italic>et al</italic>. prepared AgNPs surface-modified with
oseltamivir, amantadine, and zanamivir (Ag@OTV,<sup><xref ref-type="bibr" rid="ref34">34</xref></sup> Ag@AM,<sup><xref ref-type="bibr" rid="ref35">35</xref></sup> and Ag@ZNV<sup><xref ref-type="bibr" rid="ref36">36</xref></sup>), by chemical methods. The results showed
that these nanoparticles can directly interact with the virions, resulting in viral
function damages.</p><p>Overall different studies have reported the capacity of AgNPs to block viral entry.
However, there is not a concerted antiviral mechanism, but their activity differs from
case to case, based on viral particle adsorption, capsid structure alteration, or surface
protein denaturation. For AgNPs, the antiviral activity can be associated with different
parameters including size, shape, surface charge, and functionalization but also to the
topical release of silver ions able to disturb the viral cycle replication. As described
before, bare AgNPs can be used as disinfectant agents, however their use in biological
media is limited by their low colloidal stability and potential cytotoxicity. Surface
functionalization can alleviate cytotoxicity, but it can also mask the nanoparticle
surface, reducing their affinity for viral particles, thus reducing AgNP antiviral
activity. For these reasons, AgNPs at the moment could find application mainly for surface
disinfection and for topical administration. Further studies are needed to prepare safer
AgNP formulations for systemic administration. In particular, the clarification of the
antiviral mechanisms and the use of surface functional groups able to stabilize AgNPs in
biological fluids without affecting their prominent antiviral activity are probably the
most important challenges to tackle.</p></sec><sec id="sec2.3"><title>Gold Nanoparticles</title><p>Compared to AgNPs, AuNPs exhibit reduced toxicity on healthy cells, making them more
attractive for <italic>in vivo</italic> and clinical applications.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup>
Indeed, AuNPs have been successfully tested as inhibitors of viral entry into the host
cells. AuNPs interact with hemagglutinin (HA), where Au is able to oxidize the disulfide
bond of this glycoprotein causing its inactivation, thus impeding the membrane fusion of
the virus with host cells. Targeting HA has emerged as an alternative strategy to the
actual therapies (<italic>e</italic>.<italic>g</italic>., matrix protein 2 and
neuramidase), especially to pandemic viruses that show an accelerated mutation speed of
their surface proteins, hence a resistance to conventional treatments increasing their
infectivity and mortality.<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> This strategy has been applied to
influenza (<italic>e</italic>.<italic>g</italic>., H1N1, HCV) and herpes
viruses.<sup><xref ref-type="bibr" rid="ref39">39</xref>&#x02212;<xref ref-type="bibr" rid="ref44">44</xref></sup> The activity of AuNPs is proportional to the
surface area exposed. As a consequence, the size and the morphology of these metal NPs
play a substantial role in their antiviral activity. Recently, Kim <italic>et al</italic>.
have reported that porous AuNPs are able to inhibit influenza A infection more efficiently
than nonporous AuNPs.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> This effect has been associated with the higher
surface area of the porous material that favors their interaction with capsids and thus
increases their antiviral activity (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>).</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Schematic illustration of inactivation of influenza A virus (IAV) treated with porous
AuNP (PoGNP). PoGNP interacts with IAV surface proteins and cleaves their disulfide
bonds. Inactivated viruses exhibit lower infectivity to cells. Reproduced with
permission under a Creative Commons CC-BY license from ref (<xref ref-type="bibr" rid="ref39">39</xref>). Copyright 2020 BioMed Central Ltd., Springer
Nature.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0004" id="gr4" position="float"/></fig><p>Besides the <italic>per se</italic> antiviral activity, AuNP surface modifications have
been developed in order to enhance their overall therapeutic benefits. The engineering of
tailored AuNPs with selected ligands has allowed the preparation of efficient antiviral
nanoagents. The target ligands can be introduced directly during the particle synthesis
<italic>via</italic> ligand exchange reactions or ligand modifications. For instance,
direct reduction of gold ions in the presence of gallic acid produced homogeneous AuNPs
able to sensibly reduce herpes simplex virus infection <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="ref40">40</xref></sup> Compared to free ligand NPs, functionalized AuNPs benefit from the
multivalency effect and higher circulation times, decreasing the needed therapeutic
concentrations.<sup><xref ref-type="bibr" rid="ref39">39</xref></sup> Functionalized AuNPs can present organic groups
that mimic host cell surfaces or other specific molecular patterns that selectively target
the virus. Normally, negative charges are used to mimic cell surfaces and favor the
interaction between the particles and the capsid. In particular, sulfonates and organic
sulfates have been used for their capacity to attract the virus <italic>via</italic>
capsid protein interaction and block the HA activity.<sup><xref ref-type="bibr" rid="ref41">41</xref></sup> AuNPs
functionalized with sulfonates showed an increasing inhibition of influenza A compared to
the nanoparticles capped with succinic acid.<sup><xref ref-type="bibr" rid="ref42">42</xref></sup> This study also
demonstrated that there is not a correlation between the negative charge and the antiviral
activity, but instead the inhibition depends mainly on the organic groups used.
Thiol-capped AuNPs also displayed powerful inactivation of bovine viral diarrhea virus
<italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="ref43">43</xref></sup> Multivalency has been exploited in more
complex systems using dendrons as capping agents. This strategy allows to generate higher
concentrations of the target ligand in close proximity to the AuNPs and to increase the
binding efficiency of the nanoparticles to the capsid. The driving force of the antiviral
efficiency relies on the concentration of the targeting agent onto the particles.
Sulfonated dendrons were grafted to AuNPs <italic>via</italic> a sulfide bond and tested
for HIV inhibition.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The results showed that the decorated AuNPs
exerted a higher affinity to the virus. Additionally, comparing AuNPs functionalized with
different generation dendrons, those with a third generation displayed the highest
inhibition performance with an IC<sub>50</sub> below 0.1 &#x003bc;mol/mL, thus making them
attractive for <italic>in vivo</italic> translation. It is worth noting that the
inhibition efficiency is strictly dependent on the available sulfonate groups present on
the surface of the NPs, making crucial a thorough characterization of the material.<sup><xref ref-type="bibr" rid="ref44">44</xref></sup> The size of the AuNPs clearly plays an important role in the concentration
of targeting ligands exposed per particle.<sup><xref ref-type="bibr" rid="ref45">45</xref></sup> Indeed, too big NPs have a
limited surface area, while too small would not allow an efficient grafting of the
dendrons due to steric hindrance. For instance, it has been shown that
dendron-functionalized AuNPs showed a size-dependent antiviral activity for influenza
virus, where 14 nm particles exhibited a higher efficiency than 2 nm AuNPs. This has been
associated with the low functionalization grade of the small nanoparticles and to the
inappropriate spatial distribution of the interacting ligand/receptor pairs.</p><p>The development of viral proteomics has profoundly transformed the antiviral and
disinfection strategies. In particular, small molecules and peptides able to target and
block the viral biochemical machinery have been developed. However, despite these efforts
into the drug design, many of these molecules suffer from poor biological effect, low
concentration in the diseased areas, and undesired side effects. In this context, AuNPs
have been coupled to biologically inactive small molecules to create biologically active
multivalent AuNP therapeutics. A bright example has been reported by Bowman <italic>et
al</italic>., where the authors functionalized AuNPs with SDC-1721, a small membrane
fusion inhibitor of HIV.<sup><xref ref-type="bibr" rid="ref46">46</xref></sup> The results demonstrated that, while pure
SDC-1721 has low activity, functionalized AuNPs are able to inhibit HIV replication at
&#x003bc;M concentrations. Similar results have been reported using targeting peptides. In
particular, it was evidenced that the functionalized AuNPs can sensibly reduce the
IC<sub>50</sub> up to 2 orders of magnitude compared to pure peptides.<sup><xref ref-type="bibr" rid="ref47">47</xref></sup> Preliminary results <italic>in vivo</italic> confirmed the biosafety of
the AuNPs.<sup><xref ref-type="bibr" rid="ref48">48</xref></sup></p></sec><sec id="sec2.4"><title>Nanoparticles Generating Reactive Oxygen Species</title><p>One of the main advantages of using NPs compared to oxidized metals relies on the slow
release of ions and clusters from these particles, leading to an enhancement of the
antiviral activity. Additionally, the use of metal NPs containing Cu or Fe in ionic form
catalyzes the generation of radicals <italic>via</italic> Fenton and Fenton-like reactions
oxidizing the capsid proteins and consequently blocking the viral infection at early
stage. For instance, copper ions (derived from sulfates or iodide salts) have been widely
used as antiviral agents because of their activity on several kinds of enveloped and
non-enveloped viruses including influenza virus,<sup><xref ref-type="bibr" rid="ref49">49</xref>&#x02212;<xref ref-type="bibr" rid="ref51">51</xref></sup> herpes simplex virus<sup><xref ref-type="bibr" rid="ref52">52</xref>&#x02212;<xref ref-type="bibr" rid="ref54">54</xref></sup> and
hepatitis A virus.<sup><xref ref-type="bibr" rid="ref55">55</xref></sup> Their mechanism of action relies on the formation
of Cu<sup>+</sup> ions (from soluble salts or nanoparticles) that generate hydroxyl
radicals.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> The use of metallic copper nanostructures in the form of
particles or sheets has shown only a moderate efficiency due to the low concentration and
low release of Cu<sup>+</sup>.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> For these reasons, Cu<sup>+</sup>
salts, where the copper ions are readily present in their active monocationic form, have
been favored. In particular, CuI nanoparticles (stable at room temperature) have been
extensively studied for deactivation of feline calicivirus<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> and H1N1
pandemic influenza virus.<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> However, the use of copper salts at high
concentrations can irreversibly alter reactive oxygen species (ROS) homeostasis of healthy
cells, provoking a general toxicity for the organism, limiting their applications to
disinfection.<sup><xref ref-type="bibr" rid="ref56">56</xref></sup> Nanostructured cuprous and cupric oxides have been
also extensively employed as antiviral agents for <italic>in vitro</italic> applications.
For instance, cuprous oxide nanoparticles (CuONPs) were successfully employed against
hepatitis C.<sup><xref ref-type="bibr" rid="ref58">58</xref></sup> In particular, it was found that these NPs exerted a
favorable antiviral activity with no cytotoxic effects. CuONPs target the binding and
entry step of viral infection to hepatic cells (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig">5</xref></xref>). Similar results were reported on the use of CuONPs against HSV-1, however
without any profound investigation on the antiviral mechanism.<sup><xref ref-type="bibr" rid="ref59">59</xref></sup></p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Huh7.5.1 cells at 72 h post-infection were stained with HCV-positive serum from
patients (green signal) and with DAPI (blue signal). Cuprous oxide NPs (CuONPs) are
able to reduce viral infection <italic>in vitro</italic>. Reproduced with permission
from ref (<xref ref-type="bibr" rid="ref58">58</xref>). Copyright 2015 Elsevier B.V.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0005" id="gr5" position="float"/></fig><p>Alternatively, zinc salts have been successfully used as antimicrobial agents from
research up to clinical trials for viral warts.<sup><xref ref-type="bibr" rid="ref60">60</xref>,<xref ref-type="bibr" rid="ref61">61</xref></sup> More recently, ZnO nanoparticles (ZnONPs) were developed
for the treatment of HSV-2. ZnONPs were prepared with a tetrapod morphology.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> The results showed that they can mimic cell surface interacting with the
HS present on the viral capsid. Additionally, these particles have been used for
photocatalysis showing to efficiently destroy the viral proteins upon UV
irradiation.<sup><xref ref-type="bibr" rid="ref62">62</xref></sup> Besides all these interesting examples, <italic>in
vivo</italic> applications are still needed to validate this therapeutic modality. Due
to the generation of high levels of ROS, the toxicity of copper nanoparticles has been
widely debated. The antiviral activity of copper nanoparticles is generally associated
with the release of Cu<sup>+</sup> ions in solution, thus the leakage of cytotoxic
cationic species can be modulated by surface functionalization before <italic>in
vitro</italic> and <italic>in vivo</italic> applications. On the other side, the use of
nanomaterials generating ROS can find applications in textile and surface coating. The
general broad virucidal efficiency of copper oxide nanoparticles shown for H1N1 pandemic
influenza<sup><xref ref-type="bibr" rid="ref57">57</xref></sup> should be tested on SARS-Cov-2 and might be used for
improving mask protection efficiency.</p></sec><sec id="sec2.5"><title>Carbon Nanomaterials</title><p>Due to their diversity, versatility, and tunable surface chemistry, carbon nanomaterials
have been attractive for several types of applications. In particular, the past decade has
seen a tremendous raise in the preparation of performant carbon-based nanomaterials in the
antiviral field. Fullerene and its derivatives are the most studied carbon nanomaterials
for their virucidal activity. Due to the lack of solubility of pristine fullerene,
functionalization strategies have been developed to prepare water-soluble drugs.
Investigations in the biomedical field evidenced the membranotropic capacity of fullerene
derivatives.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> By modulating shape and functions, fullerene
derivatives have been shown to possess antiviral properties through inhibition of viral
entry and blockage of viral replication. From these results, the attention has been
directed also to other carbon nanomaterials. In particular, functional carbon dots (CDs)
and graphene oxide (GO) have been investigated for their ability to block viral entry into
host cells.</p></sec><sec id="sec2.6"><title>Glycofullerenes</title><p>The emerging of mortal viruses, like Ebola or Zika, and the lack of suitable treatments
led the academic and the industrial communities to look for alternative therapeutic
routes. Most of these pathogens are RNA enveloped viruses, and they share common infection
mechanisms that can be targeted for the preparation of wide spectrum antivirals. The
external surface of the envelope of these viruses is covered by glycans that tightly
interact with lectin receptors on host cells.<sup><xref ref-type="bibr" rid="ref64">64</xref></sup> This strong interaction
allows the attachment of the virions to the cells, followed by internalization and
infection. Blocking lectin receptors is a general strategy used to stop viral infection at
an early stage. Fullerenes have been widely investigated as antiviral molecules, drug
carriers, or tissue scaffolds.<sup><xref ref-type="bibr" rid="ref65">65</xref></sup> Fullerene applications have been
recently extended to the design of mannosylated derivatives to block the entry of viral
particles into host cells. Mannose, due to the high affinity with lectin receptors,
competes with the virus in the interaction with the host cells. For example, one of the
targets is the inhibition of viral particles through the interaction of mannose with the
dendritic cell-specific ICAM-grabbing non-integrin (DC-sign). DC-sign receptors mediate
the interactions between DCs and T cells.<sup><xref ref-type="bibr" rid="ref66">66</xref>,<xref ref-type="bibr" rid="ref67">67</xref></sup> To exploit these characteristics, mannose was combined
with fullerene in the design of the so-called glycofullerenes to study their capacity to
inhibit Ebola, Dengue, and other pathogens.</p><p>For this purpose, different glycofullerenes were synthesized by changing the number of
mannose units (from 12 to 36) and the spacers between the fullerene moieties and by
varying steric hindrance in order to obtain a library of molecules.<sup><xref ref-type="bibr" rid="ref66">66</xref></sup>
The synthetic route is composed of three steps based on &#x0201c;click chemistry&#x0201d;:
(1) assembly of glycodendrons by Cu(I)-catalyzed azide&#x02013;alkyne cycloaddition
(CuAAC), (2) synthesis of alkyne-substituted Bingel-Hirsch hexakis-adducts, and (3) the
coupling between the last two products again by CuAAC. To increase the number of mannose
moieties up to 36, the glycodendron core was changed from malonate to trialkynyl
pentaerythritol. In order to compare the different derivatives, <italic>in vitro</italic>
studies were performed. Jurkat cells (lymphocyte T CD4 immortalized cells) expressing
DC-sign were used to prove the inhibition capacity of the glycofullerenes on viral
infection of Ebola (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>, route A). The study
revealed an IC<sub>50</sub> in the &#x003bc;M range for the 12 mannose fullerene, a lower
efficiency with the 36 mannose fullerene with a short spacer (PEG, with 2 ethylene oxide
units), while a nanomolar IC<sub>50</sub> was achieved with 36 mannose fullerenes with a
longer spacer (PEG, with 3 ethylene oxide units) (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). This first proof-of-concept study was then expanded, aiming to obtain a
better antiviral activity by increasing the valence and inserting longer and flexible
spacers.<sup><xref ref-type="bibr" rid="ref68">68</xref></sup></p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Chemical design and general scheme to block the viral entry by glycofullerenes. Three
different shapes of glycofullerenes can act as inhibitor of viral infection: (A) shape
composed of monodisperse fullerene bearing mannose, (B) assembly as &#x0201c;sugar
balls&#x0201d; of tridecafullerenes exhibiting mannose on the edges, and (C)
supramolecular micellar aggregates of fullerenes bearing mannose.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0006" id="gr6" position="float"/></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Antiviral Activity of Different Fullerenes Functionalized with Mannose</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="char" char="."/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">material</th><th style="border:none;" align="center">functional groups</th><th style="border:none;" align="center">core function</th><th style="border:none;" align="center" char=".">number of mannose moieties</th><th style="border:none;" align="center">virus</th><th style="border:none;" align="center" char=".">number of atoms between fullerene and mannose</th><th style="border:none;" align="center" char=".">IC<sub>50</sub></th><th style="border:none;" align="center">ref</th></tr></thead><tbody><tr><td style="border:none;" align="left">glycofullerene</td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">malonate</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">2&#x000a0;&#x003bc;M</td><td rowspan="3" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref66">66</xref>)</td></tr><tr><td style="border:none;" align="left">glycofullerene</td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">trialkynyl pentaerythritol</td><td style="border:none;" align="char" char=".">36</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">22</td><td style="border:none;" align="char" char=".">68&#x000a0;&#x003bc;M</td></tr><tr><td style="border:none;" align="left">glycofullerene</td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">trialkynyl pentaerythritol</td><td style="border:none;" align="char" char=".">36</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">28</td><td style="border:none;" align="char" char=".">0.3&#x000a0;&#x003bc;M</td></tr><tr><td style="border:none;" align="left">trideca-fullerenes<xref rid="t3fn1" ref-type="table-fn">a</xref></td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">malonate</td><td style="border:none;" align="char" char=".">120</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">20.375&#x000a0;nM</td><td rowspan="2" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref69">69</xref>)</td></tr><tr><td style="border:none;" align="left">trideca-fullerenes<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">malonate</td><td style="border:none;" align="char" char=".">120</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">8</td><td style="border:none;" align="char" char=".">0.667&#x000a0;nM</td></tr><tr><td rowspan="2" style="border:none;" align="left">glycofullerene</td><td rowspan="2" style="border:none;" align="left">disaccharide</td><td rowspan="2" style="border:none;" align="left">trialkynyl pentaerythritol</td><td rowspan="2" style="border:none;" align="char" char=".">36</td><td style="border:none;" align="left">Zika</td><td rowspan="2" style="border:none;" align="char" char=".">29</td><td style="border:none;" align="char" char=".">8.35&#x000a0;nM</td><td rowspan="6" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref70">70</xref>)</td></tr><tr><td style="border:none;" align="left">Dengue</td><td style="border:none;" align="char" char=".">7.71&#x000a0;nM</td></tr><tr><td rowspan="2" style="border:none;" align="left">trideca-fullerenes</td><td rowspan="2" style="border:none;" align="left">disaccharide</td><td rowspan="2" style="border:none;" align="left">trialkynyl pentaerythritol</td><td rowspan="2" style="border:none;" align="char" char=".">120</td><td style="border:none;" align="left">Zika</td><td rowspan="2" style="border:none;" align="char" char=".">29</td><td style="border:none;" align="char" char=".">0.52&#x000a0;nM</td></tr><tr><td style="border:none;" align="left">Dengue</td><td style="border:none;" align="char" char=".">0.098&#x000a0;nM</td></tr><tr><td rowspan="2" style="border:none;" align="left">trideca-fullerenes</td><td rowspan="2" style="border:none;" align="left">disaccharide</td><td rowspan="2" style="border:none;" align="left">trialkynyl pentaerythritol</td><td rowspan="2" style="border:none;" align="char" char=".">360</td><td style="border:none;" align="left">Zika</td><td rowspan="2" style="border:none;" align="char" char=".">48</td><td style="border:none;" align="char" char=".">0.067&#x000a0;nM</td></tr><tr><td style="border:none;" align="left">Dengue</td><td style="border:none;" align="char" char=".">0.035&#x000a0;nM</td></tr><tr><td style="border:none;" align="left">micellar glycofullerenes</td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">trialkynyl pentaerythritol</td><td style="border:none;" align="char" char=".">6</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">23</td><td style="border:none;" align="char" char=".">424&#x000a0;nM</td><td rowspan="2" style="border:none;" align="left">(<xref ref-type="bibr" rid="ref72">72</xref>)</td></tr><tr><td style="border:none;" align="left">micellar glycofullerenes</td><td style="border:none;" align="left">monosaccharide</td><td style="border:none;" align="left">trialkynyl pentaerythritol</td><td style="border:none;" align="char" char=".">12</td><td style="border:none;" align="left">Ebola</td><td style="border:none;" align="char" char=".">25</td><td style="border:none;" align="char" char=".">196&#x000a0;nM</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Small spacer between core C<sub>60</sub> and surrounding fullerenes.</p></fn><fn id="t3fn2"><label>b</label><p>Large spacer between core C<sub>60</sub> and surrounding fullerenes.</p></fn></table-wrap-foot></table-wrap><p>Based on these studies, another class of multivalent fullerene dendrimers was then
designed. A fast and controlled synthetic route was developed to achieve giant globular
multivalent fullerenes, containing hundreds of functional groups. The first study was
performed with tridecafullerenes containing 120 mannoses.<sup><xref ref-type="bibr" rid="ref69">69</xref></sup> The
molecular structure is composed of 12 hexakis C<sub>60</sub> surrounding a C<sub>60</sub>
core (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>, route B). Compared to the
previous study, an IC<sub>50</sub> 3 orders of magnitude lower was measured on the
inhibition of Ebola virus (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>).<sup><xref ref-type="bibr" rid="ref66">66</xref>,<xref ref-type="bibr" rid="ref68">68</xref></sup> In
order to present more carbohydrates at the periphery of the dendrimer, a trialkynyl
pentaerythritol derivative allowed to afford a tridecafullerene with 360 carbohydrates. In
this case, the molecule was synthesized with a C<sub>60</sub> tridecafullerene bearing
&#x003b1;(1,2)mannobioside.<sup><xref ref-type="bibr" rid="ref70">70</xref></sup> The use of this disaccharide was already
investigated, showing an increase of affinity with DC-sign receptors by a factor of
3&#x02013;4.<sup><xref ref-type="bibr" rid="ref71">71</xref></sup> The synthetic strategy exploited also the use of
strain-promoted copper-free cycloaddition of azides to alkynes (SPAAC) for the coupling of
the core fullerene to the surrounding fullerenes. SPAAC allows an easier purification
avoiding the removal of cytotoxic copper ions. The inhibition performance of this molecule
was studied <italic>in vitro</italic> with viral pseudoparticles of Dengue and Zika. The
comparison was made between 360 and 120 disaccharides tridecafullerenes and 36
disaccharide monofullerene. The results highlighted a picomolar IC<sub>50</sub> inhibition
on both Zika and Dengue models for the 360 disaccharide glycofullerene (<xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). The ability to inhibit other types of viruses allows
the use of glycofullerenes as broad spectrum antiviral drugs. Moreover, the negligible
toxicity to other cells proved the biocompatibility of these molecules.</p><p>Following an alternative strategy, a supramolecular assembly of monodisperse
glycofullerenes, leading to the formation of micelles, was achieved and tested.<sup><xref ref-type="bibr" rid="ref72">72</xref></sup> These micelles present a uniform and spherical shape (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig">6</xref></xref>, route C). The aggregation synthetic route is faster
compared to a controlled synthesis of giant glycofullerenes, but it might suffer from low
reproducibility and batch-to-batch differences between each formulation. This
self-assembled C<sub>60</sub> functionalized with 6 or 12 mannoses exposes a large amount
of carbohydrate at the surface, leading to an inhibition of Ebola virus in the nanomolar
range (IC<sub>50</sub> of 424 nM for six mannoses and 196 nM for 12 mannoses,
respectively, <xref rid="tbl3" ref-type="other">Table <xref rid="tbl3" ref-type="other">3</xref></xref>). Further <italic>in
vitro</italic> studies evidenced again a good biocompatibility of these glycofullerenes.
While there are no <italic>in vivo</italic> studies yet, these promising results enlarge
the panel of molecules in the fight against new emerging viruses.</p><p>Functionalized fullerenes have been used for their ability to compete with viral
particles through lectin receptors in host cells. There has been a tremendous advancement
in the functionalization of fullerenes leading to the preparation of derivatives with a
high amount of mannose, capable to enhance the multivalency effect and thus to increase
the therapeutic outcome. First, glycofullerenes do not have an intrinsic virucidal
activity. They can reduce the infectivity, but they are not able to completely inactivate
the virus. Second, the mechanism of action of glycofullerenes relies on their interaction
with host cells and not with viral particles. Thus, for a therapeutic application, they
should be injected at different time points, ensuring that the local concentration is
therapeutically relevant to prevent the virus from invading the host cells. In addition,
glycofullerenes can be internalized into host cells losing their viral
&#x0201c;shield&#x0201d; activity. On the other hand, the well-developed surface chemistry
of glycofullerenes can be used for other key receptors involved in viral entry. For
instance, in the case of the current SARS-Cov-2 pandemic, a similar click chemistry
strategy can be used to anchor ligands recognized by human lung ACE2 receptors and so
inhibiting viral entry.<sup><xref ref-type="bibr" rid="ref73">73</xref></sup></p></sec><sec id="sec2.7"><title>Other Carbon Nanomaterials</title><p>Alongside fullerenes, other carbon nanomaterials (NMs) have been scrutinized for their
ability to block viral entry. CDs and GO are the most known and studied carbon NMs with
marked antiviral properties. CDs are zero-dimensional carbon nanoparticles. They are
generally produced <italic>via</italic> hydrothermal decomposition of carbon containing
&#x0201c;low-cost&#x0201d; precursors. The use of CDs in the biomedical field has been
encouraged by their easy preparation, low toxicity, fluorescence properties, and easy
surface functionalization. Pristine CDs have shown moderate viral blocking activity for
HIV infection <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> This has been associated
with the surface of the material rich in carboxylic and hydroxyl groups prone to form
noncovalent interaction with viral membranes. Moreover, due to the complexity of the
biological systems these nonspecific interactions could not be so effective <italic>in
vivo</italic>, likely reducing the antiviral efficacy. Therapeutic targeting molecules
can be grafted onto a CD surface to enhance their antiviral activity. In this context, the
design of multifunctional CD platforms can be obtained through two different strategies.
The first consists in a single-step reaction that foresees the insertion of the
therapeutic molecule directly into the step of preparation. Target molecules are
decomposed with the other precursors, generating the desired functional CDs. This protocol
is fast and efficient, however the drug loading as well as its activity are hard to
estimate. Indeed, the hydrothermal treatment can alter the chemical structure of the
active molecule, thus vanishing its therapeutic effect. For these reasons, the reaction
conditions must be carefully controlled.<sup><xref ref-type="bibr" rid="ref75">75</xref></sup> The second method is a
two-step reaction and implies the postfunctionalization <italic>via</italic> amide
formation on the surface of the CDs rich in carboxylic groups. This strategy offers a
better chemical control, but the yield and the drug loading may not be quantitative and
high, respectively. Different functionalized CDs were prepared to hamper host cell viral
entry. For instance, benzoxazine (a low water-soluble antiviral agent) was incorporated
into the CD structure during their preparation (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig">7</xref></xref>). The as-prepared CDs showed a broad spectrum viral blocking capacity
<italic>in vitro</italic> for enveloped (<italic>e</italic>.<italic>g</italic>.,
Japanese encephalitis virus, Dengue virus, and Zika virus) and non-enveloped viruses
(<italic>e</italic>.<italic>g</italic>., porcine parvovirus and adenovirus-associated
virus).<sup><xref ref-type="bibr" rid="ref76">76</xref></sup> These positive results were explained by the efficient
binding and deactivation induced by the multivalent effect of the CDs to the viral
particles</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Illustration of benzoxazine-functionalized CDs and their broad antiviral entry
activity. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref76">76</xref>). Copyright 2019 Elsevier B.V.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0007" id="gr7" position="float"/></fig><p>Amino-functionalized CDs were also tested for the treatment of human norovirus. In this
study, CDs were functionalized with 2,2&#x02032;-(ethylenedioxy)bis(ethylamine) (EDA) and
3-ethoxypropylamine (EPA) <italic>via</italic> amide bond formation.<sup><xref ref-type="bibr" rid="ref77">77</xref></sup>
These NMs exerted a good viral blockage. In particular, EPA-functionalized CDs were able
to inhibit 100% of viral infection at concentration of 2 &#x003bc;g/mL, while in the case of
CDs prepared with the other amines, 80% of inhibition was reported. These effects have
been associated with the higher positive charge of CD-EDA compared to CD-EPA. Another
surface group used for viral targeting is boronic acid (BA), which can bind glycosylated
surfaces forming boronic esters. This strategy was successfully adopted to treat HIV where
the boronic groups, linked to different nanoparticles
(<italic>e</italic>.<italic>g</italic>., silica nanoparticles and nanodiamonds) can
target gp120 receptors on the viral envelope inhibiting the infection.<sup><xref ref-type="bibr" rid="ref78">78</xref></sup> Another recent study proposed the use of CD functionalized with phenylboronic acid for
prevention of HIV infection.<sup><xref ref-type="bibr" rid="ref74">74</xref></sup> The functional materials showed good
inhibition properties compared to nonfunctionalized CDs by preventing the binding to the
target cell <italic>in vitro</italic>. Overall, the use of CDs for stopping host cell
viral entrance has shown good results <italic>in vitro</italic>. However, there is a lack
of proofs <italic>in vivo</italic> limiting their applications to surface disinfection or
masks. In addition, most of the <italic>in vitro</italic> studies foresee first the
contact of the CDs with the viral particles and then their incubation with host cells.
Deeper investigations should be performed adding the NMs at other time points (for
instance in infected cells) to understand if the antiviral activity is maintained.</p><p>In addition, CDs have been successfully used for photodynamic therapy (generating
radicals upon light irradiation) in cancer treatment. The same approach may be used to
combat viral infections, where the antiviral activity induced by the surface modification
can be sensibly enhanced by ROS generation under irradiation.</p><p>Graphene materials, and in particular GO and reduced GO (rGO), have been used for
different biomedical applications including drug delivery, biosensing, and tissue
engineering.<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> GO platforms have shown also interesting antimicrobial
activity.<sup><xref ref-type="bibr" rid="ref79">79</xref></sup> Regarding viral infection, GO was used to block the virus
entrance in host cells. GO and rGO can be considered as two-dimensional materials that
contain hydrophilic and hydrophobic domains allowing to adsorb many biological molecules
including nucleic acids and proteins. GO showed low interaction with viruses, however its
surface functionalization with target molecules can sensibly enhance its affinity for the
viral particles. Additionally, GO can be used as photothermal agent (generation of heat by
NIR irradiation) or photodynamic therapy (using visible light irradiation) inactivating
the capsids by local thermal shock or by radical formation during irradiation,
respectively. The use of phototherapies may significantly augment the antiviral properties
of the materials. However, we must keep in mind that these therapeutic modalities can be
applied only to disinfection, since the radical/heat production may be harmful for the
healthy tissues <italic>in vivo</italic>. Photodynamic therapy has been successfully
exploited using bacteriophage MS2 as a model virus.<sup><xref ref-type="bibr" rid="ref80">80</xref></sup> In this study, GO
was functionalized with an aptamer recognized by the viral surface. The results showed
that this functionalization is able to enhance the binding efficiency of the MS2 capsids
onto the GO surface compared to nonfunctionalized GO. Subsequently, irradiation in the
visible light was able to disinfect the solution, while nonfunctionalized GO showed much
less activity due to the lack of adsorption. Despite these interesting results, this
pioneer work remains at an early research stage since the use of high light dose (300 W
for 10&#x02013;140 min) and the lack of material recovery and reuse make its application
for surface disinfection difficult.</p><p>GO can be also used as a platform to link antiviral agents. Encouraging results were
reported using GO with hypericin for the treatment of a recently appeared duck
reovirus.<sup><xref ref-type="bibr" rid="ref81">81</xref></sup> More recently, Deokar <italic>et al</italic>. reported an
original rGO-based multifunctional platform for HSV-1 treatment.<sup><xref ref-type="bibr" rid="ref82">82</xref></sup> In
this work, the authors functionalized the material with organic sulfate groups and iron
oxide magnetic nanoparticles (FeNPs). The rGO functionalized with the sulfate is able to
mimic the host cell surface and to bind HSV-1. Subsequently, the viral particles captured
onto the rGO-FeNP surface can be concentrated <italic>via</italic> magnetic precipitation
and destroyed <italic>via</italic> photothermal therapy. This approach is highly efficient
for disinfection with low energy (1.6 W/cm<sup>2</sup> for 7 min) and cost effectiveness.
HS is a common entry receptor in various types of viruses
(<italic>e</italic>.<italic>g</italic>., herpes viruses, human papillomavirus, Dengue
virus).<sup><xref ref-type="bibr" rid="ref83">83</xref></sup> The use of organic sulfate-functionalized graphene sheets
mimicking HS, like GO and rGO, has been already explored. However, it is worth noting that
these NMs are prone to strongly adsorb proteins in culture environments (coronation),
likely inhibiting their antiviral efficacy.<sup><xref ref-type="bibr" rid="ref84">84</xref></sup> High loadings of sulfate
groups were introduced onto rGO using polyglycerol sulfate.<sup><xref ref-type="bibr" rid="ref85">85</xref>,<xref ref-type="bibr" rid="ref86">86</xref></sup> This approach has been used for
inhibition of orthopoxvirus, pseudorabies virus, and African swine fever virus <italic>in
vitro</italic>.<sup><xref ref-type="bibr" rid="ref85">85</xref>,<xref ref-type="bibr" rid="ref86">86</xref></sup></p><p>Graphene has also been used as antiviral material. Polysulfates and fatty amines were
grafted onto graphene surface <italic>via</italic> triazine chemistry for the treatment of
herpes simplex virus.<sup><xref ref-type="bibr" rid="ref87">87</xref></sup> This strategy promotes the synergy between the
electrostatic and hydrophobic interactions, showing incredibly high inhibition efficacy.
Overall, graphene materials have shown a good capacity to block host cell viral entry.
Disinfection with graphene family materials is also promising, offering the possibility to
couple high viral binding with phototreatments. Regarding the GO and rGO activity in
cellular environments, different parameters must be considered such as protein coronation,
blood circulation time, and activity <italic>in vivo</italic>. So far, the use of sulfonic
groups introduced <italic>via</italic> diazonium salt decomposition has been largely
privileged. We take this opportunity to encourage future studies using other targeting
groups (<italic>e</italic>.<italic>g</italic>., boronic acids) and grafting methods
(<italic>e</italic>.<italic>g</italic>., epoxide ring opening or hydroxyl esterification
reactions).</p></sec><sec id="sec2.8"><title>Mechanical Disruption of the Capsid</title><p>The most direct way to suppress viruses and stop the spreading of viral infection is to
inactivate them before the attachment to the host cells, by binding to the acceptor
proteins.<sup><xref ref-type="bibr" rid="ref88">88</xref></sup> One of the most conserved targets of viral attachment
ligands is the heparan sulfate proteoglycan (HSPG), previously mentioned. HSPGs are
expressed on the surface of almost all eukaryotic cell types, and many viruses like HIV-1,
HSV, human papilloma virus (HPV) exploit HSPGs as the target of their viral attachment
ligands. Bearing in mind this behavior, different studies have used HSPG-mimicking
materials to target this type of virus&#x02013;cell interaction and to achieve broad
spectrum efficacy. For example, in one key study, AuNPs were functionalized with
mercaptoethanesulfonate (MES) based on its mimicry of HS (Au-MES NPs). Au-MES NPs were
shown to interfere with viral attachment, viral entry, and cell-to-cell spreading.<sup><xref ref-type="bibr" rid="ref89">89</xref></sup> The importance of the polyvalent interactions with the virus makes these
NPs a good candidate for antiviral therapy. However, Au-MES NPs presented virustatic
activity, meaning that upon dilution of the NPs, the virus recovers its infectivity due to
the reversibility of the cell-virion interaction. This problem was solved by Stellacci and
colleagues who developed NPs coated with mercapto-1-undecanesulfonate (MUS) ligands
(Au-MUS NPs). The long aliphatic and flexible linkers provide stronger associations with
the viral particles compared to Au-MES NPs, leading to local distortions and eventually
inducing a global deformation and breaking of the capsid that inactivates its contagion
irreversibly (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>).<sup><xref ref-type="bibr" rid="ref90">90</xref></sup>
These Au-MUS NPs were tested against different HSPG-dependent viruses, showing a high
viricidal activity over HSV, HPV, and RSV (<xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig">9</xref></xref>A). Furthermore, the activity of the Au-MUS NPs was studied <italic>in
vivo</italic> using mice infected with RSV, indicating that the material can prevent
pulmonary dissemination of the infection and showing potential use as medically relevant
virucidal drugs to fight viral infections. More recently, the concept was further extended
to cyclodextrins modified with mercapto-1-undecanesulfonate, proposing this system as a
broad spectrum virucidal macromolecule.<sup><xref ref-type="bibr" rid="ref91">91</xref></sup> Besides Au-NPs, a similar
mechanism of disruption was studied with other materials like graphene or GO. In a study,
in which the toxicity of graphene was evaluated theoretically, it was also shown that
graphene nanosheets can interrupt the hydrophobic protein&#x02013;protein interaction,
which is essential to biological functions.<sup><xref ref-type="bibr" rid="ref92">92</xref></sup> This feature was
attributed to the hydrophobic nature of graphene. Thus, it seems energetically favorable
for graphene to slide between the interface of two proteins in contact, due to hydrophobic
interactions. In another study inspired by this behavior, the authors performed molecular
dynamics simulations of graphene nanosheets in the proximity of the surface of the Ebola
viral matrix protein VP40 showing that the nanosheets can break the hydrophobic
interactions in VP40, a key protein for the replication and stability of Ebola virus
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig">8</xref></xref>).<sup><xref ref-type="bibr" rid="ref93">93</xref></sup> These findings
suggest that graphene nanosheets might have potential antiviral activity against Ebola;
however, there is a lack of experimental evidence that corroborates this mechanism of
disruption. On the other hand, GO was tested experimentally against Pseudorabies virus and
Porcine epidemic diarrhea virus (PEDV), showing significant decrease in the
infectivity.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup> It was found that the negatively charged surface of GO
is important for the adsorption of the virus, whose surface is positively charged, and
that GO could directly interact with the viral particles and destroy their structures due
to the sharp edges of the material (<xref rid="fig8" ref-type="fig">Figures <xref rid="fig8" ref-type="fig">8</xref></xref> and
<xref rid="fig9" ref-type="fig">9</xref>B).</p><fig id="fig8" position="float"><label>Figure 8</label><caption><p>Mechanical disruption mechanisms of different NMs. Left: Au-MUS NPs inducing
mechanical forces in the virus capsid leading to inactivation.<sup><xref ref-type="bibr" rid="ref90">90</xref></sup>
Center: Graphene NSs disrupting VP40 hydrophobic interactions in Ebola.<sup><xref ref-type="bibr" rid="ref93">93</xref></sup> Right: Interaction between negatively charged surface of GO and
positively charged capsid.<sup><xref ref-type="bibr" rid="ref94">94</xref></sup></p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0008" id="gr8" position="float"/></fig><fig id="fig9" position="float"><label>Figure 9</label><caption><p>Interaction of NMs with viral capsid. A) Gold NPs acting on HSV-2 virus. After 90
min, the percentage of destroyed virus was significantly increased. Scale bars: 100
nm. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref90">90</xref>).
Copyright 2018 Springer Nature Limited. (B) GO acting on Pseudorabies virus. After
incubation with GO for 1 h, part of the virus envelope and spikes were destroyed.
Scale bars: 200 nm. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref94">94</xref>). Copyright 2015, American Chemical Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0009" id="gr9" position="float"/></fig><p>The mechanical disruption of the capsid is a peculiar antiviral mechanism associated with
some NMs. In particular, the use of specific sulfonates able to mimic heparan sulfate can
be also used to target SARS-Cov-2 infection.<sup><xref ref-type="bibr" rid="ref95">95</xref></sup></p></sec></sec><sec id="sec3"><title>Antiviral Activity Inside Host Cells</title><p>Blocking the viral entry, <italic>via</italic> liquid/surface disinfection or once in the
body, is a powerful strategy to hamper early stage viral contagions. On the other hand, when
infections have already spread and reached middle and late stages, alternative
pharmacological strategies are required. The study of the viral pathogenesis and machinery
inside host cells has allowed the preparation of different drugs. Due to the present
pandemic, such antiviral drugs are now of top interest in the scientific and medical
communities. So far, few antiviral drugs are clinically available, and their mechanisms of
action consist on the inhibition of reverse transcriptase (HIV, hepatitis), DNA inhibition
of polymerase (herpes, HIV), inhibition of protease (HIV), blockage of ion channels
(influenza), and inhibition of neuramidase (HIV, influenza, hepatitis). However, these drugs
suffer from moderate to severe side effects. Additionally, rapid mutations in the viral
machinery make them resistant to the treatments, making the control and the stop of the
infection challenging. The use of HNMs in drug delivery has shown several advantages. First,
HNMs can increase drug solubility and its circulation time. Additionally, they can be
functionalized with targeting molecules able to direct the drug to the desired organs and so
avoiding side effects and reducing the dosage. More recently, new antiviral mechanisms were
discovered. In particular, it was found that different types of HNMs are able to change the
ROS homeostasis in infected host cells, stopping the viral replication and preserving the
cell survival. In this section both drug delivery materials and HNMs with ROS modulation
properties will be critically presented (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig">10</xref></xref>).</p><fig id="fig10" position="float"><label>Figure 10</label><caption><p>Illustration of NMs interacting with host cell to prevent viral spreading. Left: NMs
are used for delivery of antiviral agents. Right: NMs can change the ROS homeostasis
slowing down the infection and helping cell survival.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0010" id="gr10" position="float"/></fig><sec id="sec3.1"><title>Nanomaterials for Drug Delivery</title><p>Different HNMs have been widely tested for drug delivery applications. The advantages of
this strategy are several including enhance drug solubility and the possibility of
targeting and multivalent effects. As a potential broad spectral antiviral agent, AgNPs
can prevent the virus from adsorbing to the host cell in the early stage of infection and
thus show strong antiviral activity. After the cells are infected by the virus, there are
ways to inhibit cell apoptosis (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, right).
For example, Lv <italic>et al</italic>. studied the anti-TGEV activity of AgNPs in swine
testicle cells and explored the possible mechanism of AgNP inhibition of TGEV
infection-induced apoptosis.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> The results showed that these AgNPs are
able to decrease cell apoptosis through the activation of p38/mitochondria-caspase-3
signaling.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup></p><p>Although the use of AgNPs has shown good antiviral action to further improve the
therapeutic effects and reduce both side effects and drug resistance, the way of binding
drugs or genes and other therapeutic agents to AgNPs has received particular attention. It
has been observed that AgNPs inhibit the activities of neuraminidase and hemagglutinin,
preventing the H1N1 influenza virus from attaching to host cells. At the same time, the
potential molecular mechanisms revealed that caspase-3-mediated apoptosis was inhibited by
ROS generation. AgNPs modified with polyethylenimine (PEI) can bind siRNA. Ag@PEI@siRNA
exhibited superior abilities for enhanced cellular uptake and blocking EV71 virus
infection and significantly decreased the apoptotic cell population, which prevented the
spread of EV71 virus.<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> In addition to drugs and siRNA, neutralizing
antibodies in combination with AgNPs were developed. The results demonstrated that there
is an additive effect between the antibody and AgNPs when combined against cell-associated
HIV-1 infection <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="ref96">96</xref></sup></p><p>The membranotropic properties of fullerenes were widely exploited. For example, pristine
C<sub>60</sub>, after accumulation at the cell membrane, can translocate into the
cytoplasm by crossing the membrane through multiple energy-dependent pathways despite its
hydrophobic character.<sup><xref ref-type="bibr" rid="ref97">97</xref></sup> Fullerenes can be made water dispersible using
surfactants, sonication or first dissolving them in appropriate organic solvents (DMSO).
The use of fullerenes as inhibitors of viruses started in 1993 with a study focused on HIV
infection.<sup><xref ref-type="bibr" rid="ref98">98</xref></sup> This work revealed the interaction between
C<sub>60</sub> derivatives and HIV protease through molecular modeling and experimental
verification. HIV protease (HIV-PR) is involved in the mechanism of replication in the
maturation of HIV virion, cleaving newly synthesized proteins. The active site of HIV
protease has a cavity of 10 &#x000c5; closed to the diameter of C<sub>60</sub> cage.<sup><xref ref-type="bibr" rid="ref99">99</xref></sup> Molecular docking and experiments on HIV-PR catalytic activity revealed a
blockage of the active site of the enzyme by van der Waals interactions leading to an
antiviral effect. The following studies were based on a structure&#x02013;activity
relationship between functionalized fullerenes and HIV-PR with the aim to increase the
antiviral activity. The introduction of pyrrolidinium salts onto C<sub>60</sub> was tested
against the activity of HIV-1 strain.<sup><xref ref-type="bibr" rid="ref100">100</xref></sup> In a second study,
C<sub>60</sub> bearing two ammonium groups was applied against the activity of HIV-1 and
HIV-2 strains.<sup><xref ref-type="bibr" rid="ref101">101</xref></sup> The results showed the importance of having two
moieties in a precise position on the fullerene cage and the influence of the charge of
the different salts sensibly increasing its antiviral activity. Further investigations
using different functional groups (<italic>e</italic>.<italic>g</italic>., amino acid
derivatives) were explored. C<sub>60</sub> functionalized with aminobutyric acid and
aminocaproic acid was able to inhibit HIV viral replication at subnanomolar
concentrations.<sup><xref ref-type="bibr" rid="ref63">63</xref></sup> In another work, anionic and cationic pyrrolidinium
salts and amino acid functionalized fullerene derivatives were used for the inhibition of
HIV reverse transcriptase (HIV-RT). Fullerene compounds were compared to nevirapine, an
available drug against HIV-RT, revealing a better inhibition compared to the pure
drug.<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> The antiviral property of carboxylated fullerenes was
confirmed by another study.<sup><xref ref-type="bibr" rid="ref103">103</xref></sup> Results obtained <italic>in
vitro</italic> on CEM cell line showed low toxicity and a submicromolar EC<sub>50</sub>
against HIV-1 and HIV-2 strain viral replication.</p><p>Several mechanisms of HIV protease inhibitors have been hypothesized and simulated. Some
studies investigated the action of fullerene derivatives on viral replication cycle and
the virus maturation (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig">11</xref></xref>).<sup><xref ref-type="bibr" rid="ref98">98</xref>,<xref ref-type="bibr" rid="ref104">104</xref></sup>
For the latter, it was suggested an impairment due to a strong interaction between
fullerene and the immature capsid.<sup><xref ref-type="bibr" rid="ref105">105</xref></sup></p><fig id="fig11" position="float"><label>Figure 11</label><caption><p>Illustration of fullerene affecting the viral replication mechanism. Interaction
between fullerene and viral protein blocking either the transcription or the
translation in the viral replication.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0011" id="gr11" position="float"/></fig><p>Other RNA viruses share ways of viral replication similar to HIV.<sup><xref ref-type="bibr" rid="ref106">106</xref></sup>
C<sub>60</sub> functionalized with an amino acid derivative was investigated against
Hepatitis C RNA polymerase (HCV-RP).<sup><xref ref-type="bibr" rid="ref102">102</xref></sup> This essential enzyme for viral
replication was inhibited in a submicromolar range, similarly to benzo-1,2,4-thiadiazine,
a potent specific inhibitor of HCV-RP. Another publication highlighted the effect of a
C<sub>70</sub> poly(carboxylic acid) derivative on different strains of influenza virus
(<italic>e</italic>.<italic>g</italic>., A, H1N1, H3N2, and B).<sup><xref ref-type="bibr" rid="ref107">107</xref></sup>
The inhibition was comparable to Tamiflu, rimantadine, ribavirin, and amantadine, but the
mechanism of action remains still unclear. These data emphasize that fullerenes
C<sub>60</sub> or C<sub>70</sub> can be potent universal antiviral drugs for RNA
enveloped viruses. However, clear elucidations of the mechanisms of action and <italic>in
vivo</italic> studies are still a missing point.</p><p>Due to their high surface/weight ratio and capacity to pass through cell membranes,
carbon nanotubes (CNTs) have been extensively explored for drug and gene delivery
applications.<sup><xref ref-type="bibr" rid="ref108">108</xref></sup> CNTs have been also successfully used for the
delivery of antiviral agents. Compared to pristine materials, oxidized CNTs (ox-CNTs)
showed an inhibitory activity for HIV viruses <italic>per se</italic>.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> This effect has been associated with the oxygenated groups that increase the
hydrophilicity and the colloidal stability of the material. The antiviral efficiency has
been correlated to the ox-CNT interaction with host cells.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> However,
it is not clear how and what kind of mechanism blocks the viral machinery in host cells.
Different anchoring strategies have been explored to link antiviral drugs onto CNT
surface. For instance, ox-CNTs were covalently linked to
2-amino-3-nitro-1-(3,5-dimethylbenzyl)-aniline (CHI360) and
<italic>N</italic>-(2-aminophenyl-3-nitro-)-3,5-dimethylbenzenesulfonamide (CHI415), two
active non-nucleoside reverse transcriptase inhibitors for HIV treatment.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> Following the covalent conjugation, only a moderate antiviral effect was
observed compared to pure drugs, indicating that most probably the NM cell trafficking
played a key role on the virucidal activity.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> In another study,
ox-CNTs functionalized with cyclodextrin were used for the delivery of acyclovir (a
prodrug inhibitor of the viral DNA polymerases) for the treatment of HSV-1. Preliminary
results showed that when acyclovir was delivered <italic>vi</italic>a the nanotubes, the
viral antireplicative effect was higher than the free drug.<sup><xref ref-type="bibr" rid="ref110">110</xref></sup> More
recently, a similar approach was applied to herpes virus using cyclodextrin and
PEI-functionalized CNTs for co-delivery of cidofovir and plasmid DNA. However, the
antiviral effect of the materials was not explained, and the transfection effect was not
satisfactory.<sup><xref ref-type="bibr" rid="ref111">111</xref></sup> Functionalized CNTs have been also used for delivery
of ribavirin <italic>in vivo</italic> using grass carp as an animal model for the study of
grass carp reovirus. ox-CNTs were first functionalized <italic>via</italic> amidation with
BSA, and then ribavirin was covalently bound to the protein <italic>vi</italic>a
esterification (<xref rid="fig12" ref-type="fig">Figure <xref rid="fig12" ref-type="fig">12</xref></xref>).<sup><xref ref-type="bibr" rid="ref112">112</xref></sup></p><fig id="fig12" position="float"><label>Figure 12</label><caption><p>Schematic procedure of the functionalization of single-walled CNTs (SWCNTs) and
ribavirin. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref112">112</xref>). Copyright 2015, Elsevier B.V.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0012" id="gr12" position="float"/></fig><p><italic>In vivo</italic> tests demonstrated that, when ribovirin was shuttled by ox-CNTs,
the antiviral efficiency was significantly increased without any evident toxicity and no
significant changes in ROS-generating enzymatic activities. The use of CNTs in drug
delivery is however still controversial.<sup><xref ref-type="bibr" rid="ref113">113</xref></sup></p><p>Graphene-based materials have been limitedly studied as antiviral drug delivery carriers.
Only a few examples can be found in the literature. Graphene quantum dots (GQDs) were used
for drug delivery of CHI360 and CHI415 and tested <italic>in vitro</italic> against HIV
similarly to CNTs.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> Both the prepared GQD-CHI360 and GQD-CHI415
showed a high antiviral activity once into host cells, with low toxicity. GO has been also
used for the delivery of DNAzyme into hepatic cells allowing to block the hepatitis C
infection. This specific DNA single strand is able to recognize the viral mRNA and to
silence its expression.<sup><xref ref-type="bibr" rid="ref114">114</xref></sup></p><p>Overall, carbon NMs proved to be interesting carriers for antiviral drugs. However,
several questions need to be answered before their safe application as antiviral
materials. Different reports have demonstrated that pristine CNTs display relevant
toxicity for healthy cells, but by oxidation of the tubes, the side effects can be
sensibly reduced.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup> In addition, more investigations should be
performed on CNT toxicity. These nanocarriers indeed are not &#x0201c;innocent delivery
agents&#x0201d;, but they play a key role in drug internalization pathway and in host cell
machinery that might be averse to the expected therapeutic effects.<sup><xref ref-type="bibr" rid="ref109">109</xref></sup>
So far, CNT application in biological systems has been studied for 20 years. However, due
to their possible toxicity, their real application in clinics seems to be steeper and
difficult to achieve.<sup><xref ref-type="bibr" rid="ref112">112</xref></sup></p></sec><sec id="sec3.2"><title>Materials Tuning Reactive Oxygen Species</title><p>ROS homeostasis in infected cells has been studied for both RNA and DNA viruses. For
instance, it was shown that infection of mice with influenza A decreased the concentration
of lung glutathione and the antioxidant vitamin C, providing evidence that the viral
infection was associated with oxidative stress <italic>in vitro</italic> as well as
<italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref115">115</xref></sup> Similarly, in HIV infection, induced
oxidative stress in host T cells and high concentrations of antioxidants are able to slow
down the cell-to-cell viral spreading.<sup><xref ref-type="bibr" rid="ref115">115</xref></sup> The increase of ROS
concentration is a common process in most of the viral infections. However, the mechanism
of radical generation is different from case to case. Several proofs suggest that
modulating ROS homeostasis in infected cells can slow down or block the infection.<sup><xref ref-type="bibr" rid="ref116">116</xref></sup></p><p>HNMs have been shown to be powerful allies against viral infections. In particular, metal
or metal oxide NMs, once internalized, can regulate the radical production into infected
host cells. In this scenario, the NMs can work following two different mechanisms: (1)
enhancing radical activity or (2) quenching ROS inside cell compartments. In the first
case, metal oxide NPs are able to convert superoxide ions into more reactive hydroxyl
radical species <italic>via</italic> Fenton or Fenton-like reactions. The excess of
superoxide ions is able to oxidize the viral proteins and the genetic material and
therefore efficiently block the infection. This approach has been reported using ZnO
NPs.<sup><xref ref-type="bibr" rid="ref117">117</xref>,<xref ref-type="bibr" rid="ref118">118</xref></sup> In
these studies, ZnO NPs have been successfully applied for the treatment of H1N1 influenza
virus and Herpes simplex virus. The preliminary results showed that PEGylated ZnO
particles were able to efficiently reduce the viral infection with IC<sub>50</sub> similar
to acyclovir. More importantly, toxicity of ZnO was modulated by functionalization with
PEG, which allowed a higher colloidal stability and a more controlled release of
Zn<sup>2+</sup> ions to catalyze ROS formation. Indeed, ROS
(<italic>e</italic>.<italic>g</italic>., superoxide and hydroxyl radicals) produced by
the NPs should be highly reactive and should not only damage the exogenous biological
molecules but also attack different cell compartments. Overproduction of ROS may reduce
virus spread but also induce cell death. Interestingly, this approach is applicable only
at the early infection stage (after 1 h incubation of the host cells with a virus), but it
loses its activity at later time points. These experimental evidences suggest that
materials capable of triggering the formation of ROS are essential in the first phase of
the viral replication, most probably inducing the arrest of the viral DNA polymerases,
which is active in the first 1&#x02013;3 h of viral contamination.<sup><xref ref-type="bibr" rid="ref117">117</xref>,<xref ref-type="bibr" rid="ref118">118</xref></sup> This specific mechanism of action
restricts ZnO NPs to an application only at the early stage of infections. However, the
same approach with other metals able to induce Fenton or Fenton-like reactions
(<italic>e</italic>.<italic>g</italic>., Fe, Cu, and Mn) has not been reported yet. The
choice of proper capping agents may allow to control the metal ion release and thus tune
the ROS-mediated antiviral activity. We would like to take an advantage here to suggest
the growth of the antiviral research in this direction.</p><p>Another successful approach relies on the reduction of ROS concentration in host cells.
ROS scavenging is able to alleviate the toxicity of the infection enhancing cell
viability, giving time to start its endogenous antiviral mechanisms. So, this approach may
both block infection and ensure host cell survival. In this context, selenium NPs (SeNPs)
have been extensively studied for their antiviral activity. The mechanism of action of
these NPs relies on the quenching of the radicals into host cells due to the infection,
stopping the mitochondria depolarization and the consequent apoptotic cascade.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> Additionally, SeNPs can also adsorb onto the viral capsid sensibly
reducing their infectivity. SeNPs can be prepared <italic>via</italic> classical mixing of
selenium salt precursors in the presence of a reducing agent. More recently, SeNPs have
been instead biosynthesized from <italic>Actinobacteria</italic> showing good stability
and capacity to inhibit Dengue virus <italic>in vitro</italic>.<sup><xref ref-type="bibr" rid="ref120">120</xref></sup>
Moreover, SeNPs were used to carry different antiviral drugs including zanamivir,<sup><xref ref-type="bibr" rid="ref121">121</xref></sup> oseltamivir,<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> amantadine,<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> and
ribavirin.<sup><xref ref-type="bibr" rid="ref119">119</xref></sup> Their functionalization with the desired drug can be
easily achieved adding the molecule during their synthesis through the Se ion controlled
reduction. These NMs have been applied for the treatment of H1N1 virus. Notably, SeNPs
with ribavirin (administered <italic>via</italic> intranasal absorption every 24 h for 3
days) showed that infected mice had much less alveolar collapse and perivascular and
peribronchiolar edema, compared to the group challenged with the virus (<xref rid="fig13" ref-type="fig">Figure <xref rid="fig13" ref-type="fig">13</xref></xref>).<sup><xref ref-type="bibr" rid="ref119">119</xref></sup></p><fig id="fig13" position="float"><label>Figure 13</label><caption><p><italic>In vivo</italic> antiviral efficiency of SeNPs functionalized with ribavirin
(Se@RBV). (a) Mice infected by H1N1 virus were treated with physiological saline
(Mock), RBV, SeNPs, or Se@RBV. (b) H&#x00026;E and tunnel staining showing that
Se@RBV-treated mice displayed reduced lung damages compared to Mock. Reproduced with
permission from ref (<xref ref-type="bibr" rid="ref119">119</xref>). Copyright 2018 Dove
Press Ltd.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0013" id="gr13" position="float"/></fig><p>Due to their efficacy and low toxicity, SeNPs can be considered a useful material for the
treatment of other viral diseases including SARS-Cov-2. As a matter of fact, oxidative
stress as well as chronic inflammation may contribute to the aggravation of the Covid-19
symptoms and to the general spread of the infection.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup> The use of
SeNPs could eventually alleviate the toxicity of infected patients, giving time for the
immune system to react against the contagion. However, the lack of preclinical studies on
SeNPs, together the scarce knowledge of their biosafety and long-term toxicity, still
remain the main challenges to tackle for clinical translation.</p></sec></sec><sec id="sec4"><title>Interaction with the Immune System</title><p>The vast majority of the studies show that human survival to viral attack is based on the
stimulation and response of our immune system. When a virus enters and starts infecting
tissues, the body reacts and triggers a strong immune response to overcome the pathogen
invasion and spread. Normally, two different immunological reactions take place. The
oxidative stress induced by infection causes the activation of the inflammasome through
upregulation of pro-inflammatory cytokines such as IL-1&#x003b2;, pro-IL-18, and NLRP3.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> Excessive upregulation of this mechanism leads to cell damage and
eventually to pyroptosis activated by caspases.<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> It was also shown that
generation of radicals is able to depolarize mitochondria, hence affecting host cell
respiration and inducing ROS-mediated apoptosis at the late stage of infection.<sup><xref ref-type="bibr" rid="ref123">123</xref></sup> Besides, activation of pro-inflammatory cytokines can alert the immune
system blocking the infection (the innate immune response).<sup><xref ref-type="bibr" rid="ref122">122</xref></sup> The second
immune response is specific (the adaptive immune response). Immune cells are trained to
attack the virus (cellular response), while specific antibodies are produced by B cells
(humoral response). In the last years, HNMs were proved to tune the immune responses,
demonstrating to be a possible alternative against viral infection. In this section the most
relevant strategies for the activation of innate and adaptive immune responses using NMs
will be described (<xref rid="fig14" ref-type="fig">Figure <xref rid="fig14" ref-type="fig">14</xref></xref>).</p><fig id="fig14" position="float"><label>Figure 14</label><caption><p>Illustration of HNM interaction with the immune system. Left: HNMs can enhance the
production of interferon (IFN) alerting the immune system of the infection. Right:
Virus-mimicking particles composed of viral proteins and HNMs can induce a strong
immunological response activating dendritic cells, T cells, and stimulating B cells to
produce specific antibodies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0014" id="gr14" position="float"/></fig><sec id="sec4.1"><title>Innate Immune Response</title><p>Innate immune response is the first response that takes place in the presence of any type
of infection. During this early stage, interferon stimulating genes (ISGs) are upregulated
in the infected cells.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> This self-defense mechanism slows down the
viral replication and alerts sentinel immune cells that start producing proinflammatory
cytokines and trigger inflammation.<sup><xref ref-type="bibr" rid="ref125">125</xref></sup> However, many viruses are able
to escape this complex mechanism, retarding the immune response and spreading the
infection. The interaction of HNMs with the immune system has been more and more studied.
In the case of antiviral HNMs, many examples can be found in the literature where the NMs
not only slow down the infection but also tune the innate immune response. Certain HMNs
can display an intrinsic immune stimulation. We have already mentioned above that in the
early stage of infection, AgNPs mainly prevent the virus from entering the host cell
through the interaction with the external capsid, but <italic>in vitro</italic> cellular
experiments lack to understand the complex interaction with primary immune cells. Recent
studies have shown that AgNPs can potentially induce the expression of genes involved in
innate and adaptive immunity-associated pathways, which are known to play crucial role in
immune regulation. For example, Toll-like receptor 7 can be upregulated by AgNPs after 24
h, by recognizing the single-stranded RNA of the viruses and regulating the antiviral
immune response.<sup><xref ref-type="bibr" rid="ref126">126</xref></sup> Another study showed that in RSV-infected mice
treated with AgNPs, the particles reduced the production of pro-inflammatory TNF-&#x003b1;
and IL-6 cytokines, but potentiated the anti-RSV activity of neutrophils in an
experimental mouse model.<sup><xref ref-type="bibr" rid="ref127">127</xref></sup> However, activation of AgNPs in the
reduction of RSV has been noted only when the NM was intranasally inoculated together with
the virus, and no results have been reported on the use of AgNPs administrated on infected
mice. In the case of influenza virus infection of lung epithelial cells, it was found that
AgNPs targeted infected lung epithelial cells and reduced viral replication, by preventing
autophagy. However, the blockage of the autophagic flux by AgNPs does not inhibit viral
replication in already infected cells. Therefore, AgNPs are more suitable as viral
preventive agents due to their pro-inflammatory response rather than drugs.<sup><xref ref-type="bibr" rid="ref128">128</xref></sup> More recently, AgNPs were combined with graphene materials and exploited
as antiviral material for the treatment of Porcine reproductive and respiratory syndrome
virus (PRRSV).<sup><xref ref-type="bibr" rid="ref129">129</xref></sup> GO-AgNPs were able to clump the virus diminishing its
fusion with cell membrane. Additionally, once GO-AgNPs were internalized in host cells,
they stimulated the ISGs that blocked viral budding and its diffusion to other cells
<italic>in vitro</italic> (<xref rid="fig15" ref-type="fig">Figure <xref rid="fig15" ref-type="fig">15</xref></xref>).<sup><xref ref-type="bibr" rid="ref129">129</xref></sup></p><fig id="fig15" position="float"><label>Figure 15</label><caption><p>Scheme of the mechanism of action of GO-AgNPs on activation of innate immunity.
Reproduced with permission from ref (<xref ref-type="bibr" rid="ref129">129</xref>).
Copyright 2018 American Chemistry Society.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0015" id="gr15" position="float"/></fig><p>Similarly, CDs used for the treatment of RSV and PRRSV were able to activate the innate
immune response <italic>via</italic> an upregulation of ISGs <italic>in
vitro</italic>.<sup><xref ref-type="bibr" rid="ref130">130</xref></sup> Gold nanorods were applied to boost the innate
immune response against RSV <italic>in vivo</italic>.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup> Interestingly,
it was shown that these nanorods (when intranasally administered with RSV) were not only
able to activate the ISGs but also to tune the production of pro- and anti-inflammatory
cytokines, resulting in the blocking of the infection with a reduced pulmonary
inflammation.<sup><xref ref-type="bibr" rid="ref131">131</xref></sup> As drug carriers, HNMs can also affect the
internalization pathways, modulate drug efficacy, and the immune cell responses. For
instance, it was found that the isoprinosine immunomodulatory antiviral drug displays a
much higher antiviral efficacy <italic>in vivo</italic> when delivered with CNTs than as a
pure drug (in zebrafish larvae food administration), probably due to a better cellular
uptake and the anti-inflammatory properties of the nanotubes.<sup><xref ref-type="bibr" rid="ref132">132</xref></sup></p><p>Fullerenes also exhibit immunomodulation properties through the release of cytokines by
bovine alveolar macrophages.<sup><xref ref-type="bibr" rid="ref133">133</xref></sup> A study explored the influence of
functionalization of C<sub>60</sub> with molecules presenting different surface charges
like hydroxyl groups and amino acids.<sup><xref ref-type="bibr" rid="ref134">134</xref></sup> The study concluded that
negative charges upregulated TNF-&#x003b1; up-secretion in RAW 264.7 macrophages, but highly
positively or negatively charged surfaces increased cell toxicity. The upregulation of the
cytokine TNF-&#x003b1; is a proof that fullerene can promote cellular immune response.</p><p>Despite these preliminary results, the actual mechanisms of interaction between HNMs and
the immune system are still at early stage of understanding. We must consider that the
immune response needs to be proportional to the infection grade. If on one side nanosized
immuno-boosters can alert more efficiently the sentinel cells, the use of HNMs that
trigger an exaggerated immune response can promote excessive inflammation, damaging
healthy cells and promoting uncontrolled side effects. In the particular context of
SARS-Cov-2, the use of AgNPs, fullerenes, or other pro-inflammatory HNMs at the middle and
late infection stage may cause an aggravation of the symptoms due to already diffused
inflammation. In particular, most of the studies showed the ability to reduce infection
when HNMs were first incubated with the pathogenic virus, thus limiting their potential
use in the early stage infection.<sup><xref ref-type="bibr" rid="ref124">124</xref></sup> The formulation of HNMs able to
both alert the immune system (<italic>e</italic>.<italic>g</italic>., upregulating
cytokine) and control lung inflammation (<italic>e</italic>.<italic>g</italic>., ROS
scavenger) even after the early stage infection may be a possible strategy for treatments
against SARS viruses.</p></sec><sec id="sec4.2"><title>Adaptive Immune Response</title><p>Adaptive immune response is the specific response that the immune system exerts against
pathogens. This mechanism is particularly active toward viral infections where the immune
system produces specialized lymphocytes (to fight the virus), called memory B cells (to be
effective in case of new infections) and antibodies (corresponding to the humoral
response).<sup><xref ref-type="bibr" rid="ref135">135</xref></sup> The stimulation of adaptive responses in case of
specific infections can be induced artificially through the introduction of attenuated
pathogens, stimulating the production of specific antibodies. This is the principle of
vaccination, which is the most common procedure for immunization of large areas of
population against many kinds of lethal viruses.<sup><xref ref-type="bibr" rid="ref135">135</xref></sup> Besides, the use of
viral proteins as antigens in the vaccine formulation leads to neutralizing antibodies,
but, due to the low immunogenicity of isolated proteins, does not always stimulate
sufficiently the immune system to reach total protection. More recently, nanotechnology
has been applied to develop more efficient vaccines
(<italic>e</italic>.<italic>g</italic>., nanovaccines). The use of nanostructures with a
size similar to virus (virus-like nanoparticles) sensibly enhances the response helping to
reach immunity.<sup><xref ref-type="bibr" rid="ref135">135</xref></sup> HNMs can adsorb viral particles and present them to
the immune system.<sup><xref ref-type="bibr" rid="ref136">136</xref>,<xref ref-type="bibr" rid="ref137">137</xref></sup> This method of vaccination has been successfully applied <italic>in
vivo</italic> for the challenge of herpes simplex 2 virus. HSV-2 starts its spreading in
vaginal tissues and then diffuses to the neurons causing death in mice. ZnO NPs (teardrop
morphology), after vaginal inoculation with HSV-2, are able not only to prevent viral cell
adhesion but also to expose viral antigens to T cells and DCs, leading to immunization.
The preclinical trials against HSV-2 showed a survival to infection higher than 90%. This
approach highlights the possibility to couple cell mimicking NMs to other co-adjuvants for
the formulation of large spectrum nanovaccines (<xref rid="fig16" ref-type="fig">Figure <xref rid="fig16" ref-type="fig">16</xref></xref>).<sup><xref ref-type="bibr" rid="ref136">136</xref>,<xref ref-type="bibr" rid="ref137">137</xref></sup></p><fig id="fig16" position="float"><label>Figure 16</label><caption><p>(A) Scanning electron microscopy images of ZnO tetrapod nanoparticles (ZOTEN)
synthesized by flame transport synthesis. (B) Mice were challenged intravaginally with
HSV-2 333 with or without ZOTEN. (C) To monitor progression of infection, mice were
observed daily for the development of lesions around the vaginal opening, and base of
the tail. Representative images from three independent experiments are shown.
Reproduced with permission from ref (<xref ref-type="bibr" rid="ref137">137</xref>).
Copyright 2016 the American Association of Immunologists, Inc.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0016" id="gr16" position="float"/></fig><p>HNMs have been also applied to the delivery of antigens, exposing them to the immune
system. Fullerenes were found as suitable carriers for the delivery of drugs or nucleic
acids.<sup><xref ref-type="bibr" rid="ref138">138</xref></sup> Functionalized fullerene can also self-assemble into
virus-sized NPs.<sup><xref ref-type="bibr" rid="ref139">139</xref></sup> Investigated as vaccines in cancer immune
therapy,<sup><xref ref-type="bibr" rid="ref140">140</xref></sup> polyhydroxy fullerenes (called fullerenols) display
interesting properties for antiviral therapy, based on their capacity to self-assemble
into virus-like particles (VLPs) and so to enhance the immunogenicity of the
antigens.<sup><xref ref-type="bibr" rid="ref141">141</xref></sup> The great advantage of this strategy relies on the easy
encapsulation process during the self-assembly making fullerenols versatile for the
formulation of different kinds of vaccines. These VLPs were investigated against
HIV-1<sup><xref ref-type="bibr" rid="ref141">141</xref></sup> and hepatitis C viruses.<sup><xref ref-type="bibr" rid="ref142">142</xref></sup> Compared to
conventional protein- or peptide-based vaccines intended to induce antigen-specific
adaptive immune responses, DNA vaccines are more stable, cost-effective, easy to
manufacture, and safe in handling.<sup><xref ref-type="bibr" rid="ref143">143</xref></sup> However, DNA vaccines have the
disadvantage of being poorly immunogenic.<sup><xref ref-type="bibr" rid="ref144">144</xref></sup> Fullerenol VLPs allow to
avoid the use of other adjuvants. In the case of a vaccine against HIV-1, fullerenol VLPs
penetrated easily into the cells resulting in an enhancement of DNA transfection. This was
proved in a study using fullerenol encapsulating DNA encoding the HIV-1 envelope protein
gp145 (<xref rid="fig17" ref-type="fig">Figure <xref rid="fig17" ref-type="fig">17</xref></xref>).<sup><xref ref-type="bibr" rid="ref141">141</xref></sup><italic>In vitro</italic> assays were performed in human embryonic kidney cells line
(HEK293) showing good transfection ability. Following various immunization routes
(<italic>e</italic>.<italic>g</italic>., activation of Toll-like receptor signaling or
effector memory T cell immune response), fullerenol VLPs can induce an innate and a
cellular immunity. A similar study was performed for hepatitis C using the HCV recombinant
protein as antigen,<sup><xref ref-type="bibr" rid="ref142">142</xref></sup> confirming the potential efficacy of using
fullerenols as antiviral vaccines. Nevertheless, these results require further mechanistic
investigations. Indeed, <italic>in vitro</italic> studies also evidenced a suppressive
effect of acquired immune response of C<sub>60</sub> pyrrolidine tris-acid and fullerenol
C<sub>60</sub>(OH)<sub>36</sub>.<sup><xref ref-type="bibr" rid="ref145">145</xref></sup> The fullerenol had a
dose-dependent effect on T cell receptor-mediated activation and antibody production by B
cells under anti-CD40/IL-4 stimulation. However, the molecular mechanism is still
unknown.</p><fig id="fig17" position="float"><label>Figure 17</label><caption><p>Use of fullerenol as co-adjuvant for vaccination. (a) The structure of fullerenol,
red balls represent O and white for H on the fullerene surface, and green balls
represent C atoms. (b) The schematic diagram of HIV Env plasmid DNA encapsulated
during the self-assembly of fullerenol. (c) TEM image of Env entrapped by fullerenol.
(d) Compared to naked Env immunization group, IFN-&#x003b3; production (immunospot) was
significantly enhanced when mice were immunized with the formulation
<italic>via</italic> various immunization routes, including intradermal (i.d.),
intramuscular (i.m.), subcutaneous (s.c.), and intranasal (i.n.) injections.
Fullerenol could decrease the antigen dosage (e) and immunization times (f).
Reproduced with permission from ref (<xref ref-type="bibr" rid="ref141">141</xref>).
Copyright 2013 John Wiley &#x00026; Sons, Inc.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0017" id="gr17" position="float"/></fig><p>Other HNMs including AuNPs (two subcutaneous injections in guinea pigs) and nanodiamonds
(three subcutaneous injections in Balb/C mice) were explored as carriers of viral proteins
for immunization of swine transmissible gastroenteritis virus and H7N9 influenza,
respectively, with good preliminary results.<sup><xref ref-type="bibr" rid="ref146">146</xref>,<xref ref-type="bibr" rid="ref147">147</xref></sup> In these cases, the vaccine formulation relies on the
adsorption of the viral antigen onto the surface of the nanoparticles. However, an
effective vaccination depends on several factors. First of all, the size of the NPs plays
a key role on the immune system. For instance, size-dependent vaccination efficacy has
been reported in mice immunization against the foot-and-mouth disease virus
(intraperitoneal and subcutaneous injection, every 7 days for 7 weeks) using AuNPs as
antigen carriers. In this study, the most effective activity to stimulate the immune
system was exerted by particles with a diameter in the range of 8 nm.<sup><xref ref-type="bibr" rid="ref148">148</xref></sup> Both smaller or bigger particles evidenced a drop-off of the immunization effect. This
aspect cannot be ascribed to the antigen concentration, but must be associated only to the
nanoparticle size; however, the mechanism of interaction remains unknown. The selected
antigen plays also a crucial role in the preparation of wide spectrum vaccines. For
instance, in the case of influenza, two major membrane glycoproteins, hemagglutinin and
neuraminidase, are generally used as antigens. However, the antibodies produced by this
vaccination strategy are selective to the dominant epitope which has a low effectiveness
or is totally ineffective against other epitopes or other kinds of influenza viruses. M2
(a viral protein responsible for the budding and scission of the influenza virus) is
commonly expressed in different types of influenza viruses with a high rate of
conservation but with low antigenicity. It has been shown that AuNPs functionalized with
M2e protein have a high immunization capacity in comparison to the antigen alone. Mice
immunized with AuNPs (two intranasal injections), and then challenged, showed a survival
rate higher than 90% to California-H1N1pdm, Victoria-H3N2, and Vietnam-H5N1
infections.<sup><xref ref-type="bibr" rid="ref149">149</xref></sup> This strategy shows that HNMs can be used to boost the
immune response of low immunogenic molecules, providing a wide spectrum vaccination
potential. Unfortunately, it has not been determined if the budding process in SARS-Cov-2
is mediated by viral proteins or <italic>via</italic> the host cell&#x02019;s endosomal
sorting complex, thus more research on the SARS-Cov-2 viral machinery is highly
desirable.</p><p>All these approaches are based on the capacity of the nanoparticles to adsorb the
antigens and expose them to the immune system in the appropriate conformation to produce
the neutralizing and protective antibodies. However, the adsorption is not an easy process
to control. For instance, AuNPs have been ineffective in the immunization against
SARS-Cov, when S viral proteins were used as antigens.<sup><xref ref-type="bibr" rid="ref150">150</xref></sup> In
particular, the immunization with the protein alone was more efficient than when it was
adsorbed onto the AuNP surface. This failure was associated with a conformational change
or denaturation of the antigen, which did not lead to the production of the specific
antibody.<sup><xref ref-type="bibr" rid="ref150">150</xref></sup></p><p>Covalent chemistry strategies offer a higher control on the antigen quantification with
higher reproducibility and possibility to bind different groups onto the surface of HNMs.
For example, calcium phosphate nanoparticles (CaPNPs) were successfully covalently
functionalized with Hen Egg lysozyme as model antigen showing an immunization 100 times
higher <italic>in vivo</italic> compared to antigens alone using (one subdermal injection
in mice).<sup><xref ref-type="bibr" rid="ref151">151</xref></sup> A similar approach was used with iron oxide NPs using
mannose (to target DCs) and hepatitis B antigen showing good immunological activity
<italic>in vitro</italic> (two subdermal injections in mice at 14 days distance).<sup><xref ref-type="bibr" rid="ref152">152</xref></sup> More recently, other types of vaccination strategies have been applied
using HNMs. A smart example has been reported using multifunctional CaPNPs on herpes
virus. In this study, CaPNPs have been covalently functionalized with alum/MPL as the
adjuvant and two peptides as antigens selected <italic>via</italic> reverse vaccination.
The NM stimulated the immune system generating highly efficient antibodies able to block
cell-to-cell infection of herpes virus <italic>in vivo</italic> (three intramuscular
injections in mice every 14 days), increasing the survival rate of immunized mice to 100%
against the controls (20% survival, <xref rid="fig18" ref-type="fig">Figure <xref rid="fig18" ref-type="fig">18</xref></xref>).<sup><xref ref-type="bibr" rid="ref153">153</xref></sup></p><fig id="fig18" position="float"><label>Figure 18</label><caption><p>Scheme of CaPNPs used for vaccine. Left: CaPNPs functionalized with CpG<sup>m</sup>
adjuvant and two different peptides as antigens. Top right: CaPNPs were able to reduce
cell-to-cell virus spread <italic>in vitro</italic>. Bottom right: CaP nanovaccines
were able to immunize mice against HSV-1. Reproduced with permission from ref (<xref ref-type="bibr" rid="ref153">153</xref>). Copyright 2019 Elsevier B.V.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="nn0c04117_0018" id="gr18" position="float"/></fig></sec></sec><sec id="sec5"><title>Summary and Perspectives</title><p>The recent history has shown the spread of different viral pandemics such as H1N1 flu, HIV,
and SARS. Nowadays, the SARS-Cov-2 pandemic global lockdown has profoundly changed the daily
life of most humans, causing uncertainty in short and middle time perspectives. In this
context, the scientific community has responded to protect the population by studying new
vaccines and disinfection methods to be applied in the near future. Despite this tough work,
a SARS-Cov-2 vaccination will hopefully be available in 1&#x02013;2 years, making this
epidemic transient period gloomy with increased instability. The study of more effective
vaccines and the production of a wide range antiviral agents is nowadays an extremely hot
topic.</p><p>HNMs comprise a family of materials that share a nanostructured hard core and a tunable
surface chemistry. In this contribution, we have methodically reviewed different HNMs for
antiviral properties. HNMs can have antiviral properties <italic>per se</italic>, blocking
the viral replication and diffusion, or their antiviral properties can be tailored, playing
with surface chemistry. HNMs can be used to block viral entry and arrest infection at the
early stage. The mechanisms rely on different actions including breaking of capsid disulfide
bonds (<italic>e</italic>.<italic>g</italic>., noble metal nanoparticles), capsid oxidation
(<italic>e</italic>.<italic>g</italic>., CuONPs), mimicking of cell surface
(<italic>e</italic>.<italic>g</italic>., carbon NMs), or mechanical disruption
(<italic>e</italic>.<italic>g</italic>., AuNPs or graphene). Surface functionalization
additionally confers a higher specificity and pharmacological activity toward the targeted
virus. In particular, the high local concentration of ligands on functionalized HNM surface
imparts a high multivalent effect, enhancing the viral trapping efficiency of NMs.
Interestingly, HNMs that show an intrinsic antiviral activity can further enhance their
antiviral efficacy <italic>via</italic> surface functionalization. Some antiviral HNMs are
good photosensitizers (<italic>e</italic>.<italic>g</italic>., CuONPs) or exert photothermal
activity (<italic>e</italic>.<italic>g</italic>., carbon NMs), thus their antiviral activity
can be trigged by light stimulation. More importantly, most of the settled strategies target
common viral entry mechanisms and can be adopted to fight a wide viral spectrum. HNMs have
been also applied as antiviral agents by their interaction with host cells. HNMs are able to
block viral replication machinery in host cells (<italic>e</italic>.<italic>g</italic>.,
CNTs and fullerenes), inhibiting endogenous enzyme activity. Additionally, HNMs can be
explored for the delivery of antiviral molecules, showing a better antiviral activity and
reducing side effects <italic>in vitro</italic> and <italic>in vivo</italic>. Some HNMs can
also regulate the ROS homeostasis of host cells, reduce apoptosis, and enhance host cell
survival during the infection. Finally, we have reviewed the role of HNMs on immunity. In
particular, HNMs can stimulate the innate immune response, mainly inducing overexpression of
interferon and cytokines. This effect can alert sentinel cells and generally warn the immune
system of the infection. HNMs can be also used for the activation of the adaptive immune
response, foreseeing vaccination. Due to the similar size of a virus, functionalized HNMs
with antiviral molecules (virus-like particles) can enhance their immunogenicity.</p><p>Certainly a huge effort should be done for translation of the research into clinics.
Indeed, HNM applications as antivirals are still in the early phase of research. Several
challenges still need to be tackled before their safe use. At the current stage, some HNMs
have been approved only for surface disinfection. For instance, CuNPs have been used in
filters for the preparation of highly efficient broad spectrum antiviral masks.<sup><xref ref-type="bibr" rid="ref50">50</xref></sup> Some HNMs have been already clinically approved. For example, FeNPs were
approved for imaging and as a drug to treat iron deficiency anemia in adult patients with
chronic kidney disease, while AuNPs are in clinical trials for the treatment of prostate
cancer (photothermal therapy).<sup><xref ref-type="bibr" rid="ref154">154</xref>,<xref ref-type="bibr" rid="ref155">155</xref></sup> However, at the moment no clinical trials are running for the use of
HNMs as antiviral agents. In fact, there are still several concerns on the applications of
HNMs in drug formulations. Compared to molecules, where mainly concentration and exposure
routes are concerned, solving HNM toxicity issues is much more complicated. Composition,
size, shape, and surface functionalization must be considered to respond to the requirement
for safety regulations. Additionally, interaction on HNMs with the immune system must be
better elucidated. In particular, the activation of the immune system and complement
activation-related pseudoallergy must be taken into account.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> For
instance, ferumoxytol (a FeNP-based drug) has been reported to generate severe anaphylactic
reactions in humans, 18 of which were fatal.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> This is due to the
possible interaction of HNMs with mast cells, provoking their degranulation/activation and
release of histamine even at the first exposure (pseudoallergic-mediated hypersensitivity).
Besides, the mechanism of activation of these cells is still unknown, although it was found
that it depends on the HNM composition, size, and surface chemistry and on the corona
formation.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> On the other hand, it has been demonstrated that HNMs can
travel to the draining lymph nodes, targeting resident dendritic cells and macrophages.
Therefore, they are able to interact with antigen presenting cells to stimulate innate and
adaptive immune responses.<sup><xref ref-type="bibr" rid="ref156">156</xref></sup> We believe that a joint venture of
different chemists, materials scientists, virologists, toxicologists, and medical doctors
can push forward the preparation and safe application of HNMs in this field, hoping to
prevent and eventually block the rise of new viral pandemics.</p></sec></body><back><notes notes-type="COI-statement" id="NOTES-d7e2259-autogenerated"><p>The authors declare no competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>The authors gratefully acknowledge the financial support from the EU Graphene Flagship
project (no. 881603). This work was partly supported the Agence Nationale de la Recherche
(ANR) through the LabEx project Chemistry of Complex Systems (ANR-10-LABX-0026_CSC). We wish
to acknowledge the Centre National de la Recherche Scientifique (CNRS) and the International
Center for Frontier Research in Chemistry (icFRC). S.P. is indebted to the Chinese
Scholarship Council for supporting her Ph.D. internship as a visiting Ph.D. student. A.F.A.
wish to thanks the EUR CSC Graduate School (Strasbourg, France) for supporting his Master
studies.</p></ack><glossary id="dl1"><def-list><title>Vocabulary</title><def-item><term>Hard nanomaterial</term><def><p>nonpolymeric organic or inorganic materials with sizes comprised between 1 and 100
nm</p></def></def-item><def-item><term>antiviral</term><def><p>medical term used for any agent or drug altering virus integrity or process involved in
viral infection disease</p></def></def-item><def-item><term>viral infection</term><def><p>process by which viruses invade the body through multiple pathways and multiply in
susceptible host cells</p></def></def-item><def-item><term>viral pathogenesis</term><def><p>approach in biomedical research to understand the process by which a viral infection
leads to disease, including mechanism of infection into the host (<italic>e.g.,</italic>
viral entry, viral replication) and factors that affect this mechanism
(<italic>e.g.,</italic> virus susceptibility to host defenses)</p></def></def-item><def-item><term>membranotropism</term><def><p>the ability of an organism or an agent to interact with biological barriers</p></def></def-item><def-item><term>immunogenicity</term><def><p>capacity of an exogenous substance or material to trigger an immune response in humans
and other animals or to induce a humoral and/or cellular immune responses</p></def></def-item><def-item><term>multifunctional platform</term><def><p>material modified with different functionalities to achieve a variety of combined
treatments</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="weblink" id="cit1"><article-title>Statistics and
Facts</article-title>. <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/">https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy/</uri>
(accessed 2020/04/27).</mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>van Doremalen</surname><given-names>N.</given-names></name>; <name><surname>Bushmaker</surname><given-names>T.</given-names></name>; <name><surname>Morris</surname><given-names>D. H.</given-names></name>; <name><surname>Holbrook</surname><given-names>M. G.</given-names></name>; <name><surname>Gamble</surname><given-names>A.</given-names></name>; <name><surname>Williamson</surname><given-names>B. N.</given-names></name>; <name><surname>Tamin</surname><given-names>A.</given-names></name>; <name><surname>Harcourt</surname><given-names>J. L.</given-names></name>; <name><surname>Thornburg</surname><given-names>N. J.</given-names></name>; <name><surname>Gerber</surname><given-names>S. I.</given-names></name>; <name><surname>Lloyd-Smith</surname><given-names>J. O.</given-names></name>; <name><surname>de Wit</surname><given-names>E.</given-names></name>; <name><surname>Munster</surname><given-names>V. J.</given-names></name>
<article-title>Aerosol and Surface Stability of SARS-CoV-2 as Compared with
SARS-CoV-1</article-title>. <source>N. Engl. J. Med.</source>
<year>2020</year>, <volume>382</volume>, <fpage>1564</fpage>&#x02013;<lpage>1567</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMc2004973</pub-id>.<pub-id pub-id-type="pmid">32182409</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Mei</surname><given-names>X.</given-names></name>; <name><surname>Hu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>Y.</given-names></name>; <name><surname>Weng</surname><given-names>X.</given-names></name>; <name><surname>Liang</surname><given-names>R.</given-names></name>; <name><surname>Wei</surname><given-names>M.</given-names></name>
<article-title>Recent Advancements in Two-Dimensional Nanomaterials for Drug
Delivery</article-title>. <source>Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.</source>
<year>2020</year>, <volume>12</volume>, <elocation-id>e1596</elocation-id><pub-id pub-id-type="doi">10.1002/wnan.1596</pub-id>.<pub-id pub-id-type="pmid">31650709</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Makvandi</surname><given-names>P.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Zare</surname><given-names>E. N.</given-names></name>; <name><surname>Borzacchiello</surname><given-names>A.</given-names></name>; <name><surname>Niu</surname><given-names>L.</given-names></name>; <name><surname>Tay</surname><given-names>F. R.</given-names></name>
<article-title>Metal-Based Nanomaterials in Biomedical Applications: Antimicrobial
Activity and Cytotoxicity Aspects</article-title>. <source>Adv. Funct. Mater.</source>
<year>2020</year>, <volume>30</volume>, <fpage>1910021</fpage><pub-id pub-id-type="doi">10.1002/adfm.201910021</pub-id>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Reina</surname><given-names>G.</given-names></name>; <name><surname>Gonz&#x000e1;lez-Dom&#x000ed;nguez</surname><given-names>J. M.</given-names></name>; <name><surname>Criado</surname><given-names>A.</given-names></name>; <name><surname>V&#x000e1;zquez</surname><given-names>E.</given-names></name>; <name><surname>Bianco</surname><given-names>A.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>
<article-title>Promises, Facts and Challenges for Graphene in Biomedical
Applications</article-title>. <source>Chem. Soc. Rev.</source>
<year>2017</year>, <volume>46</volume>, <fpage>4400</fpage>&#x02013;<lpage>4416</lpage>. <pub-id pub-id-type="doi">10.1039/C7CS00363C</pub-id>.<pub-id pub-id-type="pmid">28722038</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Bort</surname><given-names>G.</given-names></name>; <name><surname>Lux</surname><given-names>F.</given-names></name>; <name><surname>Dufort</surname><given-names>S.</given-names></name>; <name><surname>Cr&#x000e9;millieux</surname><given-names>Y.</given-names></name>; <name><surname>Verry</surname><given-names>C.</given-names></name>; <name><surname>Tillement</surname><given-names>O.</given-names></name>
<article-title>EPR-Mediated Tumor Targeting Using Ultrasmall-Hybrid Nanoparticles: From
Animal to Human with Theranostic AGuIX Nanoparticles</article-title>. <source>Theranostics</source>
<year>2020</year>, <volume>10</volume>, <fpage>1319</fpage>&#x02013;<lpage>1331</lpage>. <pub-id pub-id-type="doi">10.7150/thno.37543</pub-id>.<pub-id pub-id-type="pmid">31938067</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Gansukh</surname><given-names>E.</given-names></name>; <name><surname>Anthonydhason</surname><given-names>V.</given-names></name>; <name><surname>Jung</surname><given-names>S.</given-names></name>; <name><surname>Kim</surname><given-names>D. H.</given-names></name>; <name><surname>Muthu</surname><given-names>M.</given-names></name>; <name><surname>Gopal</surname><given-names>J.</given-names></name>; <name><surname>Chun</surname><given-names>S.</given-names></name>
<article-title>Nanotherapeutic Anti-Influenza Solutions: Current Knowledge and Future
Challenges</article-title>. <source>J. Cluster Sci.</source>
<year>2018</year>, <volume>29</volume>, <fpage>933</fpage>&#x02013;<lpage>941</lpage>. <pub-id pub-id-type="doi">10.1007/s10876-018-1417-z</pub-id>.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Rudramurthy</surname><given-names>G. R.</given-names></name>; <name><surname>Swamy</surname><given-names>M. K.</given-names></name>; <name><surname>Sinniah</surname><given-names>U. R.</given-names></name>; <name><surname>Ghasemzadeh</surname><given-names>A.</given-names></name>
<article-title>Nanoparticles: Alternatives against Drug-Resistant Pathogenic
Microbes</article-title>. <source>Molecules</source>
<year>2016</year>, <volume>21</volume>, <fpage>836</fpage><pub-id pub-id-type="doi">10.3390/molecules21070836</pub-id>.</mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Liang</surname><given-names>J.</given-names></name>
<article-title>An Overview of Functional Nanoparticles as Novel Emerging Antiviral
Therapeutic Agents</article-title>. <source>Mater. Sci. Eng., C</source>
<year>2020</year>, <volume>112</volume>, <fpage>110924</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.110924</pub-id>.</mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Barras</surname><given-names>A.</given-names></name>; <name><surname>Pagneux</surname><given-names>Q.</given-names></name>; <name><surname>Sane</surname><given-names>F.</given-names></name>; <name><surname>Wang</surname><given-names>Q.</given-names></name>; <name><surname>Boukherroub</surname><given-names>R.</given-names></name>; <name><surname>Hober</surname><given-names>D.</given-names></name>; <name><surname>Szunerits</surname><given-names>S.</given-names></name>
<article-title>High Efficiency of Functional Carbon Nanodots as Entry Inhibitors of Herpes
Simplex Virus Type 1</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2016</year>, <volume>8</volume>, <fpage>9004</fpage>&#x02013;<lpage>9013</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.6b01681</pub-id>.<pub-id pub-id-type="pmid">27015417</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Elechiguerra</surname><given-names>J. L.</given-names></name>; <name><surname>Burt</surname><given-names>J. L.</given-names></name>; <name><surname>Morones</surname><given-names>J. R.</given-names></name>; <name><surname>Camacho-Bragado</surname><given-names>A.</given-names></name>; <name><surname>Gao</surname><given-names>X.</given-names></name>; <name><surname>Lara</surname><given-names>H. H.</given-names></name>; <name><surname>Yacaman</surname><given-names>M. J.</given-names></name>
<article-title>Interaction of Silver Nanoparticles with HIV-1</article-title>. <source>J. Nanobiotechnol.</source>
<year>2005</year>, <volume>3</volume>, <fpage>6</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-3-6</pub-id>.</mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Khandelwal</surname><given-names>N.</given-names></name>; <name><surname>Kaur</surname><given-names>G.</given-names></name>; <name><surname>Chaubey</surname><given-names>K. K.</given-names></name>; <name><surname>Singh</surname><given-names>P.</given-names></name>; <name><surname>Sharma</surname><given-names>S.</given-names></name>; <name><surname>Tiwari</surname><given-names>A.</given-names></name>; <name><surname>Singh</surname><given-names>S. V.</given-names></name>; <name><surname>Kumar</surname><given-names>N.</given-names></name>
<article-title>Silver Nanoparticles Impair Peste Des Petits Ruminants Virus
Replication</article-title>. <source>Virus Res.</source>
<year>2014</year>, <volume>190</volume>, <fpage>1</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.06.011</pub-id>.<pub-id pub-id-type="pmid">24979044</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Trefry</surname><given-names>J. C.</given-names></name>; <name><surname>Wooley</surname><given-names>D. P.</given-names></name>
<article-title>Silver Nanoparticles Inhibit Vaccinia Virus Infection by Preventing Viral
Entry through a Macropinocytosis-Dependent Mechanism</article-title>. <source>J. Biomed. Nanotechnol.</source>
<year>2013</year>, <volume>9</volume>, <fpage>1624</fpage>&#x02013;<lpage>1635</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2013.1659</pub-id>.<pub-id pub-id-type="pmid">23980510</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Rai</surname><given-names>M.</given-names></name>; <name><surname>Deshmukh</surname><given-names>S. D.</given-names></name>; <name><surname>Ingle</surname><given-names>A. P.</given-names></name>; <name><surname>Gupta</surname><given-names>I. R.</given-names></name>; <name><surname>Galdiero</surname><given-names>M.</given-names></name>; <name><surname>Galdiero</surname><given-names>S.</given-names></name>
<article-title>Metal Nanoparticles: The Protective Nanoshield against Virus
Infection</article-title>. <source>Crit. Rev. Microbiol.</source>
<year>2016</year>, <volume>42</volume>, <fpage>46</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.3109/1040841X.2013.879849</pub-id>.<pub-id pub-id-type="pmid">24754250</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Chen</surname><given-names>N.</given-names></name>; <name><surname>Zheng</surname><given-names>Y.</given-names></name>; <name><surname>Yin</surname><given-names>J.</given-names></name>; <name><surname>Li</surname><given-names>X.</given-names></name>; <name><surname>Zheng</surname><given-names>C.</given-names></name>
<article-title>Inhibitory Effects of Silver Nanoparticles against Adenovirus Type 3
<italic>In Vitro</italic></article-title>. <source>J. Virol. Methods</source>
<year>2013</year>, <volume>193</volume>, <fpage>470</fpage>&#x02013;<lpage>477</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2013.07.020</pub-id>.<pub-id pub-id-type="pmid">23886562</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Lu</surname><given-names>L.</given-names></name>; <name><surname>Sun</surname><given-names>R. W.</given-names></name>; <name><surname>Chen</surname><given-names>R.</given-names></name>; <name><surname>Hui</surname><given-names>C.-K.</given-names></name>; <name><surname>Ho</surname><given-names>C.-M.</given-names></name>; <name><surname>Luk</surname><given-names>J. M.</given-names></name>; <name><surname>Lau</surname><given-names>G. K.</given-names></name>; <name><surname>Che</surname><given-names>C.-M.</given-names></name>
<article-title>Silver Nanoparticles Inhibit Hepatitis B Virus Replication</article-title>. <source>Antivir. Ther.</source>
<year>2008</year>, <volume>13</volume>, <fpage>253</fpage>.<pub-id pub-id-type="pmid">18505176</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Mohammed Fayaz</surname><given-names>A.</given-names></name>; <name><surname>Ao</surname><given-names>Z.</given-names></name>; <name><surname>Girilal</surname><given-names>M.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>Xiao</surname><given-names>X.</given-names></name>; <name><surname>Kalaichelvan</surname><given-names>P.</given-names></name>; <name><surname>Yao</surname><given-names>X.</given-names></name>
<article-title>Inactivation of Microbial Infectiousness by Silver Nanoparticles-Coated
Condom: A New Approach to Inhibit HIV- and HSV-Transmitted Infection</article-title>. <source>Int. J. Nanomed.</source>
<year>2012</year>, <volume>7</volume>, <fpage>5007</fpage>&#x02013;<lpage>5018</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S34973</pub-id>.</mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Lv</surname><given-names>X.</given-names></name>; <name><surname>Wang</surname><given-names>P.</given-names></name>; <name><surname>Bai</surname><given-names>R.</given-names></name>; <name><surname>Cong</surname><given-names>Y.</given-names></name>; <name><surname>Suo</surname><given-names>S.</given-names></name>; <name><surname>Ren</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Inhibitory Effect of Silver Nanomaterials on Transmissible Virus-Induced
Host Cell Infections</article-title>. <source>Biomaterials</source>
<year>2014</year>, <volume>35</volume>, <fpage>4195</fpage>&#x02013;<lpage>4203</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.01.054</pub-id>.<pub-id pub-id-type="pmid">24524838</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Lara</surname><given-names>H. H.</given-names></name>; <name><surname>Ayala-Nu&#x000f1;ez</surname><given-names>N. V.</given-names></name>; <name><surname>Ixtepan-Turrent</surname><given-names>L.</given-names></name>; <name><surname>Rodriguez-Padilla</surname><given-names>C.</given-names></name>
<article-title>Mode of Antiviral Action of Silver Nanoparticles against
HIV-1</article-title>. <source>J. Nanobiotechnol.</source>
<year>2010</year>, <volume>8</volume>, <fpage>1</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-8-1</pub-id>.</mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Gaikwad</surname><given-names>S.</given-names></name>; <name><surname>Ingle</surname><given-names>A.</given-names></name>; <name><surname>Gade</surname><given-names>A.</given-names></name>; <name><surname>Rai</surname><given-names>M.</given-names></name>; <name><surname>Falanga</surname><given-names>A.</given-names></name>; <name><surname>Incoronato</surname><given-names>N.</given-names></name>; <name><surname>Russo</surname><given-names>L.</given-names></name>; <name><surname>Galdiero</surname><given-names>S.</given-names></name>; <name><surname>Galdiero</surname><given-names>M.</given-names></name>
<article-title>Antiviral Activity of Mycosynthesized Silver Nanoparticles against Herpes
Simplex Virus and Human Parainfluenza Virus Type 3</article-title>. <source>Int. J. Nanomed.</source>
<year>2013</year>, <volume>8</volume>, <fpage>4303</fpage>&#x02013;<lpage>4314</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S50070</pub-id>.</mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Xiang</surname><given-names>D.</given-names></name>; <name><surname>Chen</surname><given-names>Q.</given-names></name>; <name><surname>Pang</surname><given-names>L.</given-names></name>; <name><surname>Zheng</surname><given-names>C.</given-names></name>
<article-title>Inhibitory Effects of Silver Nanoparticles on H1N1 Influenza A Virus
<italic>In Vitro</italic></article-title>. <source>J. Virol. Methods</source>
<year>2011</year>, <volume>178</volume>, <fpage>137</fpage>&#x02013;<lpage>142</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2011.09.003</pub-id>.<pub-id pub-id-type="pmid">21945220</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Rogers</surname><given-names>J. V.</given-names></name>; <name><surname>Parkinson</surname><given-names>C. V.</given-names></name>; <name><surname>Choi</surname><given-names>Y. W.</given-names></name>; <name><surname>Speshock</surname><given-names>J. L.</given-names></name>; <name><surname>Hussain</surname><given-names>S. M.</given-names></name>
<article-title>A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox
Virus Plaque Formation</article-title>. <source>Nanoscale Res. Lett.</source>
<year>2008</year>, <volume>3</volume>, <fpage>129</fpage>&#x02013;<lpage>133</lpage>. <pub-id pub-id-type="doi">10.1007/s11671-008-9128-2</pub-id>.</mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Speshock</surname><given-names>J. L.</given-names></name>; <name><surname>Murdock</surname><given-names>R. C.</given-names></name>; <name><surname>Braydich-Stolle</surname><given-names>L. K.</given-names></name>; <name><surname>Schrand</surname><given-names>A. M.</given-names></name>; <name><surname>Hussain</surname><given-names>S. M.</given-names></name>
<article-title>Interaction of Silver Nanoparticles with Tacaribe Virus</article-title>. <source>J. Nanobiotechnol.</source>
<year>2010</year>, <volume>8</volume>, <fpage>19</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-8-19</pub-id>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Huy</surname><given-names>T. Q.</given-names></name>; <name><surname>Hien Thanh</surname><given-names>N. T.</given-names></name>; <name><surname>Thuy</surname><given-names>N. T.</given-names></name>; <name><surname>Van Chung</surname><given-names>P.</given-names></name>; <name><surname>Hung</surname><given-names>P. N.</given-names></name>; <name><surname>Le</surname><given-names>A.-T.</given-names></name>; <name><surname>Hong Hanh</surname><given-names>N. T.</given-names></name>
<article-title>Cytotoxicity and Antiviral Activity of Electrochemical &#x02013; Synthesized
Silver Nanoparticles against Poliovirus</article-title>. <source>J. Virol. Methods</source>
<year>2017</year>, <volume>241</volume>, <fpage>52</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2016.12.015</pub-id>.<pub-id pub-id-type="pmid">28040515</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Sharma</surname><given-names>V. K.</given-names></name>; <name><surname>Siskova</surname><given-names>K. M.</given-names></name>; <name><surname>Zboril</surname><given-names>R.</given-names></name>; <name><surname>Gardea-Torresdey</surname><given-names>J. L.</given-names></name>
<article-title>Organic-Coated Silver Nanoparticles in Biological and Environmental
Conditions: Fate, Stability and Toxicity</article-title>. <source>Adv. Colloid Interface Sci.</source>
<year>2014</year>, <volume>204</volume>, <fpage>15</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.cis.2013.12.002</pub-id>.<pub-id pub-id-type="pmid">24406050</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Sun</surname><given-names>L.</given-names></name>; <name><surname>Singh</surname><given-names>A. K.</given-names></name>; <name><surname>Vig</surname><given-names>K.</given-names></name>; <name><surname>Pillai</surname><given-names>S. R.</given-names></name>; <name><surname>Singh</surname><given-names>S. R.</given-names></name>
<article-title>Silver Nanoparticles Inhibit Replication of Respiratory Syncytial
Virus</article-title>. <source>J. Biomed. Nanotechnol.</source>
<year>2008</year>, <volume>4</volume>, <fpage>149</fpage>&#x02013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2008.012</pub-id>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Hu</surname><given-names>R. L.</given-names></name>; <name><surname>Li</surname><given-names>S. R.</given-names></name>; <name><surname>Kong</surname><given-names>F. J.</given-names></name>; <name><surname>Hou</surname><given-names>R. J.</given-names></name>; <name><surname>Guan</surname><given-names>X. L.</given-names></name>; <name><surname>Guo</surname><given-names>F.</given-names></name>
<article-title>Inhibition Effect of Silver Nanoparticles on Herpes Simplex Virus
2</article-title>. <source>GMR, Genet. Mol. Res.</source>
<year>2014</year>, <volume>13</volume>, <fpage>7022</fpage>&#x02013;<lpage>7028</lpage>. <pub-id pub-id-type="doi">10.4238/2014.March.19.2</pub-id>.<pub-id pub-id-type="pmid">24682984</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>Orlowski</surname><given-names>P.</given-names></name>; <name><surname>Tomaszewska</surname><given-names>E.</given-names></name>; <name><surname>Gniadek</surname><given-names>M.</given-names></name>; <name><surname>Baska</surname><given-names>P.</given-names></name>; <name><surname>Nowakowska</surname><given-names>J.</given-names></name>; <name><surname>Sokolowska</surname><given-names>J.</given-names></name>; <name><surname>Nowak</surname><given-names>Z.</given-names></name>; <name><surname>Donten</surname><given-names>M.</given-names></name>; <name><surname>Celichowski</surname><given-names>G.</given-names></name>; <name><surname>Grobelny</surname><given-names>J.</given-names></name>; <name><surname>Krzyzowska</surname><given-names>M.</given-names></name>
<article-title>Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes
Simplex Virus Type 2 Infection</article-title>. <source>PLoS One</source>
<year>2014</year>, <volume>9</volume>, <elocation-id>e104113</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104113</pub-id>.<pub-id pub-id-type="pmid">25117537</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>Sofy</surname><given-names>A. R.</given-names></name>; <name><surname>Hmed</surname><given-names>A. A.</given-names></name>; <name><surname>Abd El Haliem</surname><given-names>N. F.</given-names></name>; <name><surname>Zein</surname><given-names>M. A.-E.</given-names></name>; <name><surname>Elshaarawy</surname><given-names>R. F. M.</given-names></name>
<article-title>Polyphosphonium-Oligochitosans Decorated with Nanosilver as New Prospective
Inhibitors for Common Human Enteric Viruses</article-title>. <source>Carbohydr. Polym.</source>
<year>2019</year>, <volume>226</volume>, <fpage>115261</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2019.115261</pub-id>.<pub-id pub-id-type="pmid">31582052</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>Baram-Pinto</surname><given-names>D.</given-names></name>; <name><surname>Shukla</surname><given-names>S.</given-names></name>; <name><surname>Perkas</surname><given-names>N.</given-names></name>; <name><surname>Gedanken</surname><given-names>A.</given-names></name>; <name><surname>Sarid</surname><given-names>R.</given-names></name>
<article-title>Inhibition of Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles
Capped with Mercaptoethane Sulfonate</article-title>. <source>Bioconjugate Chem.</source>
<year>2009</year>, <volume>20</volume>, <fpage>1497</fpage>&#x02013;<lpage>1502</lpage>. <pub-id pub-id-type="doi">10.1021/bc900215b</pub-id>.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Obata</surname><given-names>K.</given-names></name>; <name><surname>Kojima</surname><given-names>T.</given-names></name>; <name><surname>Masaki</surname><given-names>T.</given-names></name>; <name><surname>Okabayashi</surname><given-names>T.</given-names></name>; <name><surname>Yokota</surname><given-names>S.</given-names></name>; <name><surname>Hirakawa</surname><given-names>S.</given-names></name>; <name><surname>Nomura</surname><given-names>K.</given-names></name>; <name><surname>Takasawa</surname><given-names>A.</given-names></name>; <name><surname>Murata</surname><given-names>M.</given-names></name>; <name><surname>Tanaka</surname><given-names>S.</given-names></name>; et al. <article-title>Curcumin Prevents Replication of Respiratory Syncytial Virus and the
Epithelial Responses to It in Human Nasal Epithelial Cells</article-title>. <source>PLoS One</source>
<year>2013</year>, <volume>8</volume>, <elocation-id>e70225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0070225</pub-id>.<pub-id pub-id-type="pmid">24058438</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Anand</surname><given-names>P.</given-names></name>; <name><surname>Kunnumakkara</surname><given-names>A. B.</given-names></name>; <name><surname>Newman</surname><given-names>R. A.</given-names></name>; <name><surname>Aggarwal</surname><given-names>B. B.</given-names></name>
<article-title>Bioavailability of Curcumin: Problems and Promises</article-title>. <source>Mol. Pharmaceutics</source>
<year>2007</year>, <volume>4</volume>, <fpage>807</fpage>&#x02013;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1021/mp700113r</pub-id>.</mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Yang</surname><given-names>X. X.</given-names></name>; <name><surname>Li</surname><given-names>C. M.</given-names></name>; <name><surname>Huang</surname><given-names>C. Z.</given-names></name>
<article-title>Curcumin Modified Silver Nanoparticles for Highly Efficient Inhibition of
Respiratory Syncytial Virus Infection</article-title>. <source>Nanoscale</source>
<year>2016</year>, <volume>8</volume>, <fpage>3040</fpage>&#x02013;<lpage>3048</lpage>. <pub-id pub-id-type="doi">10.1039/C5NR07918G</pub-id>.<pub-id pub-id-type="pmid">26781043</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Hua</surname><given-names>L.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Xia</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Silver Nanoparticle Based Codelivery of Oseltamivir to Inhibit the Activity
of the H1N1 Influenza Virus through ROS-Mediated Signaling Pathways</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2016</year>, <volume>8</volume>, <fpage>24385</fpage>&#x02013;<lpage>24393</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.6b06613</pub-id>.<pub-id pub-id-type="pmid">27588566</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Xia</surname><given-names>H.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Reversal of H1N1 Influenza Virus-Induced Apoptosis by Silver Nanoparticles
Functionalized with Amantadine</article-title>. <source>RSC Adv.</source>
<year>2016</year>, <volume>6</volume>, <fpage>89679</fpage>&#x02013;<lpage>89686</lpage>. <pub-id pub-id-type="doi">10.1039/C6RA18493F</pub-id>.</mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>T.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>The Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Silver
Nanoparticles Functionalized with Zanamivir</article-title>. <source>RSC Adv.</source>
<year>2017</year>, <volume>7</volume>, <fpage>742</fpage>&#x02013;<lpage>750</lpage>. <pub-id pub-id-type="doi">10.1039/C6RA25010F</pub-id>.</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>H.</given-names></name>; <name><surname>Deng</surname><given-names>N.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Delivery of VP1 SiRNA to Inhibit the EV71 Virus Using Functionalized Silver
Nanoparticles through ROS-Mediated Signaling Pathways</article-title>. <source>RSC Adv.</source>
<year>2017</year>, <volume>7</volume>, <fpage>1453</fpage>&#x02013;<lpage>1463</lpage>. <pub-id pub-id-type="doi">10.1039/C6RA26472G</pub-id>.</mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Thompson</surname><given-names>C. I.</given-names></name>; <name><surname>Barclay</surname><given-names>W. S.</given-names></name>; <name><surname>Zambon</surname><given-names>M. C.</given-names></name>
<article-title>Changes in <italic>In Vitro</italic> Susceptibility of Influenza A H3N2
Viruses to a Neuraminidase Inhibitor Drug During Evolution in the Human
Host</article-title>. <source>J. Antimicrob. Chemother.</source>
<year>2004</year>, <volume>53</volume>, <fpage>759</fpage>&#x02013;<lpage>765</lpage>. <pub-id pub-id-type="doi">10.1093/jac/dkh155</pub-id>.<pub-id pub-id-type="pmid">15028666</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Kim</surname><given-names>J.</given-names></name>; <name><surname>Yeom</surname><given-names>M.</given-names></name>; <name><surname>Lee</surname><given-names>T.</given-names></name>; <name><surname>Kim</surname><given-names>H.-O.</given-names></name>; <name><surname>Na</surname><given-names>W.</given-names></name>; <name><surname>Kang</surname><given-names>A.</given-names></name>; <name><surname>Lim</surname><given-names>J.-W.</given-names></name>; <name><surname>Park</surname><given-names>G.</given-names></name>; <name><surname>Park</surname><given-names>C.</given-names></name>; <name><surname>Song</surname><given-names>D.</given-names></name>; <name><surname>Haam</surname><given-names>S.</given-names></name>
<article-title>Porous Gold Nanoparticles for Attenuating Infectivity of Influenza A
Virus</article-title>. <source>J. Nanobiotechnol.</source>
<year>2020</year>, <volume>18</volume>, <fpage>54</fpage><pub-id pub-id-type="doi">10.1186/s12951-020-00611-8</pub-id>.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal" id="cit40"><name><surname>Halder</surname><given-names>A.</given-names></name>; <name><surname>Das</surname><given-names>S.</given-names></name>; <name><surname>Ojha</surname><given-names>D.</given-names></name>; <name><surname>Chattopadhyay</surname><given-names>D.</given-names></name>; <name><surname>Mukherjee</surname><given-names>A.</given-names></name>
<article-title>Highly Monodispersed Gold Nanoparticles Synthesis and Inhibition of Herpes
Simplex Virus Infections</article-title>. <source>Mater. Sci. Eng., C</source>
<year>2018</year>, <volume>89</volume>, <fpage>413</fpage>&#x02013;<lpage>421</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2018.04.005</pub-id>.</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal" id="cit41"><name><surname>Skehel</surname><given-names>J. J.</given-names></name>; <name><surname>Wiley</surname><given-names>D. C.</given-names></name>
<article-title>Receptor Binding and Membrane Fusion in Virus Entry: The Influenza
Hemagglutinin</article-title>. <source>Annu. Rev. Biochem.</source>
<year>2000</year>, <volume>69</volume>, <fpage>531</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.biochem.69.1.531</pub-id>.<pub-id pub-id-type="pmid">10966468</pub-id></mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal" id="cit42"><name><surname>Sametband</surname><given-names>M.</given-names></name>; <name><surname>Shukla</surname><given-names>S.</given-names></name>; <name><surname>Meningher</surname><given-names>T.</given-names></name>; <name><surname>Hirsh</surname><given-names>S.</given-names></name>; <name><surname>Mendelson</surname><given-names>E.</given-names></name>; <name><surname>Sarid</surname><given-names>R.</given-names></name>; <name><surname>Gedanken</surname><given-names>A.</given-names></name>; <name><surname>Mandelboim</surname><given-names>M.</given-names></name>
<article-title>Effective Multi-Strain Inhibition of Influenza Virus by Anionic Gold
Nanoparticles</article-title>. <source>MedChemComm</source>
<year>2011</year>, <volume>2</volume>, <fpage>421</fpage>&#x02013;<lpage>423</lpage>. <pub-id pub-id-type="doi">10.1039/c0md00229a</pub-id>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal" id="cit43"><name><surname>El-Gaffary</surname><given-names>M.</given-names></name>; <name><surname>Bashandy</surname><given-names>M.</given-names></name>; <name><surname>Ahmed</surname><given-names>A. R.</given-names></name>; <name><surname>El-Borady</surname><given-names>O. M.</given-names></name>
<article-title>Self-Assembled Gold Nanoparticles for <italic>In Vitro</italic> Inhibition
of Bovine Viral Diarrhea Virus as Surrogate Model for HCV</article-title>. <source>Mater. Res. Express</source>
<year>2019</year>, <volume>6</volume>, <elocation-id>075075</elocation-id><pub-id pub-id-type="doi">10.1088/2053-1591/ab18b6</pub-id>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal" id="cit44"><name><surname>Pe&#x000f1;a-Gonz&#x000e1;lez</surname><given-names>C. E.</given-names></name>; <name><surname>Garc&#x000ed;a-Broncano</surname><given-names>P.</given-names></name>; <name><surname>Ottaviani</surname><given-names>M. F.</given-names></name>; <name><surname>Cangiotti</surname><given-names>M.</given-names></name>; <name><surname>Fattori</surname><given-names>A.</given-names></name>; <name><surname>Hierro-Oliva</surname><given-names>M.</given-names></name>; <name><surname>Gonz&#x000e1;lez-Mart&#x000ed;n</surname><given-names>M. L.</given-names></name>; <name><surname>P&#x000e9;rez-Serrano</surname><given-names>J.</given-names></name>; <name><surname>G&#x000f3;mez</surname><given-names>R.</given-names></name>; <name><surname>Mu&#x000f1;oz-Fern&#x000e1;ndez</surname><given-names>M. &#x000c1;.</given-names></name>; <name><surname>S&#x000e1;nchez-Nieves</surname><given-names>J.</given-names></name>; <name><surname>de la Mata</surname><given-names>F. J.</given-names></name>
<article-title>Dendronized Anionic Gold Nanoparticles: Synthesis, Characterization and
Antiviral Activity</article-title>. <source>Chem. - Eur. J.</source>
<year>2016</year>, <volume>22</volume>, <fpage>2987</fpage>&#x02013;<lpage>2999</lpage>. <pub-id pub-id-type="doi">10.1002/chem.201504262</pub-id>.<pub-id pub-id-type="pmid">26875938</pub-id></mixed-citation></ref><ref id="ref45"><mixed-citation publication-type="journal" id="cit45"><name><surname>Papp</surname><given-names>I.</given-names></name>; <name><surname>Sieben</surname><given-names>C.</given-names></name>; <name><surname>Ludwig</surname><given-names>K.</given-names></name>; <name><surname>Roskamp</surname><given-names>M.</given-names></name>; <name><surname>B&#x000f6;ttcher</surname><given-names>C.</given-names></name>; <name><surname>Schlecht</surname><given-names>S.</given-names></name>; <name><surname>Herrmann</surname><given-names>A.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Inhibition of Influenza Virus Infection by Multivalent Sialic-Acid-
Functionalized Gold Nanoparticles</article-title>. <source>Small</source>
<year>2010</year>, <volume>6</volume>, <fpage>2900</fpage>&#x02013;<lpage>2906</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201001349</pub-id>.<pub-id pub-id-type="pmid">21104827</pub-id></mixed-citation></ref><ref id="ref46"><mixed-citation publication-type="journal" id="cit46"><name><surname>Bowman</surname><given-names>M. C.</given-names></name>; <name><surname>Ballard</surname><given-names>T. E.</given-names></name>; <name><surname>Ackerson</surname><given-names>C. J.</given-names></name>; <name><surname>Feldheim</surname><given-names>D. L.</given-names></name>; <name><surname>Margolis</surname><given-names>D. M.</given-names></name>; <name><surname>Melander</surname><given-names>C.</given-names></name>
<article-title>Inhibition of HIV Fusion with Multivalent Gold
Nanoparticles</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2008</year>, <volume>130</volume>, <fpage>6896</fpage>&#x02013;<lpage>6897</lpage>. <pub-id pub-id-type="doi">10.1021/ja710321g</pub-id>.<pub-id pub-id-type="pmid">18473457</pub-id></mixed-citation></ref><ref id="ref47"><mixed-citation publication-type="journal" id="cit47"><name><surname>Bastian</surname><given-names>A. R.</given-names></name>; <name><surname>Ang</surname><given-names>C. G.</given-names></name>; <name><surname>Kamanna</surname><given-names>K.</given-names></name>; <name><surname>Shaheen</surname><given-names>F.</given-names></name>; <name><surname>Huang</surname><given-names>Y. H.</given-names></name>; <name><surname>McFadden</surname><given-names>K.</given-names></name>; <name><surname>Duffy</surname><given-names>C.</given-names></name>; <name><surname>Bailey</surname><given-names>L. D.</given-names></name>; <name><surname>Sundaram</surname><given-names>R. V. K.</given-names></name>; <name><surname>Chaiken</surname><given-names>I.</given-names></name>
<article-title>Targeting Cell Surface HIV-1 Env Protein to Suppress Infectious Virus
Formation</article-title>. <source>Virus Res.</source>
<year>2017</year>, <volume>235</volume>, <fpage>33</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2017.04.003</pub-id>.<pub-id pub-id-type="pmid">28390972</pub-id></mixed-citation></ref><ref id="ref48"><mixed-citation publication-type="journal" id="cit48"><name><surname>Huang</surname><given-names>X.</given-names></name>; <name><surname>Li</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>J.</given-names></name>; <name><surname>Meng</surname><given-names>X.</given-names></name>; <name><surname>An</surname><given-names>X.</given-names></name>; <name><surname>Sun</surname><given-names>L.</given-names></name>; <name><surname>Guo</surname><given-names>L.</given-names></name>; <name><surname>Shan</surname><given-names>X.</given-names></name>; <name><surname>Ge</surname><given-names>J.</given-names></name>; <name><surname>Chen</surname><given-names>J.</given-names></name>; <name><surname>Luo</surname><given-names>Y.</given-names></name>; <name><surname>Wu</surname><given-names>H.</given-names></name>; <name><surname>Zhang</surname><given-names>Y.</given-names></name>; <name><surname>Jiang</surname><given-names>Q.</given-names></name>; <name><surname>Ning</surname><given-names>X.</given-names></name>
<article-title>Novel Gold Nanorod-Based HR1 Peptide Inhibitor for Middle East Respiratory
Syndrome Coronavirus</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2019</year>, <volume>11</volume>, <fpage>19799</fpage>&#x02013;<lpage>19807</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.9b04240</pub-id>.<pub-id pub-id-type="pmid">31099550</pub-id></mixed-citation></ref><ref id="ref49"><mixed-citation publication-type="journal" id="cit49"><name><surname>Noyce</surname><given-names>J. O.</given-names></name>; <name><surname>Michels</surname><given-names>H.</given-names></name>; <name><surname>Keevil</surname><given-names>C. W.</given-names></name>
<article-title>Inactivation of Influenza A Virus on Copper <italic>Versus</italic>
Stainless Steel Surfaces</article-title>. <source>Appl. Environ. Microbiol.</source>
<year>2007</year>, <volume>73</volume>, <fpage>2748</fpage>&#x02013;<lpage>2750</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.01139-06</pub-id>.<pub-id pub-id-type="pmid">17259354</pub-id></mixed-citation></ref><ref id="ref50"><mixed-citation publication-type="journal" id="cit50"><name><surname>Borkow</surname><given-names>G.</given-names></name>; <name><surname>Zhou</surname><given-names>S. S.</given-names></name>; <name><surname>Page</surname><given-names>T.</given-names></name>; <name><surname>Gabbay</surname><given-names>J.</given-names></name>
<article-title>A Novel Anti-Influenza Copper Oxide Containing Respiratory Face
Mask</article-title>. <source>PLoS One</source>
<year>2010</year>, <volume>5</volume>, <elocation-id>e11295</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0011295</pub-id>.<pub-id pub-id-type="pmid">20592763</pub-id></mixed-citation></ref><ref id="ref51"><mixed-citation publication-type="journal" id="cit51"><name><surname>Horie</surname><given-names>M.</given-names></name>; <name><surname>Ogawa</surname><given-names>H.</given-names></name>; <name><surname>Yoshida</surname><given-names>Y.</given-names></name>; <name><surname>Yamada</surname><given-names>K.</given-names></name>; <name><surname>Hara</surname><given-names>A.</given-names></name>; <name><surname>Ozawa</surname><given-names>K.</given-names></name>; <name><surname>Matsuda</surname><given-names>S.</given-names></name>; <name><surname>Mizota</surname><given-names>C.</given-names></name>; <name><surname>Tani</surname><given-names>M.</given-names></name>; <name><surname>Yamamoto</surname><given-names>Y.</given-names></name>; <name><surname>Yamada</surname><given-names>M.</given-names></name>; <name><surname>Nakamura</surname><given-names>K.</given-names></name>; <name><surname>Imai</surname><given-names>K.</given-names></name>
<article-title>Inactivation and Morphological Changes of Avian Influenza Virus by Copper
Ions</article-title>. <source>Arch. Virol.</source>
<year>2008</year>, <volume>153</volume>, <fpage>1467</fpage>&#x02013;<lpage>1472</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-008-0154-2</pub-id>.<pub-id pub-id-type="pmid">18592130</pub-id></mixed-citation></ref><ref id="ref52"><mixed-citation publication-type="journal" id="cit52"><name><surname>Betanzos-Cabrera</surname><given-names>G.</given-names></name>; <name><surname>Ram&#x000ed;rez</surname><given-names>F. J.</given-names></name>; <name><surname>Mu&#x000f1;oz</surname><given-names>J. L.</given-names></name>; <name><surname>Barr&#x000f3;n</surname><given-names>B. L.</given-names></name>; <name><surname>Maldonado</surname><given-names>R.</given-names></name>
<article-title>Inactivation of HSV-2 by Ascorbate-Cu(II) and Its Protecting Evaluation in
CF-1 Mice against Encephalitis</article-title>. <source>J. Virol. Methods</source>
<year>2004</year>, <volume>120</volume>, <fpage>161</fpage>&#x02013;<lpage>165</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2004.05.003</pub-id>.<pub-id pub-id-type="pmid">15288958</pub-id></mixed-citation></ref><ref id="ref53"><mixed-citation publication-type="journal" id="cit53"><name><surname>Sagripanti</surname><given-names>J. L.</given-names></name>; <name><surname>Routson</surname><given-names>L. B.</given-names></name>; <name><surname>Bonifacino</surname><given-names>A. C.</given-names></name>; <name><surname>Lytle</surname><given-names>C. D.</given-names></name>
<article-title>Mechanism of Copper-Mediated Inactivation of Herpes Simplex
Virus</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>1997</year>, <volume>41</volume>, <fpage>812</fpage>&#x02013;<lpage>817</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.41.4.812</pub-id>.<pub-id pub-id-type="pmid">9087495</pub-id></mixed-citation></ref><ref id="ref54"><mixed-citation publication-type="journal" id="cit54"><name><surname>White</surname><given-names>L. A.</given-names></name>; <name><surname>Freeman</surname><given-names>C. Y.</given-names></name>; <name><surname>Forrester</surname><given-names>B. D.</given-names></name>; <name><surname>Chappell</surname><given-names>W. A.</given-names></name>
<article-title><italic>In Vitro</italic> Effect of Ascorbic Acid on Infectivity of
Herpesviruses and Paramyxoviruses</article-title>. <source>J. Clin. Microbiol.</source>
<year>1986</year>, <volume>24</volume>, <fpage>527</fpage>&#x02013;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.24.4.527-531.1986</pub-id>.<pub-id pub-id-type="pmid">3021808</pub-id></mixed-citation></ref><ref id="ref55"><mixed-citation publication-type="journal" id="cit55"><name><surname>Abad</surname><given-names>F. X.</given-names></name>; <name><surname>Pinto</surname><given-names>R. M.</given-names></name>; <name><surname>Diez</surname><given-names>J. M.</given-names></name>; <name><surname>Bosch</surname><given-names>A.</given-names></name>
<article-title>Disinfection of Human Enteric Viruses in Water by Copper and Silver in
Combination with Low Levels of Chlorine</article-title>. <source>Appl. Environ. Microbiol.</source>
<year>1994</year>, <volume>60</volume>, <fpage>2377</fpage>&#x02013;<lpage>2383</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.60.7.2377-2383.1994</pub-id>.<pub-id pub-id-type="pmid">8074518</pub-id></mixed-citation></ref><ref id="ref56"><mixed-citation publication-type="journal" id="cit56"><name><surname>Shionoiri</surname><given-names>N.</given-names></name>; <name><surname>Sato</surname><given-names>T.</given-names></name>; <name><surname>Fujimori</surname><given-names>Y.</given-names></name>; <name><surname>Nakayama</surname><given-names>T.</given-names></name>; <name><surname>Nemoto</surname><given-names>M.</given-names></name>; <name><surname>Matsunaga</surname><given-names>T.</given-names></name>; <name><surname>Tanaka</surname><given-names>T.</given-names></name>
<article-title>Investigation of the Antiviral Properties of Copper Iodide Nanoparticles
against Feline Calicivirus</article-title>. <source>J. Biosci. Bioeng.</source>
<year>2012</year>, <volume>113</volume>, <fpage>580</fpage>&#x02013;<lpage>586</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiosc.2011.12.006</pub-id>.<pub-id pub-id-type="pmid">22227118</pub-id></mixed-citation></ref><ref id="ref57"><mixed-citation publication-type="journal" id="cit57"><name><surname>Fujimori</surname><given-names>Y.</given-names></name>; <name><surname>Sato</surname><given-names>T.</given-names></name>; <name><surname>Hayata</surname><given-names>T.</given-names></name>; <name><surname>Nagao</surname><given-names>T.</given-names></name>; <name><surname>Nakayama</surname><given-names>M.</given-names></name>; <name><surname>Nakayama</surname><given-names>T.</given-names></name>; <name><surname>Sugamata</surname><given-names>R.</given-names></name>; <name><surname>Suzuki</surname><given-names>K.</given-names></name>
<article-title>Novel Antiviral Characteristics of Nanosized Copper(i) Iodide Particles
Showing Inactivation Activity against 2009 Pandemic H1N1 Influenza Virus</article-title>. <source>Appl. Environ. Microbiol.</source>
<year>2012</year>, <volume>78</volume> (<issue>78</issue>), <fpage>951</fpage>&#x02013;<lpage>955</lpage>. <pub-id pub-id-type="doi">10.1128/AEM.06284-11</pub-id>.<pub-id pub-id-type="pmid">22156433</pub-id></mixed-citation></ref><ref id="ref58"><mixed-citation publication-type="journal" id="cit58"><name><surname>Hang</surname><given-names>X.</given-names></name>; <name><surname>Peng</surname><given-names>H.</given-names></name>; <name><surname>Song</surname><given-names>H.</given-names></name>; <name><surname>Qi</surname><given-names>Z.</given-names></name>; <name><surname>Miao</surname><given-names>X.</given-names></name>; <name><surname>Xu</surname><given-names>W.</given-names></name>
<article-title>Antiviral Activity of Cuprous Oxide Nanoparticles against Hepatitis C Virus
<italic>In Vitro</italic></article-title>. <source>J. Virol. Methods</source>
<year>2015</year>, <volume>222</volume>, <fpage>150</fpage>&#x02013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.jviromet.2015.06.010</pub-id>.<pub-id pub-id-type="pmid">26116793</pub-id></mixed-citation></ref><ref id="ref59"><mixed-citation publication-type="journal" id="cit59"><name><surname>Tavakoli</surname><given-names>A.</given-names></name>; <name><surname>Hashemzadeh</surname><given-names>M. S.</given-names></name>
<article-title>Inhibition of Herpes Simplex Virus Type 1 by Copper Oxide
Nanoparticles</article-title>. <source>J. Virol. Methods</source>
<year>2020</year>, <volume>275</volume>, <fpage>113688</fpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2019.113688</pub-id>.<pub-id pub-id-type="pmid">31271792</pub-id></mixed-citation></ref><ref id="ref60"><mixed-citation publication-type="journal" id="cit60"><name><surname>Sharquie</surname><given-names>K. E.</given-names></name>; <name><surname>Khorsheed</surname><given-names>A. A.</given-names></name>; <name><surname>Al-Nuaimy</surname><given-names>A. A.</given-names></name>
<article-title>Topical Zinc Sulphate Solution for Treatment of Viral Warts</article-title>. <source>Saudi Med. J.</source>
<year>2007</year>, <volume>28</volume>, <fpage>1418</fpage>&#x02013;<lpage>1421</lpage>.<pub-id pub-id-type="pmid">17768472</pub-id></mixed-citation></ref><ref id="ref61"><mixed-citation publication-type="journal" id="cit61"><name><surname>Khattar</surname><given-names>J. A.</given-names></name>; <name><surname>Musharrafieh</surname><given-names>U. M.</given-names></name>; <name><surname>Tamim</surname><given-names>H.</given-names></name>; <name><surname>Hamadeh</surname><given-names>G. N.</given-names></name>
<article-title>Topical Zinc Oxide <italic>vs.</italic> Salicylic Acid-Lactic Acid
Combination in the Treatment of Warts</article-title>. <source>Int. J. Dermatol.</source>
<year>2007</year>, <volume>46</volume>, <fpage>427</fpage>&#x02013;<lpage>430</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-4632.2006.03138.x</pub-id>.<pub-id pub-id-type="pmid">17442091</pub-id></mixed-citation></ref><ref id="ref62"><mixed-citation publication-type="journal" id="cit62"><name><surname>Antoine</surname><given-names>T. E.</given-names></name>; <name><surname>Mishra</surname><given-names>Y. K.</given-names></name>; <name><surname>Trigilio</surname><given-names>J.</given-names></name>; <name><surname>Tiwari</surname><given-names>V.</given-names></name>; <name><surname>Adelung</surname><given-names>R.</given-names></name>; <name><surname>Shukla</surname><given-names>D.</given-names></name>
<article-title>Prophylactic, Therapeutic and Neutralizing Effects of Zinc Oxide Tetrapod
Structures against Herpes Simplex Virus Type-2 Infection</article-title>. <source>Antiviral Res.</source>
<year>2012</year>, <volume>96</volume>, <fpage>363</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2012.09.020</pub-id>.<pub-id pub-id-type="pmid">23047013</pub-id></mixed-citation></ref><ref id="ref63"><mixed-citation publication-type="journal" id="cit63"><name><surname>Kotelnikova</surname><given-names>R. A.</given-names></name>; <name><surname>Bogdanov</surname><given-names>G. N.</given-names></name>; <name><surname>Frog</surname><given-names>E. C.</given-names></name>; <name><surname>Kotelnikov</surname><given-names>A. I.</given-names></name>; <name><surname>Shtolko</surname><given-names>V. N.</given-names></name>; <name><surname>Romanova</surname><given-names>V. S.</given-names></name>; <name><surname>Andreev</surname><given-names>S. M.</given-names></name>; <name><surname>Kushch</surname><given-names>A. A.</given-names></name>; <name><surname>Fedorova</surname><given-names>N. E.</given-names></name>; <name><surname>Medzhidova</surname><given-names>A. A.</given-names></name>; <name><surname>Miller</surname><given-names>G. G.</given-names></name>
<article-title>Nanobionics of Pharmacologically Active Derivatives of Fullerene C
60</article-title>. <source>J. Nanopart. Res.</source>
<year>2003</year>, <volume>5</volume>, <fpage>561</fpage>&#x02013;<lpage>566</lpage>. <pub-id pub-id-type="doi">10.1023/B:NANO.0000006070.61144.93</pub-id>.</mixed-citation></ref><ref id="ref64"><mixed-citation publication-type="journal" id="cit64"><name><surname>Bunney</surname><given-names>P. E.</given-names></name>; <name><surname>Zink</surname><given-names>A. N.</given-names></name>; <name><surname>Holm</surname><given-names>A. A.</given-names></name>; <name><surname>Billington</surname><given-names>C. J.</given-names></name>; <name><surname>Kotz</surname><given-names>C. M.</given-names></name>
<article-title>Orexin Activation Counteracts Decreases in Nonexercise Activity
Thermogenesis (NEAT) Caused by High-Fat Diet</article-title>. <source>Physiol. Behav.</source>
<year>2017</year>, <volume>176</volume>, <fpage>139</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.physbeh.2017.03.040</pub-id>.<pub-id pub-id-type="pmid">28363838</pub-id></mixed-citation></ref><ref id="ref65"><mixed-citation publication-type="journal" id="cit65"><name><surname>Goodarzi</surname><given-names>S.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Conde</surname><given-names>J.</given-names></name>; <name><surname>Sefat</surname><given-names>F.</given-names></name>; <name><surname>Mozafari</surname><given-names>M.</given-names></name>
<article-title>Fullerene: Biomedical Engineers Get to Revisit an Old
Friend</article-title>. <source>Mater. Today</source>
<year>2017</year>, <volume>20</volume>, <fpage>460</fpage>&#x02013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.mattod.2017.03.017</pub-id>.</mixed-citation></ref><ref id="ref66"><mixed-citation publication-type="journal" id="cit66"><name><surname>Luczkowiak</surname><given-names>J.</given-names></name>; <name><surname>Mu&#x000f1;oz</surname><given-names>A.</given-names></name>; <name><surname>S&#x000e1;nchez-Navarro</surname><given-names>M.</given-names></name>; <name><surname>Ribeiro-Viana</surname><given-names>R.</given-names></name>; <name><surname>Ginieis</surname><given-names>A.</given-names></name>; <name><surname>Illescas</surname><given-names>B. M.</given-names></name>; <name><surname>Mart&#x000ed;n</surname><given-names>N.</given-names></name>; <name><surname>Delgado</surname><given-names>R.</given-names></name>; <name><surname>Rojo</surname><given-names>J.</given-names></name>
<article-title>Glycofullerenes Inhibit Viral Infection</article-title>. <source>Biomacromolecules</source>
<year>2013</year>, <volume>14</volume>, <fpage>431</fpage>&#x02013;<lpage>437</lpage>. <pub-id pub-id-type="doi">10.1021/bm3016658</pub-id>.<pub-id pub-id-type="pmid">23281578</pub-id></mixed-citation></ref><ref id="ref67"><mixed-citation publication-type="journal" id="cit67"><name><surname>Di Gianvincenzo</surname><given-names>P.</given-names></name>; <name><surname>Chiodo</surname><given-names>F.</given-names></name>; <name><surname>Marradi</surname><given-names>M.</given-names></name>; <name><surname>Penad&#x000e9;s</surname><given-names>S.</given-names></name>
<article-title>Gold Manno-Glyconanoparticles for Intervening in HIV Gp120
Carbohydrate-Mediated Processes</article-title>. <source>Methods Enzymol.</source>
<year>2012</year>, <volume>509</volume>, <fpage>21</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-391858-1.00002-2</pub-id>.<pub-id pub-id-type="pmid">22568899</pub-id></mixed-citation></ref><ref id="ref68"><mixed-citation publication-type="journal" id="cit68"><name><surname>Nierengarten</surname><given-names>I.</given-names></name>; <name><surname>Nierengarten</surname><given-names>J. F.</given-names></name>
<article-title>Fullerene Sugar Balls: A New Class of Biologically Active
Fullerene</article-title>. <source>Chem. - Asian J.</source>
<year>2014</year>, <volume>9</volume>, <fpage>1436</fpage>&#x02013;<lpage>1444</lpage>. <pub-id pub-id-type="doi">10.1002/asia.201400133</pub-id>.<pub-id pub-id-type="pmid">24678063</pub-id></mixed-citation></ref><ref id="ref69"><mixed-citation publication-type="journal" id="cit69"><name><surname>Mu&#x000f1;oz</surname><given-names>A.</given-names></name>; <name><surname>Sigwalt</surname><given-names>D.</given-names></name>; <name><surname>Illescas</surname><given-names>B. M.</given-names></name>; <name><surname>Luczkowiak</surname><given-names>J.</given-names></name>; <name><surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname><given-names>L.</given-names></name>; <name><surname>Nierengarten</surname><given-names>I.</given-names></name>; <name><surname>Holler</surname><given-names>M.</given-names></name>; <name><surname>Remy</surname><given-names>J. S.</given-names></name>; <name><surname>Buffet</surname><given-names>K.</given-names></name>; <name><surname>Vincent</surname><given-names>S. P.</given-names></name>; <name><surname>Rojo</surname><given-names>J.</given-names></name>; <name><surname>Delgado</surname><given-names>R.</given-names></name>; <name><surname>Nierengarten</surname><given-names>J. F.</given-names></name>; <name><surname>Mart&#x000ed;n</surname><given-names>N.</given-names></name>
<article-title>Synthesis of Giant Globular Multivalent Glycofullerenes as Potent
Inhibitors in a Model of Ebola Virus Infection</article-title>. <source>Nat. Chem.</source>
<year>2016</year>, <volume>8</volume>, <fpage>50</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nchem.2387</pub-id>.<pub-id pub-id-type="pmid">27055288</pub-id></mixed-citation></ref><ref id="ref70"><mixed-citation publication-type="journal" id="cit70"><name><surname>Ramos-Soriano</surname><given-names>J.</given-names></name>; <name><surname>Reina</surname><given-names>J. J.</given-names></name>; <name><surname>Illescas</surname><given-names>B. M.</given-names></name>; <name><surname>De La Cruz</surname><given-names>N.</given-names></name>; <name><surname>Rodr&#x000ed;guez-P&#x000e9;rez</surname><given-names>L.</given-names></name>; <name><surname>Lasala</surname><given-names>F.</given-names></name>; <name><surname>Rojo</surname><given-names>J.</given-names></name>; <name><surname>Delgado</surname><given-names>R.</given-names></name>; <name><surname>Mart&#x000ed;n</surname><given-names>N.</given-names></name>
<article-title>Synthesis of Highly Efficient Multivalent Disaccharide/[60]Fullerene
Nanoballs for Emergent Viruses</article-title>. <source>J. Am. Chem. Soc.</source>
<year>2019</year>, <volume>141</volume>, <fpage>15403</fpage>&#x02013;<lpage>15412</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b08003</pub-id>.<pub-id pub-id-type="pmid">31469952</pub-id></mixed-citation></ref><ref id="ref71"><mixed-citation publication-type="journal" id="cit71"><name><surname>Feinberg</surname><given-names>H.</given-names></name>; <name><surname>Castelli</surname><given-names>R.</given-names></name>; <name><surname>Drickamer</surname><given-names>K.</given-names></name>; <name><surname>Seeberger</surname><given-names>P. H.</given-names></name>; <name><surname>Weis</surname><given-names>W. I.</given-names></name>
<article-title>Multiple Modes of Binding Enhance the Affinity of DC-SIGN for High Mannose
N-Linked Glycans Found on Viral Glycoproteins</article-title>. <source>J. Biol. Chem.</source>
<year>2006</year>, <volume>282</volume>, <fpage>4202</fpage>&#x02013;<lpage>4209</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M609689200</pub-id>.<pub-id pub-id-type="pmid">17150970</pub-id></mixed-citation></ref><ref id="ref72"><mixed-citation publication-type="journal" id="cit72"><name><surname>Mu&#x000f1;oz</surname><given-names>A.</given-names></name>; <name><surname>Illescas</surname><given-names>B. M.</given-names></name>; <name><surname>Luczkowiak</surname><given-names>J.</given-names></name>; <name><surname>Lasala</surname><given-names>F.</given-names></name>; <name><surname>Ribeiro-Viana</surname><given-names>R.</given-names></name>; <name><surname>Rojo</surname><given-names>J.</given-names></name>; <name><surname>Delgado</surname><given-names>R.</given-names></name>; <name><surname>Mart&#x000ed;n</surname><given-names>N.</given-names></name>
<article-title>Antiviral Activity of Self-Assembled Glycodendro[60]Fullerene
Monoadducts</article-title>. <source>J. Mater. Chem. B</source>
<year>2017</year>, <volume>5</volume>, <fpage>6566</fpage>&#x02013;<lpage>6571</lpage>. <pub-id pub-id-type="doi">10.1039/C7TB01379E</pub-id>.<pub-id pub-id-type="pmid">32264418</pub-id></mixed-citation></ref><ref id="ref73"><mixed-citation publication-type="journal" id="cit73"><name><surname>Li</surname><given-names>S. R.</given-names></name>; <name><surname>Tang</surname><given-names>Z. J.</given-names></name>; <name><surname>Li</surname><given-names>Z. H.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>
<article-title>Searching Therapeutic Strategy of New Coronavirus Pneumonia from
Angiotensin-Converting Enzyme 2: The Target of COVID-19 and SARS-CoV</article-title>. <source>Eur. J. Clin. Microbiol. Infect. Dis.</source>
<year>2020</year>, <volume>39</volume>, <fpage>1021</fpage><pub-id pub-id-type="doi">10.1007/s10096-020-03883-y</pub-id>.<pub-id pub-id-type="pmid">32285293</pub-id></mixed-citation></ref><ref id="ref74"><mixed-citation publication-type="journal" id="cit74"><name><surname>Fahmi</surname><given-names>M. Z.</given-names></name>; <name><surname>Sukmayani</surname><given-names>W.</given-names></name>; <name><surname>Khairunisa</surname><given-names>S. Q.</given-names></name>; <name><surname>Witaningrum</surname><given-names>A. M.</given-names></name>; <name><surname>Indriati</surname><given-names>D. W.</given-names></name>; <name><surname>Matondang</surname><given-names>M. Q. Y.</given-names></name>; <name><surname>Chang</surname><given-names>J. Y.</given-names></name>; <name><surname>Kotaki</surname><given-names>T.</given-names></name>; <name><surname>Kameoka</surname><given-names>M.</given-names></name>
<article-title>Design of Boronic Acid-Attributed Carbon Dots on Inhibits HIV-1
Entry</article-title>. <source>RSC Adv.</source>
<year>2016</year>, <volume>6</volume>, <fpage>92996</fpage>&#x02013;<lpage>93002</lpage>. <pub-id pub-id-type="doi">10.1039/C6RA21062G</pub-id>.</mixed-citation></ref><ref id="ref75"><mixed-citation publication-type="journal" id="cit75"><name><surname>Tong</surname><given-names>T.</given-names></name>; <name><surname>Hu</surname><given-names>H.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Deng</surname><given-names>S.</given-names></name>; <name><surname>Zhang</surname><given-names>X.</given-names></name>; <name><surname>Tang</surname><given-names>W.</given-names></name>; <name><surname>Fang</surname><given-names>L.</given-names></name>; <name><surname>Xiao</surname><given-names>S.</given-names></name>; <name><surname>Liang</surname><given-names>J.</given-names></name>
<article-title>Glycyrrhizic-Acid-Based Carbon Dots with High Antiviral Activity by
Multisite Inhibition Mechanisms</article-title>. <source>Small</source>
<year>2020</year>, <volume>16</volume>, <fpage>1906206</fpage><pub-id pub-id-type="doi">10.1002/smll.201906206</pub-id>.</mixed-citation></ref><ref id="ref76"><mixed-citation publication-type="journal" id="cit76"><name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Gu</surname><given-names>J.</given-names></name>; <name><surname>Ye</surname><given-names>J.</given-names></name>; <name><surname>Fang</surname><given-names>B.</given-names></name>; <name><surname>Wan</surname><given-names>S.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Ashraf</surname><given-names>U.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Wang</surname><given-names>X.</given-names></name>; <name><surname>Shao</surname><given-names>L.</given-names></name>; <name><surname>Song</surname><given-names>Y.</given-names></name>; <name><surname>Zheng</surname><given-names>X.</given-names></name>; <name><surname>Cao</surname><given-names>F.</given-names></name>; <name><surname>Cao</surname><given-names>S.</given-names></name>
<article-title>Benzoxazine Monomer Derived Carbon Dots as a Broad-Spectrum Agent to Block
Viral Infectivity</article-title>. <source>J. Colloid Interface Sci.</source>
<year>2019</year>, <volume>542</volume>, <fpage>198</fpage>&#x02013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcis.2019.02.010</pub-id>.<pub-id pub-id-type="pmid">30739009</pub-id></mixed-citation></ref><ref id="ref77"><mixed-citation publication-type="journal" id="cit77"><name><surname>Dong</surname><given-names>X.</given-names></name>; <name><surname>Moyer</surname><given-names>M. M.</given-names></name>; <name><surname>Yang</surname><given-names>F.</given-names></name>; <name><surname>Sun</surname><given-names>Y. P.</given-names></name>; <name><surname>Yang</surname><given-names>L.</given-names></name>
<article-title>Carbon Dots&#x02019; Antiviral Functions against Noroviruses</article-title>. <source>Sci. Rep.</source>
<year>2017</year>, <volume>7</volume>, <fpage>519</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-00675-x</pub-id>.<pub-id pub-id-type="pmid">28364126</pub-id></mixed-citation></ref><ref id="ref78"><mixed-citation publication-type="journal" id="cit78"><name><surname>Khanal</surname><given-names>M.</given-names></name>; <name><surname>Vausselin</surname><given-names>T.</given-names></name>; <name><surname>Barras</surname><given-names>A.</given-names></name>; <name><surname>Bande</surname><given-names>O.</given-names></name>; <name><surname>Turcheniuk</surname><given-names>K.</given-names></name>; <name><surname>Benazza</surname><given-names>M.</given-names></name>; <name><surname>Zaitsev</surname><given-names>V.</given-names></name>; <name><surname>Teodorescu</surname><given-names>C. M.</given-names></name>; <name><surname>Boukherroub</surname><given-names>R.</given-names></name>; <name><surname>Siriwardena</surname><given-names>A.</given-names></name>; <name><surname>Dubuisson</surname><given-names>J.</given-names></name>; <name><surname>Szunerits</surname><given-names>S.</given-names></name>
<article-title>Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral
Therapeutics</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2013</year>, <volume>5</volume>, <fpage>12488</fpage>&#x02013;<lpage>12498</lpage>. <pub-id pub-id-type="doi">10.1021/am403770q</pub-id>.<pub-id pub-id-type="pmid">24180242</pub-id></mixed-citation></ref><ref id="ref79"><mixed-citation publication-type="journal" id="cit79"><name><surname>Kumar</surname><given-names>P.</given-names></name>; <name><surname>Huo</surname><given-names>P.</given-names></name>; <name><surname>Zhang</surname><given-names>R.</given-names></name>; <name><surname>Liu</surname><given-names>B.</given-names></name>
<source>Nanomaterials</source>
<year>2019</year>, <volume>9</volume>, <fpage>737</fpage><pub-id pub-id-type="doi">10.3390/nano9050737</pub-id>.</mixed-citation></ref><ref id="ref80"><mixed-citation publication-type="journal" id="cit80"><name><surname>Hu</surname><given-names>X.</given-names></name>; <name><surname>Mu</surname><given-names>L.</given-names></name>; <name><surname>Wen</surname><given-names>J.</given-names></name>; <name><surname>Zhou</surname><given-names>Q.</given-names></name>
<article-title>Covalently Synthesized Graphene Oxide-Aptamer Nanosheets for Efficient
Visible-Light Photocatalysis of Nucleic Acids and Proteins of Viruses</article-title>. <source>Carbon</source>
<year>2012</year>, <volume>50</volume>, <fpage>2772</fpage>&#x02013;<lpage>2781</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbon.2012.02.038</pub-id>.</mixed-citation></ref><ref id="ref81"><mixed-citation publication-type="journal" id="cit81"><name><surname>Du</surname><given-names>X.</given-names></name>; <name><surname>Xiao</surname><given-names>R.</given-names></name>; <name><surname>Fu</surname><given-names>H.</given-names></name>; <name><surname>Yuan</surname><given-names>Z.</given-names></name>; <name><surname>Zhang</surname><given-names>W.</given-names></name>; <name><surname>Yin</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Zhou</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>G.</given-names></name>; <name><surname>Shu</surname><given-names>G.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>
<article-title>Hypericin-Loaded Graphene Oxide Protects Ducks against a Novel Duck
Reovirus</article-title>. <source>Mater. Sci. Eng., C</source>
<year>2019</year>, <volume>105</volume>, <fpage>110052</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2019.110052</pub-id>.</mixed-citation></ref><ref id="ref82"><mixed-citation publication-type="journal" id="cit82"><name><surname>Deokar</surname><given-names>A. R.</given-names></name>; <name><surname>Nagvenkar</surname><given-names>A. P.</given-names></name>; <name><surname>Kalt</surname><given-names>I.</given-names></name>; <name><surname>Shani</surname><given-names>L.</given-names></name>; <name><surname>Yeshurun</surname><given-names>Y.</given-names></name>; <name><surname>Gedanken</surname><given-names>A.</given-names></name>; <name><surname>Sarid</surname><given-names>R.</given-names></name>
<article-title>Graphene-Based &#x0201c;Hot Plate&#x0201d; for the Capture and Destruction of
the Herpes Simplex Virus Type 1</article-title>. <source>Bioconjugate Chem.</source>
<year>2017</year>, <volume>28</volume>, <fpage>1115</fpage>&#x02013;<lpage>1122</lpage>. <pub-id pub-id-type="doi">10.1021/acs.bioconjchem.7b00030</pub-id>.</mixed-citation></ref><ref id="ref83"><mixed-citation publication-type="journal" id="cit83"><name><surname>Cagno</surname><given-names>V.</given-names></name>; <name><surname>Tseligka</surname><given-names>E. D.</given-names></name>; <name><surname>Jones</surname><given-names>S. T.</given-names></name>; <name><surname>Tapparel</surname><given-names>C.</given-names></name>
<article-title>Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or
Adaptation Bias?</article-title>. <source>Viruses</source>
<year>2019</year>, <volume>11</volume>, <fpage>596</fpage><pub-id pub-id-type="doi">10.3390/v11070596</pub-id>.</mixed-citation></ref><ref id="ref84"><mixed-citation publication-type="journal" id="cit84"><name><surname>Sametband</surname><given-names>M.</given-names></name>; <name><surname>Kalt</surname><given-names>I.</given-names></name>; <name><surname>Gedanken</surname><given-names>A.</given-names></name>; <name><surname>Sarid</surname><given-names>R.</given-names></name>
<article-title>Herpes Simplex Virus Type-1 Attachment Inhibition by Functionalized
Graphene Oxide</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2014</year>, <volume>6</volume>, <fpage>1228</fpage>&#x02013;<lpage>1235</lpage>. <pub-id pub-id-type="doi">10.1021/am405040z</pub-id>.<pub-id pub-id-type="pmid">24364493</pub-id></mixed-citation></ref><ref id="ref85"><mixed-citation publication-type="journal" id="cit85"><name><surname>Ziem</surname><given-names>B.</given-names></name>; <name><surname>Thien</surname><given-names>H.</given-names></name>; <name><surname>Achazi</surname><given-names>K.</given-names></name>; <name><surname>Yue</surname><given-names>C.</given-names></name>; <name><surname>Stern</surname><given-names>D.</given-names></name>; <name><surname>Silberreis</surname><given-names>K.</given-names></name>; <name><surname>Gholami</surname><given-names>M. F.</given-names></name>; <name><surname>Beckert</surname><given-names>F.</given-names></name>; <name><surname>Gr&#x000f6;ger</surname><given-names>D.</given-names></name>; <name><surname>M&#x000fc;lhaupt</surname><given-names>R.</given-names></name>; <name><surname>Rabe</surname><given-names>J. P.</given-names></name>; <name><surname>Nitsche</surname><given-names>A.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Highly Efficient Multivalent 2D Nanosystems for Inhibition of Orthopoxvirus
Particles</article-title>. <source>Adv. Healthcare Mater.</source>
<year>2016</year>, <volume>5</volume>, <fpage>2922</fpage>&#x02013;<lpage>2930</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201600812</pub-id>.</mixed-citation></ref><ref id="ref86"><mixed-citation publication-type="journal" id="cit86"><name><surname>Ziem</surname><given-names>B.</given-names></name>; <name><surname>Rahn</surname><given-names>J.</given-names></name>; <name><surname>Donskyi</surname><given-names>I.</given-names></name>; <name><surname>Silberreis</surname><given-names>K.</given-names></name>; <name><surname>Cuellar</surname><given-names>L.</given-names></name>; <name><surname>Dernedde</surname><given-names>J.</given-names></name>; <name><surname>Keil</surname><given-names>G.</given-names></name>; <name><surname>Mettenleiter</surname><given-names>T. C.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Polyvalent 2D Entry Inhibitors for Pseudorabies and African Swine Fever
Virus</article-title>. <source>Macromol. Biosci.</source>
<year>2017</year>, <volume>17</volume>, <fpage>1600499</fpage><pub-id pub-id-type="doi">10.1002/mabi.201600499</pub-id>.</mixed-citation></ref><ref id="ref87"><mixed-citation publication-type="journal" id="cit87"><name><surname>Donskyi</surname><given-names>I. S.</given-names></name>; <name><surname>Azab</surname><given-names>W.</given-names></name>; <name><surname>Cuellar-Camacho</surname><given-names>J. L.</given-names></name>; <name><surname>Guday</surname><given-names>G.</given-names></name>; <name><surname>Lippitz</surname><given-names>A.</given-names></name>; <name><surname>Unger</surname><given-names>W. E. S.</given-names></name>; <name><surname>Osterrieder</surname><given-names>K.</given-names></name>; <name><surname>Adeli</surname><given-names>M.</given-names></name>; <name><surname>Haag</surname><given-names>R.</given-names></name>
<article-title>Functionalized Nanographene Sheets with High Antiviral Activity through
Synergistic Electrostatic and Hydrophobic Interactions</article-title>. <source>Nanoscale</source>
<year>2019</year>, <volume>11</volume>, <fpage>15804</fpage>&#x02013;<lpage>15809</lpage>. <pub-id pub-id-type="doi">10.1039/C9NR05273A</pub-id>.<pub-id pub-id-type="pmid">31433428</pub-id></mixed-citation></ref><ref id="ref88"><mixed-citation publication-type="book" id="cit88"><person-group person-group-type="allauthors"><name><surname>Milovanovic</surname><given-names>M.</given-names></name>;
<name><surname>Arsenijevic</surname><given-names>A.</given-names></name>;
<name><surname>Kanjevac</surname><given-names>T.</given-names></name>;
<name><surname>Arsenijevic</surname><given-names>N.</given-names></name></person-group><source>Nanoparticles in Antiviral Therapy</source>;
<publisher-name>Elsevier</publisher-name>: <publisher-loc>New York</publisher-loc>,
<year>2017</year>; pp <fpage>383</fpage>&#x02013;<lpage>410</lpage>.</mixed-citation></ref><ref id="ref89"><mixed-citation publication-type="journal" id="cit89"><name><surname>Baram-Pinto</surname><given-names>D.</given-names></name>; <name><surname>Shukla</surname><given-names>S.</given-names></name>; <name><surname>Gedanken</surname><given-names>A.</given-names></name>; <name><surname>Sarid</surname><given-names>R.</given-names></name>
<article-title>Inhibition of HSV-1 Attachment, Entry, and Cell-To-Cell Spread by
Functionalized Multivalent Gold Nanoparticles</article-title>. <source>Small</source>
<year>2010</year>, <volume>6</volume>, <fpage>1044</fpage>&#x02013;<lpage>1050</lpage>. <pub-id pub-id-type="doi">10.1002/smll.200902384</pub-id>.<pub-id pub-id-type="pmid">20394070</pub-id></mixed-citation></ref><ref id="ref90"><mixed-citation publication-type="journal" id="cit90"><name><surname>Cagno</surname><given-names>V.</given-names></name>; <name><surname>Andreozzi</surname><given-names>P.</given-names></name>; <name><surname>D&#x02019;Alicarnasso</surname><given-names>M.</given-names></name>; <name><surname>Jacob Silva</surname><given-names>P.</given-names></name>; <name><surname>Mueller</surname><given-names>M.</given-names></name>; <name><surname>Galloux</surname><given-names>M.</given-names></name>; <name><surname>Le Goffic</surname><given-names>R.</given-names></name>; <name><surname>Jones</surname><given-names>S. T.</given-names></name>; <name><surname>Vallino</surname><given-names>M.</given-names></name>; <name><surname>Hodek</surname><given-names>J.</given-names></name>; <name><surname>Weber</surname><given-names>J.</given-names></name>; <name><surname>Sen</surname><given-names>S.</given-names></name>; <name><surname>Jane&#x0010d;ek</surname><given-names>E.-R.</given-names></name>; <name><surname>Bekdemir</surname><given-names>A.</given-names></name>; <name><surname>Sanavio</surname><given-names>B.</given-names></name>; <name><surname>Martinelli</surname><given-names>C.</given-names></name>; <name><surname>Donalisio</surname><given-names>M.</given-names></name>; <name><surname>Rameix Welti</surname><given-names>M.-A.</given-names></name>; <name><surname>Eleouet</surname><given-names>J.-F.</given-names></name>; <name><surname>Han</surname><given-names>Y.</given-names></name>; et al. <article-title>Broad-Spectrum Non-Toxic Antiviral Nanoparticles with a Virucidal
Inhibition Mechanism</article-title>. <source>Nat. Mater.</source>
<year>2018</year>, <volume>17</volume>, <fpage>195</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1038/nmat5053</pub-id>.<pub-id pub-id-type="pmid">29251725</pub-id></mixed-citation></ref><ref id="ref91"><mixed-citation publication-type="journal" id="cit91"><name><surname>Jones</surname><given-names>S. T.</given-names></name>; <name><surname>Cagno</surname><given-names>V.</given-names></name>; <name><surname>Jane&#x0010d;ek</surname><given-names>M.</given-names></name>; <name><surname>Ortiz</surname><given-names>D.</given-names></name>; <name><surname>Gasilova</surname><given-names>N.</given-names></name>; <name><surname>Piret</surname><given-names>J.</given-names></name>; <name><surname>Gasbarri</surname><given-names>M.</given-names></name>; <name><surname>Constant</surname><given-names>D. A.</given-names></name>; <name><surname>Han</surname><given-names>Y.</given-names></name>; <name><surname>Vukovi&#x00107;</surname><given-names>L.</given-names></name>; <name><surname>Kr&#x000e1;l</surname><given-names>P.</given-names></name>; <name><surname>Kaiser</surname><given-names>L.</given-names></name>; <name><surname>Huang</surname><given-names>S.</given-names></name>; <name><surname>Constant</surname><given-names>S.</given-names></name>; <name><surname>Kirkegaard</surname><given-names>K.</given-names></name>; <name><surname>Boivin</surname><given-names>G.</given-names></name>; <name><surname>Stellacci</surname><given-names>F.</given-names></name>; <name><surname>Tapparel</surname><given-names>C.</given-names></name>
<article-title>Modified Cyclodextrins as Broad-Spectrum Antivirals</article-title>. <source>Sci. Adv.</source>
<year>2020</year>, <volume>6</volume>, <fpage>eaax9318</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aax9318</pub-id>.<pub-id pub-id-type="pmid">32064341</pub-id></mixed-citation></ref><ref id="ref92"><mixed-citation publication-type="journal" id="cit92"><name><surname>Luan</surname><given-names>B.</given-names></name>; <name><surname>Huynh</surname><given-names>T.</given-names></name>; <name><surname>Zhao</surname><given-names>L.</given-names></name>; <name><surname>Zhou</surname><given-names>R.</given-names></name>
<article-title>Potential Toxicity of Graphene to Cell Functions <italic>via</italic>
Disrupting Protein&#x02013;Protein Interactions</article-title>. <source>ACS Nano</source>
<year>2015</year>, <volume>9</volume>, <fpage>663</fpage>&#x02013;<lpage>669</lpage>. <pub-id pub-id-type="doi">10.1021/nn506011j</pub-id>.<pub-id pub-id-type="pmid">25494677</pub-id></mixed-citation></ref><ref id="ref93"><mixed-citation publication-type="journal" id="cit93"><name><surname>Jeevan</surname><given-names>B. G. C.</given-names></name>; <name><surname>Pokhrel</surname><given-names>R.</given-names></name>; <name><surname>Bhattarai</surname><given-names>N.</given-names></name>; <name><surname>Johnson</surname><given-names>K. A.</given-names></name>; <name><surname>Gerstman</surname><given-names>B. S.</given-names></name>; <name><surname>Stahelin</surname><given-names>R. V.</given-names></name>; <name><surname>Chapagain</surname><given-names>P. P.</given-names></name>
<article-title>Graphene-VP40 Interactions and Potential Disruption of the Ebola Virus
Matrix Filaments</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<year>2017</year>, <volume>493</volume>, <fpage>176</fpage>&#x02013;<lpage>181</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2017.09.052</pub-id>.<pub-id pub-id-type="pmid">28917841</pub-id></mixed-citation></ref><ref id="ref94"><mixed-citation publication-type="journal" id="cit94"><name><surname>Ye</surname><given-names>S.</given-names></name>; <name><surname>Shao</surname><given-names>K.</given-names></name>; <name><surname>Li</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>N.</given-names></name>; <name><surname>Zuo</surname><given-names>Y.</given-names></name>; <name><surname>Li</surname><given-names>Q.</given-names></name>; <name><surname>Lu</surname><given-names>Z.</given-names></name>; <name><surname>Chen</surname><given-names>L.</given-names></name>; <name><surname>He</surname><given-names>Q.</given-names></name>; <name><surname>Han</surname><given-names>H.</given-names></name>
<article-title>Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge
Matter</article-title>. <source>ACS Appl. Mater. Interfaces</source>
<year>2015</year>, <volume>7</volume>, <fpage>21571</fpage>&#x02013;<lpage>21579</lpage>. <pub-id pub-id-type="doi">10.1021/acsami.5b06876</pub-id>.<pub-id pub-id-type="pmid">26370151</pub-id></mixed-citation></ref><ref id="ref95"><mixed-citation publication-type="weblink" id="cit95"><person-group person-group-type="allauthors"><name><surname>Liu</surname><given-names>L.</given-names></name>;
<name><surname>Chopra</surname><given-names>P.</given-names></name>;
<name><surname>Li</surname><given-names>X.</given-names></name>;
<name><surname>Wolfert</surname><given-names>M. A.</given-names></name>;
<name><surname>Tompkins</surname><given-names>S. M.</given-names></name>;
<name><surname>Boons</surname><given-names>G.-J.</given-names></name></person-group><article-title>SARS-CoV-2 Spike Protein Binds Heparan Sulfate in a Length- and
Sequence-Dependent Manner</article-title>. <source>bioRxiv</source>. May 15,
<year>2020</year>. <pub-id pub-id-type="doi">10.1101/2020.05.10.087288</pub-id>.</mixed-citation></ref><ref id="ref96"><mixed-citation publication-type="journal" id="cit96"><name><surname>Lara</surname><given-names>H. H.</given-names></name>; <name><surname>Ixtepan-Turrent</surname><given-names>L.</given-names></name>; <name><surname>Garza Trevi&#x000f1;o</surname><given-names>E. N.</given-names></name>; <name><surname>Singh</surname><given-names>D. K.</given-names></name>
<article-title>Use of Silver Nanoparticles Increased Inhibition of Cell-Associated HIV-1
Infection by Neutralizing Antibodies Developed against HIV-1 Envelope
Proteins</article-title>. <source>J. Nanobiotechnol.</source>
<year>2011</year>, <volume>9</volume>, <fpage>38</fpage><pub-id pub-id-type="doi">10.1186/1477-3155-9-38</pub-id>.</mixed-citation></ref><ref id="ref97"><mixed-citation publication-type="journal" id="cit97"><name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Ebrahimi</surname><given-names>A.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Cui</surname><given-names>Q.</given-names></name>
<article-title>Fullerene-Biomolecule Conjugates and Their Biomedicinal
Applications</article-title>. <source>Int. J. Nanomed.</source>
<year>2013</year>, <volume>9</volume>, <fpage>77</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S52829</pub-id>.</mixed-citation></ref><ref id="ref98"><mixed-citation publication-type="journal" id="cit98"><name><surname>Friedman</surname><given-names>S. H.</given-names></name>; <name><surname>DeCamp</surname><given-names>D. L.</given-names></name>; <name><surname>Kenyon</surname><given-names>G. L.</given-names></name>; <name><surname>Sijbesma</surname><given-names>R. P.</given-names></name>; <name><surname>Srdanov</surname><given-names>G.</given-names></name>; <name><surname>Wudl</surname><given-names>F.</given-names></name>
<article-title>Inhibition of the HIV-1 Protease by Fullerene Derivatives: Model Building
Studies and Experimental Verification</article-title>. <source>J. Am. Chem. Soc.</source>
<year>1993</year>, <volume>115</volume>, <fpage>6506</fpage>&#x02013;<lpage>6509</lpage>. <pub-id pub-id-type="doi">10.1021/ja00068a005</pub-id>.</mixed-citation></ref><ref id="ref99"><mixed-citation publication-type="journal" id="cit99"><name><surname>Bosi</surname><given-names>S.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Spalluto</surname><given-names>G.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>
<article-title>Fullerene Derivatives: An Attractive Tool for Biological
Applications</article-title>. <source>Eur. J. Med. Chem.</source>
<year>2003</year>, <volume>38</volume>, <fpage>913</fpage>&#x02013;<lpage>923</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2003.09.005</pub-id>.<pub-id pub-id-type="pmid">14642323</pub-id></mixed-citation></ref><ref id="ref100"><mixed-citation publication-type="journal" id="cit100"><name><surname>Bosi</surname><given-names>S.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Spalluto</surname><given-names>G.</given-names></name>; <name><surname>Balzarini</surname><given-names>J.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>
<article-title>Synthesis and Anti-HIV Properties of New Water-Soluble Bis-
Functionalized[60]Fullerene Derivatives</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2003</year>, <volume>13</volume>, <fpage>4437</fpage>&#x02013;<lpage>4440</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2003.09.016</pub-id>.<pub-id pub-id-type="pmid">14643341</pub-id></mixed-citation></ref><ref id="ref101"><mixed-citation publication-type="journal" id="cit101"><name><surname>Marchesan</surname><given-names>S.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Spalluto</surname><given-names>G.</given-names></name>; <name><surname>Balzarini</surname><given-names>J.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>
<article-title>Anti-HIV Properties of Cationic Fullerene Derivatives</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2005</year>, <volume>15</volume>, <fpage>3615</fpage>&#x02013;<lpage>3618</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2005.05.069</pub-id>.<pub-id pub-id-type="pmid">15978810</pub-id></mixed-citation></ref><ref id="ref102"><mixed-citation publication-type="journal" id="cit102"><name><surname>Mashino</surname><given-names>T.</given-names></name>; <name><surname>Shimotohno</surname><given-names>K.</given-names></name>; <name><surname>Ikegami</surname><given-names>N.</given-names></name>; <name><surname>Nishikawa</surname><given-names>D.</given-names></name>; <name><surname>Okuda</surname><given-names>K.</given-names></name>; <name><surname>Takahashi</surname><given-names>K.</given-names></name>; <name><surname>Nakamura</surname><given-names>S.</given-names></name>; <name><surname>Mochizuki</surname><given-names>M.</given-names></name>
<article-title>Human Immunodeficiency Virus-Reverse Transcriptase Inhibition and Hepatitis
C Virus RNA-Dependent RNA Polymerase Inhibition Activities of Fullerene
Derivatives</article-title>. <source>Bioorg. Med. Chem. Lett.</source>
<year>2005</year>, <volume>15</volume>, <fpage>1107</fpage>&#x02013;<lpage>1109</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2004.12.030</pub-id>.<pub-id pub-id-type="pmid">15686922</pub-id></mixed-citation></ref><ref id="ref103"><mixed-citation publication-type="journal" id="cit103"><name><surname>Troshina</surname><given-names>O. A.</given-names></name>; <name><surname>Troshin</surname><given-names>P. A.</given-names></name>; <name><surname>Peregudov</surname><given-names>A. S.</given-names></name>; <name><surname>Kozlovskiy</surname><given-names>V. I.</given-names></name>; <name><surname>Balzarini</surname><given-names>J.</given-names></name>; <name><surname>Lyubovskaya</surname><given-names>R. N.</given-names></name>
<article-title>Chlorofullerene C60Cl6: A Precursor for Straightforward Preparation of
Highly Water-Soluble Polycarboxylic Fullerene Derivatives Active against
HIV</article-title>. <source>Org. Biomol. Chem.</source>
<year>2007</year>, <volume>5</volume>, <fpage>2783</fpage>&#x02013;<lpage>2791</lpage>. <pub-id pub-id-type="doi">10.1039/b705331b</pub-id>.<pub-id pub-id-type="pmid">17700846</pub-id></mixed-citation></ref><ref id="ref104"><mixed-citation publication-type="journal" id="cit104"><name><surname>Martinez</surname><given-names>Z. S.</given-names></name>; <name><surname>Castro</surname><given-names>E.</given-names></name>; <name><surname>Seong</surname><given-names>C. S.</given-names></name>; <name><surname>Cer&#x000f3;n</surname><given-names>M. R.</given-names></name>; <name><surname>Echegoyen</surname><given-names>L.</given-names></name>; <name><surname>Llano</surname><given-names>M.</given-names></name>
<article-title>Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus
Maturation without Impairing Protease Activity</article-title>. <source>Antimicrob. Agents Chemother.</source>
<year>2016</year>, <volume>60</volume>, <fpage>5731</fpage>&#x02013;<lpage>5741</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00341-16</pub-id>.<pub-id pub-id-type="pmid">27431232</pub-id></mixed-citation></ref><ref id="ref105"><mixed-citation publication-type="journal" id="cit105"><name><surname>Castro</surname><given-names>E.</given-names></name>; <name><surname>Cer&#x000f3;n</surname><given-names>M. R.</given-names></name>; <name><surname>Garcia</surname><given-names>A. H.</given-names></name>; <name><surname>Kim</surname><given-names>Q.</given-names></name>; <name><surname>Etcheverry-Berr&#x000ed;os</surname><given-names>A.</given-names></name>; <name><surname>Morel</surname><given-names>M. J.</given-names></name>; <name><surname>D&#x000ed;az-Torres</surname><given-names>R.</given-names></name>; <name><surname>Qian</surname><given-names>W.</given-names></name>; <name><surname>Martinez</surname><given-names>Z.</given-names></name>; <name><surname>Mendez</surname><given-names>L.</given-names></name>; <name><surname>Perez</surname><given-names>F.</given-names></name>; <name><surname>Santoyo</surname><given-names>C. A.</given-names></name>; <name><surname>Gimeno-Mu&#x000f1;oz</surname><given-names>R.</given-names></name>; <name><surname>Esper</surname><given-names>R.</given-names></name>; <name><surname>Gutierrez</surname><given-names>D. A.</given-names></name>; <name><surname>Varela-Ramirez</surname><given-names>A.</given-names></name>; <name><surname>Aguilera</surname><given-names>R. J.</given-names></name>; <name><surname>Llano</surname><given-names>M.</given-names></name>; <name><surname>Soler</surname><given-names>M.</given-names></name>; <name><surname>Aliaga-Alcalde</surname><given-names>N.</given-names></name>; et al. <article-title>A New Family of Fullerene Derivatives: Fullerene-Curcumin Conjugates for
Biological and Photovoltaic Applications</article-title>. <source>RSC Adv.</source>
<year>2018</year>, <volume>8</volume>, <fpage>41692</fpage>&#x02013;<lpage>41698</lpage>. <pub-id pub-id-type="doi">10.1039/C8RA08334G</pub-id>.<pub-id pub-id-type="pmid">31543960</pub-id></mixed-citation></ref><ref id="ref106"><mixed-citation publication-type="journal" id="cit106"><name><surname>Tao</surname><given-names>Y. J.</given-names></name>; <name><surname>Ye</surname><given-names>Q.</given-names></name>
<article-title>RNA Virus Replication Complexes</article-title>. <source>PLoS Pathog.</source>
<year>2010</year>, <volume>6</volume>, <fpage>e1000943</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000943</pub-id>.<pub-id pub-id-type="pmid">20661480</pub-id></mixed-citation></ref><ref id="ref107"><mixed-citation publication-type="journal" id="cit107"><name><surname>Kornev</surname><given-names>A. B.</given-names></name>; <name><surname>Peregudov</surname><given-names>A. S.</given-names></name>; <name><surname>Martynenko</surname><given-names>V. M.</given-names></name>; <name><surname>Balzarini</surname><given-names>J.</given-names></name>; <name><surname>Hoorelbeke</surname><given-names>B.</given-names></name>; <name><surname>Troshin</surname><given-names>P. A.</given-names></name>
<article-title>Synthesis and Antiviral Activity of Highly Water-Soluble Polycarboxylic
Derivatives of [70]Fullerene</article-title>. <source>Chem. Commun.</source>
<year>2011</year>, <volume>47</volume>, <fpage>8298</fpage>&#x02013;<lpage>8300</lpage>. <pub-id pub-id-type="doi">10.1039/c1cc12209f</pub-id>.</mixed-citation></ref><ref id="ref108"><mixed-citation publication-type="journal" id="cit108"><name><surname>Ezzati Nazhad Dolatabadi</surname><given-names>J.</given-names></name>; <name><surname>Omidi</surname><given-names>Y.</given-names></name>; <name><surname>Losic</surname><given-names>D.</given-names></name>
<article-title>Carbon Nanotubes as an Advanced Drug and Gene Delivery
Nanosystem</article-title>. <source>Curr. Nanosci.</source>
<year>2011</year>, <volume>7</volume>, <fpage>297</fpage>&#x02013;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.2174/157341311795542444</pub-id>.</mixed-citation></ref><ref id="ref109"><mixed-citation publication-type="journal" id="cit109"><name><surname>Iannazzo</surname><given-names>D.</given-names></name>; <name><surname>Pistone</surname><given-names>A.</given-names></name>; <name><surname>Galvagno</surname><given-names>S.</given-names></name>; <name><surname>Ferro</surname><given-names>S.</given-names></name>; <name><surname>De Luca</surname><given-names>L.</given-names></name>; <name><surname>Monforte</surname><given-names>A. M.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Hadad</surname><given-names>C.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>; <name><surname>Pannecouque</surname><given-names>C.</given-names></name>
<article-title>Synthesis and Anti-HIV Activity of Carboxylated and Drug-Conjugated
Multi-Walled Carbon Nanotubes</article-title>. <source>Carbon</source>
<year>2015</year>, <volume>82</volume>, <fpage>548</fpage>&#x02013;<lpage>561</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbon.2014.11.007</pub-id>.</mixed-citation></ref><ref id="ref110"><mixed-citation publication-type="journal" id="cit110"><name><surname>Iannazzo</surname><given-names>D.</given-names></name>; <name><surname>Mazzaglia</surname><given-names>A.</given-names></name>; <name><surname>Scala</surname><given-names>A.</given-names></name>; <name><surname>Pistone</surname><given-names>A.</given-names></name>; <name><surname>Galvagno</surname><given-names>S.</given-names></name>; <name><surname>Lanza</surname><given-names>M.</given-names></name>; <name><surname>Riccucci</surname><given-names>C.</given-names></name>; <name><surname>Ingo</surname><given-names>G. M.</given-names></name>; <name><surname>Colao</surname><given-names>I.</given-names></name>; <name><surname>Sciortino</surname><given-names>M. T.</given-names></name>; <name><surname>Valle</surname><given-names>F.</given-names></name>; <name><surname>Piperno</surname><given-names>A.</given-names></name>; <name><surname>Grassi</surname><given-names>G.</given-names></name>
<article-title>&#x003b2;-Cyclodextrin-Grafted on Multiwalled Carbon Nanotubes as Versatile
Nanoplatform for Entrapment of Guanine-Based Drugs</article-title>. <source>Colloids Surf., B</source>
<year>2014</year>, <volume>123</volume>, <fpage>264</fpage>&#x02013;<lpage>270</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2014.09.025</pub-id>.</mixed-citation></ref><ref id="ref111"><mixed-citation publication-type="journal" id="cit111"><name><surname>Mazzaglia</surname><given-names>A.</given-names></name>; <name><surname>Scala</surname><given-names>A.</given-names></name>; <name><surname>Sortino</surname><given-names>G.</given-names></name>; <name><surname>Zagami</surname><given-names>R.</given-names></name>; <name><surname>Zhu</surname><given-names>Y.</given-names></name>; <name><surname>Sciortino</surname><given-names>M. T.</given-names></name>; <name><surname>Pennisi</surname><given-names>R.</given-names></name>; <name><surname>Pizzo</surname><given-names>M. M.</given-names></name>; <name><surname>Neri</surname><given-names>G.</given-names></name>; <name><surname>Grassi</surname><given-names>G.</given-names></name>; <name><surname>Piperno</surname><given-names>A.</given-names></name>
<article-title>Intracellular Trafficking and Therapeutic Outcome of Multiwalled Carbon
Nanotubes Modified with Cyclodextrins and Polyethylenimine</article-title>. <source>Colloids Surf., B</source>
<year>2018</year>, <volume>163</volume>, <fpage>55</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/j.colsurfb.2017.12.028</pub-id>.</mixed-citation></ref><ref id="ref112"><mixed-citation publication-type="journal" id="cit112"><name><surname>Zhu</surname><given-names>B.</given-names></name>; <name><surname>Liu</surname><given-names>G. L.</given-names></name>; <name><surname>Ling</surname><given-names>F.</given-names></name>; <name><surname>Wang</surname><given-names>G. X.</given-names></name>
<article-title>Carbon Nanotube-Based Nanocarrier Loaded with Ribavirin against Grass Carp
Reovirus</article-title>. <source>Antiviral Res.</source>
<year>2015</year>, <volume>118</volume>, <fpage>29</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2015.03.006</pub-id>.<pub-id pub-id-type="pmid">25796971</pub-id></mixed-citation></ref><ref id="ref113"><mixed-citation publication-type="journal" id="cit113"><name><surname>Heller</surname><given-names>D. A.</given-names></name>; <name><surname>Jena</surname><given-names>P. V.</given-names></name>; <name><surname>Pasquali</surname><given-names>M.</given-names></name>; <name><surname>Kostarelos</surname><given-names>K.</given-names></name>; <name><surname>Delogu</surname><given-names>L. G.</given-names></name>; <name><surname>Meidl</surname><given-names>R. E.</given-names></name>; <name><surname>Rotkin</surname><given-names>S. V.</given-names></name>; <name><surname>Scheinberg</surname><given-names>D. A.</given-names></name>; <name><surname>Schwartz</surname><given-names>R. E.</given-names></name>; <name><surname>Terrones</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>Y. H.</given-names></name>; <name><surname>Bianco</surname><given-names>A.</given-names></name>; <name><surname>Boghossian</surname><given-names>A. A.</given-names></name>; <name><surname>Cambr&#x000e9;</surname><given-names>S.</given-names></name>; <name><surname>Cognet</surname><given-names>L.</given-names></name>; <name><surname>Corrie</surname><given-names>S. R.</given-names></name>; <name><surname>Demokritou</surname><given-names>P.</given-names></name>; <name><surname>Giordani</surname><given-names>S.</given-names></name>; <name><surname>Hertel</surname><given-names>T.</given-names></name>; <name><surname>Ignatova</surname><given-names>T.</given-names></name>; et al. <article-title>Banning Carbon Nanotubes Would Be Scientifically Unjustified and Damaging
to Innovation</article-title>. <source>Nat. Nanotechnol.</source>
<year>2020</year>, <volume>15</volume>, <fpage>164</fpage>&#x02013;<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1038/s41565-020-0656-y</pub-id>.</mixed-citation></ref><ref id="ref114"><mixed-citation publication-type="journal" id="cit114"><name><surname>Kim</surname><given-names>S.</given-names></name>; <name><surname>Ryoo</surname><given-names>S. R.</given-names></name>; <name><surname>Na</surname><given-names>H. K.</given-names></name>; <name><surname>Kim</surname><given-names>Y. K.</given-names></name>; <name><surname>Choi</surname><given-names>B. S.</given-names></name>; <name><surname>Lee</surname><given-names>Y.</given-names></name>; <name><surname>Kim</surname><given-names>D. E.</given-names></name>; <name><surname>Min</surname><given-names>D. H.</given-names></name>
<article-title>Deoxyribozyme-Loaded Nano-Graphene Oxide for Simultaneous Sensing and
Silencing of the Hepatitis C Virus Gene in Liver Cells</article-title>. <source>Chem. Commun.</source>
<year>2013</year>, <volume>49</volume>, <fpage>8241</fpage>&#x02013;<lpage>8243</lpage>. <pub-id pub-id-type="doi">10.1039/c3cc43368d</pub-id>.</mixed-citation></ref><ref id="ref115"><mixed-citation publication-type="journal" id="cit115"><name><surname>Schwarz</surname><given-names>K. B.</given-names></name>
<article-title>Oxidative Stress during Viral Infection: A Review</article-title>. <source>Free Radical Biol. Med.</source>
<year>1996</year>, <volume>21</volume>, <fpage>641</fpage>&#x02013;<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1016/0891-5849(96)00131-1</pub-id>.<pub-id pub-id-type="pmid">8891667</pub-id></mixed-citation></ref><ref id="ref116"><mixed-citation publication-type="journal" id="cit116"><name><surname>Snelgrove</surname><given-names>R. J.</given-names></name>; <name><surname>Edwards</surname><given-names>L.</given-names></name>; <name><surname>Rae</surname><given-names>A. J.</given-names></name>; <name><surname>Hussell</surname><given-names>T.</given-names></name>
<article-title>An Absence of Reactive Oxygen Species Improves the Resolution of Lung
Influenza Infection</article-title>. <source>Eur. J. Immunol.</source>
<year>2006</year>, <volume>36</volume>, <fpage>1364</fpage>&#x02013;<lpage>1373</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200635977</pub-id>.<pub-id pub-id-type="pmid">16703568</pub-id></mixed-citation></ref><ref id="ref117"><mixed-citation publication-type="journal" id="cit117"><name><surname>Tavakoli</surname><given-names>A.</given-names></name>; <name><surname>Ataei-Pirkooh</surname><given-names>A.</given-names></name>; <name><surname>Mm Sadeghi</surname><given-names>G.</given-names></name>; <name><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name>; <name><surname>Sahrapour</surname><given-names>P.</given-names></name>; <name><surname>Kiani</surname><given-names>S. J.</given-names></name>; <name><surname>Moghoofei</surname><given-names>M.</given-names></name>; <name><surname>Farahmand</surname><given-names>M.</given-names></name>; <name><surname>Javanmard</surname><given-names>D.</given-names></name>; <name><surname>Monavari</surname><given-names>S. H.</given-names></name>
<article-title>Polyethylene Glycol-Coated Zinc Oxide Nanoparticle: An Efficient Nanoweapon
to Fight against Herpes Simplex Virus Type 1</article-title>. <source>Nanomedicine</source>
<year>2018</year>, <volume>13</volume>, <fpage>2675</fpage>&#x02013;<lpage>2690</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2018-0089</pub-id>.<pub-id pub-id-type="pmid">30346253</pub-id></mixed-citation></ref><ref id="ref118"><mixed-citation publication-type="journal" id="cit118"><name><surname>Ghaffari</surname><given-names>H.</given-names></name>; <name><surname>Tavakoli</surname><given-names>A.</given-names></name>; <name><surname>Moradi</surname><given-names>A.</given-names></name>; <name><surname>Tabarraei</surname><given-names>A.</given-names></name>; <name><surname>Bokharaei-Salim</surname><given-names>F.</given-names></name>; <name><surname>Zahmatkeshan</surname><given-names>M.</given-names></name>; <name><surname>Farahmand</surname><given-names>M.</given-names></name>; <name><surname>Javanmard</surname><given-names>D.</given-names></name>; <name><surname>Kiani</surname><given-names>S. J.</given-names></name>; <name><surname>Esghaei</surname><given-names>M.</given-names></name>; <name><surname>Pirhajati-Mahabadi</surname><given-names>V.</given-names></name>; <name><surname>Ataei-Pirkooh</surname><given-names>A.</given-names></name>; <name><surname>Monavari</surname><given-names>S. H.</given-names></name>
<article-title>Inhibition of H1N1 Influenza Virus Infection by Zinc Oxide Nanoparticles:
Another Emerging Application of Nanomedicine</article-title>. <source>J. Biomed. Sci.</source>
<year>2019</year>, <volume>26</volume>, <fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s12929-019-0563-4</pub-id>.<pub-id pub-id-type="pmid">31500628</pub-id></mixed-citation></ref><ref id="ref119"><mixed-citation publication-type="journal" id="cit119"><name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Gong</surname><given-names>G.</given-names></name>; <name><surname>Xia</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Chen</surname><given-names>Y.</given-names></name>; <name><surname>Hua</surname><given-names>L.</given-names></name>; <name><surname>Zhong</surname><given-names>J.</given-names></name>; <name><surname>Tang</surname><given-names>Y.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Restriction of H1N1 Influenza Virus Infection by Selenium Nanoparticles
Loaded with Ribavirin <italic>via</italic> Resisting Caspase-3 Apoptotic
Pathway</article-title>. <source>Int. J. Nanomed.</source>
<year>2018</year>, <volume>13</volume>, <fpage>5787</fpage>&#x02013;<lpage>5797</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S177658</pub-id>.</mixed-citation></ref><ref id="ref120"><mixed-citation publication-type="journal" id="cit120"><name><surname>Ramya</surname><given-names>S.</given-names></name>; <name><surname>Shanmugasundaram</surname><given-names>T.</given-names></name>; <name><surname>Balagurunathan</surname><given-names>R.</given-names></name>
<article-title>Biomedical Potential of Actinobacterially Synthesized Selenium
Nanoparticles with Special Reference to Anti-Biofilm, Anti-Oxidant, Wound Healing,
Cytotoxic and Anti-Viral Activities</article-title>. <source>J. Trace Elem. Med. Biol.</source>
<year>2015</year>, <volume>32</volume>, <fpage>30</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtemb.2015.05.005</pub-id>.<pub-id pub-id-type="pmid">26302909</pub-id></mixed-citation></ref><ref id="ref121"><mixed-citation publication-type="journal" id="cit121"><name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Xiao</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Xia</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Inhibition of H1N1 Influenza Virus by Selenium Nanoparticles Loaded with
Zanamivir through P38 and JNK Signaling Pathways</article-title>. <source>RSC Adv.</source>
<year>2017</year>, <volume>7</volume>, <fpage>35290</fpage>&#x02013;<lpage>35296</lpage>. <pub-id pub-id-type="doi">10.1039/C7RA06477B</pub-id>.</mixed-citation></ref><ref id="ref122"><mixed-citation publication-type="journal" id="cit122"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Xia</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Chen</surname><given-names>T.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Inhibitory Activity of Selenium Nanoparticles Functionalized with
Oseltamivir on H1N1 Influenza Virus</article-title>. <source>Int. J. Nanomed.</source>
<year>2017</year>, <volume>12</volume>, <fpage>5733</fpage>&#x02013;<lpage>5743</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S140939</pub-id>.</mixed-citation></ref><ref id="ref123"><mixed-citation publication-type="journal" id="cit123"><name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Lin</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Zhao</surname><given-names>M.</given-names></name>; <name><surname>Xia</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Xu</surname><given-names>T.</given-names></name>; <name><surname>Zhu</surname><given-names>B.</given-names></name>
<article-title>Inhibition of H1N1 Influenza Virus-Induced Apoptosis by Functionalized
Selenium Nanoparticles with Amantadine through ROS-Mediated AKT Signaling
Pathways</article-title>. <source>Int. J. Nanomed.</source>
<year>2018</year>, <volume>13</volume>, <fpage>2005</fpage>&#x02013;<lpage>2016</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S155994</pub-id>.</mixed-citation></ref><ref id="ref124"><mixed-citation publication-type="journal" id="cit124"><name><surname>Delgado-Roche</surname><given-names>L.</given-names></name>; <name><surname>Mesta</surname><given-names>F.</given-names></name>
<article-title>Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome
Coronavirus (SARS-CoV) Infection</article-title>. <source>Arch. Med. Res.</source>
<year>2020</year>, <volume>51</volume>, <fpage>384</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/j.arcmed.2020.04.019</pub-id>.<pub-id pub-id-type="pmid">32402576</pub-id></mixed-citation></ref><ref id="ref125"><mixed-citation publication-type="journal" id="cit125"><name><surname>Fensterl</surname><given-names>V.</given-names></name>; <name><surname>Sen</surname><given-names>G. C.</given-names></name>
<article-title>Interferon-Induced Ifit Proteins: Their Role in Viral
Pathogenesis</article-title>. <source>J. Virol.</source>
<year>2015</year>, <volume>89</volume>, <fpage>2462</fpage>&#x02013;<lpage>2468</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02744-14</pub-id>.<pub-id pub-id-type="pmid">25428874</pub-id></mixed-citation></ref><ref id="ref126"><mixed-citation publication-type="journal" id="cit126"><name><surname>Poon</surname><given-names>W.-L.</given-names></name>; <name><surname>Alenius</surname><given-names>H.</given-names></name>; <name><surname>Ndika</surname><given-names>J.</given-names></name>; <name><surname>Fortino</surname><given-names>V.</given-names></name>; <name><surname>Kolhinen</surname><given-names>V.</given-names></name>; <name><surname>Me&#x00161;&#x0010d;eriakovas</surname><given-names>A.</given-names></name>; <name><surname>Wang</surname><given-names>M.</given-names></name>; <name><surname>Greco</surname><given-names>D.</given-names></name>; <name><surname>L&#x000e4;hde</surname><given-names>A.</given-names></name>; <name><surname>Jokiniemi</surname><given-names>J.</given-names></name>; <name><surname>Lee</surname><given-names>J. C.-Y.</given-names></name>; <name><surname>El-Nezami</surname><given-names>H.</given-names></name>; <name><surname>Karisola</surname><given-names>P.</given-names></name>
<article-title>Nano-Sized Zinc Oxide and Silver, but Not Titanium Dioxide, Induce Innate
and Adaptive Immunity and Antiviral Response in Differentiated THP-1
Cells</article-title>. <source>Nanotoxicology</source>
<year>2017</year>, <volume>11</volume>, <fpage>936</fpage>&#x02013;<lpage>951</lpage>. <pub-id pub-id-type="doi">10.1080/17435390.2017.1382600</pub-id>.<pub-id pub-id-type="pmid">28958187</pub-id></mixed-citation></ref><ref id="ref127"><mixed-citation publication-type="journal" id="cit127"><name><surname>Morris</surname><given-names>D.</given-names></name>; <name><surname>Ansar</surname><given-names>M.</given-names></name>; <name><surname>Speshock</surname><given-names>J.</given-names></name>; <name><surname>Ivanciuc</surname><given-names>T.</given-names></name>; <name><surname>Qu</surname><given-names>Y.</given-names></name>; <name><surname>Casola</surname><given-names>A.</given-names></name>; <name><surname>Garofalo</surname><given-names>P. R.</given-names></name>
<article-title>Antiviral and Immunomodulatory Activity of Silver Nanoparticles in
Experimental RSV Infection</article-title>. <source>Viruses</source>
<year>2019</year>, <volume>11</volume>, <fpage>732</fpage><pub-id pub-id-type="doi">10.3390/v11080732</pub-id>.</mixed-citation></ref><ref id="ref128"><mixed-citation publication-type="journal" id="cit128"><name><surname>Villeret</surname><given-names>B.</given-names></name>; <name><surname>Dieu</surname><given-names>A.</given-names></name>; <name><surname>Straube</surname><given-names>M.</given-names></name>; <name><surname>Solhonne</surname><given-names>B.</given-names></name>; <name><surname>Miklavc</surname><given-names>P.</given-names></name>; <name><surname>Hamadi</surname><given-names>S.</given-names></name>; <name><surname>Le Borgne</surname><given-names>R.</given-names></name>; <name><surname>Mailleux</surname><given-names>A.</given-names></name>; <name><surname>Norel</surname><given-names>X.</given-names></name>; <name><surname>Aerts</surname><given-names>J.</given-names></name>; <name><surname>Diallo</surname><given-names>D.</given-names></name>; <name><surname>Rouzet</surname><given-names>F.</given-names></name>; <name><surname>Dietl</surname><given-names>P.</given-names></name>; <name><surname>Sallenave</surname><given-names>J.-M.</given-names></name>; <name><surname>Garcia-Verdugo</surname><given-names>I.</given-names></name>
<article-title>Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated
Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial
Cells</article-title>. <source>ACS Nano</source>
<year>2018</year>, <volume>12</volume>, <fpage>1188</fpage>&#x02013;<lpage>1202</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b06934</pub-id>.<pub-id pub-id-type="pmid">29357226</pub-id></mixed-citation></ref><ref id="ref129"><mixed-citation publication-type="journal" id="cit129"><name><surname>Du</surname><given-names>T.</given-names></name>; <name><surname>Lu</surname><given-names>J.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>Dong</surname><given-names>N.</given-names></name>; <name><surname>Fang</surname><given-names>L.</given-names></name>; <name><surname>Xiao</surname><given-names>S.</given-names></name>; <name><surname>Han</surname><given-names>H.</given-names></name>
<article-title>Antiviral Activity of Graphene Oxide-Silver Nanocomposites by Preventing
Viral Entry and Activation of the Antiviral Innate Immune Response</article-title>. <source>ACS Appl. Bio Mater.</source>
<year>2018</year>, <volume>1</volume>, <fpage>1286</fpage>&#x02013;<lpage>1293</lpage>. <pub-id pub-id-type="doi">10.1021/acsabm.8b00154</pub-id>.</mixed-citation></ref><ref id="ref130"><mixed-citation publication-type="journal" id="cit130"><name><surname>Du</surname><given-names>T.</given-names></name>; <name><surname>Liang</surname><given-names>J.</given-names></name>; <name><surname>Dong</surname><given-names>N.</given-names></name>; <name><surname>Liu</surname><given-names>L.</given-names></name>; <name><surname>Fang</surname><given-names>L.</given-names></name>; <name><surname>Xiao</surname><given-names>S.</given-names></name>; <name><surname>Han</surname><given-names>H.</given-names></name>
<article-title>Carbon Dots as Inhibitors of Virus by Activation of Type I Interferon
Response</article-title>. <source>Carbon</source>
<year>2016</year>, <volume>110</volume>, <fpage>278</fpage>&#x02013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbon.2016.09.032</pub-id>.</mixed-citation></ref><ref id="ref131"><mixed-citation publication-type="journal" id="cit131"><name><surname>Bawage</surname><given-names>S. S.</given-names></name>; <name><surname>Tiwari</surname><given-names>P. M.</given-names></name>; <name><surname>Singh</surname><given-names>A.</given-names></name>; <name><surname>Dixit</surname><given-names>S.</given-names></name>; <name><surname>Pillai</surname><given-names>S. R.</given-names></name>; <name><surname>Dennis</surname><given-names>V. A.</given-names></name>; <name><surname>Singh</surname><given-names>S. R.</given-names></name>
<article-title>Gold Nanorods Inhibit Respiratory Syncytial Virus by Stimulating the Innate
Immune Response</article-title>. <source>Nanomedicine</source>
<year>2016</year>, <volume>12</volume>, <fpage>2299</fpage>&#x02013;<lpage>2310</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2016.06.006</pub-id>.<pub-id pub-id-type="pmid">27381068</pub-id></mixed-citation></ref><ref id="ref132"><mixed-citation publication-type="journal" id="cit132"><name><surname>Zhu</surname><given-names>S.</given-names></name>; <name><surname>Li</surname><given-names>J.</given-names></name>; <name><surname>Huang</surname><given-names>A. G.</given-names></name>; <name><surname>Huang</surname><given-names>J. Q.</given-names></name>; <name><surname>Huang</surname><given-names>Y. Q.</given-names></name>; <name><surname>Wang</surname><given-names>G. X.</given-names></name>
<article-title>Anti-Betanodavirus Activity of Isoprinosine and Improved Efficacy Using
Carbon Nanotubes Based Drug Delivery System</article-title>. <source>Aquaculture</source>
<year>2019</year>, <volume>512</volume>, <fpage>734377</fpage><pub-id pub-id-type="doi">10.1016/j.aquaculture.2019.734377</pub-id>.</mixed-citation></ref><ref id="ref133"><mixed-citation publication-type="journal" id="cit133"><name><surname>Baierl</surname><given-names>T.</given-names></name>; <name><surname>Seidel</surname><given-names>A.</given-names></name>
<article-title><italic>In Vitro</italic> Effects of Fullerene C60 and Fullerene Black on
Immuno-Functions of Macrophages</article-title>. <source>Fullerene Sci. Technol.</source>
<year>1996</year>, <volume>4</volume>, <fpage>1073</fpage>&#x02013;<lpage>1085</lpage>. <pub-id pub-id-type="doi">10.1080/10641229608001164</pub-id>.</mixed-citation></ref><ref id="ref134"><mixed-citation publication-type="journal" id="cit134"><name><surname>Xiang</surname><given-names>K.</given-names></name>; <name><surname>Dou</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Zhu</surname><given-names>J.</given-names></name>; <name><surname>Yang</surname><given-names>S.</given-names></name>; <name><surname>Sun</surname><given-names>H.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>
<article-title>Cytotoxicity and TNF-&#x003b1; Secretion in RAW264.7 Macrophages Exposed to
Different Fullerene Derivatives</article-title>. <source>J. Nanosci. Nanotechnol.</source>
<year>2012</year>, <volume>12</volume>, <fpage>2169</fpage>&#x02013;<lpage>2178</lpage>. <pub-id pub-id-type="doi">10.1166/jnn.2012.5681</pub-id>.<pub-id pub-id-type="pmid">22755034</pub-id></mixed-citation></ref><ref id="ref135"><mixed-citation publication-type="journal" id="cit135"><name><surname>Gheibi Hayat</surname><given-names>S. M.</given-names></name>; <name><surname>Darroudi</surname><given-names>M.</given-names></name>
<article-title>Nanovaccine: A Novel Approach in Immunization</article-title>. <source>J. Cell. Physiol.</source>
<year>2019</year>, <volume>234</volume>, <fpage>12530</fpage>&#x02013;<lpage>12536</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.28120</pub-id>.<pub-id pub-id-type="pmid">30633361</pub-id></mixed-citation></ref><ref id="ref136"><mixed-citation publication-type="journal" id="cit136"><name><surname>Agelidis</surname><given-names>A.</given-names></name>; <name><surname>Koujah</surname><given-names>L.</given-names></name>; <name><surname>Suryawanshi</surname><given-names>R.</given-names></name>; <name><surname>Yadavalli</surname><given-names>T.</given-names></name>; <name><surname>Mishra</surname><given-names>Y. K.</given-names></name>; <name><surname>Adelung</surname><given-names>R.</given-names></name>; <name><surname>Shukla</surname><given-names>D.</given-names></name>
<article-title>An Intra-Vaginal Zinc Oxide Tetrapod Nanoparticles (ZOTEN) and Genital
Herpesvirus Cocktail Can Provide a Novel Platform for Live Virus Vaccine</article-title>. <source>Front. Immunol.</source>
<year>2019</year>, <volume>10</volume>, <fpage>500</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00500</pub-id>.<pub-id pub-id-type="pmid">30949169</pub-id></mixed-citation></ref><ref id="ref137"><mixed-citation publication-type="journal" id="cit137"><name><surname>Antoine</surname><given-names>T. E.</given-names></name>; <name><surname>Hadigal</surname><given-names>S. R.</given-names></name>; <name><surname>Yakoub</surname><given-names>A. M.</given-names></name>; <name><surname>Mishra</surname><given-names>Y. K.</given-names></name>; <name><surname>Bhattacharya</surname><given-names>P.</given-names></name>; <name><surname>Haddad</surname><given-names>C.</given-names></name>; <name><surname>Valyi-Nagy</surname><given-names>T.</given-names></name>; <name><surname>Adelung</surname><given-names>R.</given-names></name>; <name><surname>Prabhakar</surname><given-names>B. S.</given-names></name>; <name><surname>Shukla</surname><given-names>D.</given-names></name>
<article-title>Intravaginal Zinc Oxide Tetrapod Nanoparticles as Novel Immunoprotective
Agents against Genital Herpes</article-title>. <source>J. Immunol.</source>
<year>2016</year>, <volume>196</volume>, <fpage>4566</fpage>&#x02013;<lpage>4575</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1502373</pub-id>.<pub-id pub-id-type="pmid">27183601</pub-id></mixed-citation></ref><ref id="ref138"><mixed-citation publication-type="journal" id="cit138"><name><surname>Montellano</surname><given-names>A.</given-names></name>; <name><surname>Da Ros</surname><given-names>T.</given-names></name>; <name><surname>Bianco</surname><given-names>A.</given-names></name>; <name><surname>Prato</surname><given-names>M.</given-names></name>
<article-title>Fullerene C60 as a Multifunctional System for Drug and Gene
Delivery</article-title>. <source>Nanoscale</source>
<year>2011</year>, <volume>3</volume>, <fpage>4035</fpage>&#x02013;<lpage>4041</lpage>. <pub-id pub-id-type="doi">10.1039/c1nr10783f</pub-id>.<pub-id pub-id-type="pmid">21897967</pub-id></mixed-citation></ref><ref id="ref139"><mixed-citation publication-type="journal" id="cit139"><name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Role of Nanotechnology in HIV/AIDS Vaccine Development</article-title>. <source>Adv. Drug Delivery Rev.</source>
<year>2016</year>, <volume>103</volume>, <fpage>76</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2016.02.010</pub-id>.</mixed-citation></ref><ref id="ref140"><mixed-citation publication-type="journal" id="cit140"><name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Xu</surname><given-names>Y.</given-names></name>; <name><surname>Tian</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>; <name><surname>Wang</surname><given-names>C.</given-names></name>; <name><surname>Jiang</surname><given-names>X.</given-names></name>
<article-title>Functional Nanomaterials Can Optimize the Efficacy of
Vaccines</article-title>. <source>Small</source>
<year>2014</year>, <volume>10</volume> (<issue>22</issue>), <fpage>4505</fpage>&#x02013;<lpage>4520</lpage>. <pub-id pub-id-type="doi">10.1002/smll.201401707</pub-id>.<pub-id pub-id-type="pmid">25238620</pub-id></mixed-citation></ref><ref id="ref141"><mixed-citation publication-type="journal" id="cit141"><name><surname>Xu</surname><given-names>L.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Li</surname><given-names>W.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Wang</surname><given-names>L.</given-names></name>; <name><surname>Ma</surname><given-names>L.</given-names></name>; <name><surname>Shao</surname><given-names>Y.</given-names></name>; <name><surname>Zhao</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>Morphologically Virus-Like Fullerenol Nanoparticles Act as the
Dual-Functional Nanoadjuvant for HIV-1 Vaccine</article-title>. <source>Adv. Mater.</source>
<year>2013</year>, <volume>25</volume>, <fpage>5928</fpage>&#x02013;<lpage>5936</lpage>. <pub-id pub-id-type="doi">10.1002/adma.201300583</pub-id>.<pub-id pub-id-type="pmid">23963730</pub-id></mixed-citation></ref><ref id="ref142"><mixed-citation publication-type="journal" id="cit142"><name><surname>Liu</surname><given-names>J.</given-names></name>; <name><surname>Feng</surname><given-names>X.</given-names></name>; <name><surname>Chen</surname><given-names>Z.</given-names></name>; <name><surname>Yang</surname><given-names>X.</given-names></name>; <name><surname>Shen</surname><given-names>Z.</given-names></name>; <name><surname>Guo</surname><given-names>M.</given-names></name>; <name><surname>Deng</surname><given-names>F.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Zhang</surname><given-names>H.</given-names></name>; <name><surname>Chen</surname><given-names>C.</given-names></name>
<article-title>The Adjuvant Effect of C 60 (OH)<sub>22</sub> Nanoparticles Promoting Both
Humoral and Cellular Immune Responses to HCV Recombinant Proteins</article-title>. <source>Mater. Sci. Eng., C</source>
<year>2019</year>, <volume>97</volume>, <fpage>753</fpage>&#x02013;<lpage>759</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2018.12.088</pub-id>.</mixed-citation></ref><ref id="ref143"><mixed-citation publication-type="journal" id="cit143"><name><surname>Hobernik</surname><given-names>D.</given-names></name>; <name><surname>Bros</surname><given-names>M.</given-names></name>
<article-title>DNA Vaccines&#x02014;How Far from Clinical Use?</article-title>. <source>Int. J. Mol. Sci.</source>
<year>2018</year>, <volume>19</volume>, <fpage>3605</fpage><pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id>.</mixed-citation></ref><ref id="ref144"><mixed-citation publication-type="journal" id="cit144"><name><surname>Mumper</surname><given-names>R. J.</given-names></name>; <name><surname>Ledebur</surname><given-names>H. C.</given-names></name>
<article-title>Dendritic Cell Delivery of Plasmid DNA: Applications for Controlled Genetic
Immunization</article-title>. <source>Mol. Biotechnol.</source>
<year>2001</year>, <volume>19</volume>, <fpage>79</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1385/MB:19:1:079</pub-id>.<pub-id pub-id-type="pmid">11697222</pub-id></mixed-citation></ref><ref id="ref145"><mixed-citation publication-type="journal" id="cit145"><name><surname>Hirai</surname><given-names>T.</given-names></name>; <name><surname>Yoshioka</surname><given-names>Y.</given-names></name>; <name><surname>Udaka</surname><given-names>A.</given-names></name>; <name><surname>Uemura</surname><given-names>E.</given-names></name>; <name><surname>Ohe</surname><given-names>T.</given-names></name>; <name><surname>Aoshima</surname><given-names>H.</given-names></name>; <name><surname>Gao</surname><given-names>J. Q.</given-names></name>; <name><surname>Kokubo</surname><given-names>K.</given-names></name>; <name><surname>Oshima</surname><given-names>T.</given-names></name>; <name><surname>Nagano</surname><given-names>K.</given-names></name>; <name><surname>Higashisaka</surname><given-names>K.</given-names></name>; <name><surname>Mashino</surname><given-names>T.</given-names></name>; <name><surname>Tsutsumi</surname><given-names>Y.</given-names></name>
<article-title>Potential Suppressive Effects of Two C<sub>60</sub> Fullerene Derivatives
on Acquired Immunity</article-title>. <source>Nanoscale Res. Lett.</source>
<year>2016</year>, <volume>11</volume>, <fpage>499</fpage><pub-id pub-id-type="doi">10.1186/s11671-016-1663-7</pub-id>.<pub-id pub-id-type="pmid">27844462</pub-id></mixed-citation></ref><ref id="ref146"><mixed-citation publication-type="journal" id="cit146"><name><surname>Staroverov</surname><given-names>S. A.</given-names></name>; <name><surname>Volkov</surname><given-names>A. A.</given-names></name>; <name><surname>Mezhenny</surname><given-names>P. V.</given-names></name>; <name><surname>Domnitsky</surname><given-names>I. Y.</given-names></name>; <name><surname>Fomin</surname><given-names>A. S.</given-names></name>; <name><surname>Kozlov</surname><given-names>S. V.</given-names></name>; <name><surname>Dykman</surname><given-names>L. A.</given-names></name>; <name><surname>Guliy</surname><given-names>O. I.</given-names></name>
<article-title>Prospects for the Use of Spherical Gold Nanoparticles in
Immunization</article-title>. <source>Appl. Microbiol. Biotechnol.</source>
<year>2019</year>, <volume>103</volume>, <fpage>437</fpage>&#x02013;<lpage>447</lpage>. <pub-id pub-id-type="doi">10.1007/s00253-018-9476-5</pub-id>.<pub-id pub-id-type="pmid">30402771</pub-id></mixed-citation></ref><ref id="ref147"><mixed-citation publication-type="journal" id="cit147"><name><surname>Pham</surname><given-names>N. B.</given-names></name>; <name><surname>Ho</surname><given-names>T. T.</given-names></name>; <name><surname>Nguyen</surname><given-names>G. T.</given-names></name>; <name><surname>Le</surname><given-names>T. T.</given-names></name>; <name><surname>Le</surname><given-names>N. T.</given-names></name>; <name><surname>Chang</surname><given-names>H. C.</given-names></name>; <name><surname>Pham</surname><given-names>M. D.</given-names></name>; <name><surname>Conrad</surname><given-names>U.</given-names></name>; <name><surname>Chu</surname><given-names>H. H.</given-names></name>
<article-title>Nanodiamond Enhances Immune Responses in Mice against Recombinant HA/H7N9
Protein</article-title>. <source>J. Nanobiotechnol.</source>
<year>2017</year>, <volume>15</volume>, <fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s12951-017-0305-2</pub-id>.</mixed-citation></ref><ref id="ref148"><mixed-citation publication-type="journal" id="cit148"><name><surname>Chen</surname><given-names>Y.-S.</given-names></name>; <name><surname>Hung</surname><given-names>Y.-C.</given-names></name>; <name><surname>Lin</surname><given-names>W.-H.</given-names></name>; <name><surname>Huang</surname><given-names>G. S.</given-names></name>
<article-title>Assessment of Gold Nanoparticles as a Size-Dependent Vaccine Carrier for
Enhancing the Antibody Response against Synthetic Foot-And-Mouth Disease Virus
Peptide</article-title>. <source>Nanotechnology</source>
<year>2010</year>, <volume>21</volume>, <fpage>195101</fpage><pub-id pub-id-type="doi">10.1088/0957-4484/21/19/195101</pub-id>.<pub-id pub-id-type="pmid">20400818</pub-id></mixed-citation></ref><ref id="ref149"><mixed-citation publication-type="journal" id="cit149"><name><surname>Tao</surname><given-names>W.</given-names></name>; <name><surname>Hurst</surname><given-names>B. L.</given-names></name>; <name><surname>Shakya</surname><given-names>A. K.</given-names></name>; <name><surname>Uddin</surname><given-names>M. J.</given-names></name>; <name><surname>Ingrole</surname><given-names>R. S. J.</given-names></name>; <name><surname>Hernandez-Sanabria</surname><given-names>M.</given-names></name>; <name><surname>Arya</surname><given-names>R. P.</given-names></name>; <name><surname>Bimler</surname><given-names>L.</given-names></name>; <name><surname>Paust</surname><given-names>S.</given-names></name>; <name><surname>Tarbet</surname><given-names>E. B.</given-names></name>; <name><surname>Gill</surname><given-names>H. S.</given-names></name>
<article-title>Consensus M2e Peptide Conjugated to Gold Nanoparticles Confers Protection
against H1N1, H3N2 and H5N1 Influenza A Viruses</article-title>. <source>Antiviral Res.</source>
<year>2017</year>, <volume>141</volume>, <fpage>62</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.01.021</pub-id>.<pub-id pub-id-type="pmid">28161578</pub-id></mixed-citation></ref><ref id="ref150"><mixed-citation publication-type="journal" id="cit150"><name><surname>Sekimukai</surname><given-names>H.</given-names></name>; <name><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name>; <name><surname>Fukushi</surname><given-names>S.</given-names></name>; <name><surname>Tani</surname><given-names>H.</given-names></name>; <name><surname>Kataoka</surname><given-names>M.</given-names></name>; <name><surname>Suzuki</surname><given-names>T.</given-names></name>; <name><surname>Hasegawa</surname><given-names>H.</given-names></name>; <name><surname>Niikura</surname><given-names>K.</given-names></name>; <name><surname>Arai</surname><given-names>K.</given-names></name>; <name><surname>Nagata</surname><given-names>N.</given-names></name>
<article-title>Gold Nanoparticle-Adjuvanted S Protein Induces a Strong Antigen-specific
IgG Response against Severe Acute Respiratory Syndrome-Related Coronavirus Infection,
but Fails to Induce Protective Antibodies and Limit Eosinophilic Infiltration in
Lungs</article-title>. <source>Microbiol. Immunol.</source>
<year>2020</year>, <volume>64</volume>, <fpage>33</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12754</pub-id>.<pub-id pub-id-type="pmid">31692019</pub-id></mixed-citation></ref><ref id="ref151"><mixed-citation publication-type="journal" id="cit151"><name><surname>Zilker</surname><given-names>C.</given-names></name>; <name><surname>Kozlova</surname><given-names>D.</given-names></name>; <name><surname>Sokolova</surname><given-names>V.</given-names></name>; <name><surname>Yan</surname><given-names>H.</given-names></name>; <name><surname>Epple</surname><given-names>M.</given-names></name>; <name><surname>&#x000dc;berla</surname><given-names>K.</given-names></name>; <name><surname>Temchura</surname><given-names>V.</given-names></name>
<article-title>Nanoparticle-Based B-Cell Targeting Vaccines: Tailoring of Humoral Immune
Responses by Functionalization with Different TLR-Ligands</article-title>. <source>Nanomedicine</source>
<year>2017</year>, <volume>13</volume>, <fpage>173</fpage>&#x02013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2016.08.028</pub-id>.<pub-id pub-id-type="pmid">27593489</pub-id></mixed-citation></ref><ref id="ref152"><mixed-citation publication-type="journal" id="cit152"><name><surname>Rezaei</surname><given-names>M.</given-names></name>; <name><surname>Hosseini</surname><given-names>S. N.</given-names></name>; <name><surname>Khavari-Nejad</surname><given-names>R. A.</given-names></name>; <name><surname>Najafi</surname><given-names>F.</given-names></name>; <name><surname>Mahdavi</surname><given-names>M.</given-names></name>
<article-title>HBs Antigen and Mannose Loading on the Surface of Iron Oxide Nanoparticles
in Order to Immuno-Targeting: Fabrication, Characterization, Cellular and Humoral
Immunoassay</article-title>. <source>Artif. Cells, Nanomed., Biotechnol.</source>
<year>2019</year>, <volume>47</volume>, <fpage>1543</fpage>&#x02013;<lpage>1558</lpage>. <pub-id pub-id-type="doi">10.1080/21691401.2019.1577888</pub-id>.<pub-id pub-id-type="pmid">31007088</pub-id></mixed-citation></ref><ref id="ref153"><mixed-citation publication-type="journal" id="cit153"><name><surname>Kopp</surname><given-names>M.</given-names></name>; <name><surname>Aufderhorst</surname><given-names>U. W.</given-names></name>; <name><surname>Alt</surname><given-names>M.</given-names></name>; <name><surname>Dittmer</surname><given-names>U.</given-names></name>; <name><surname>Eis-H&#x000fc;binger</surname><given-names>A. M.</given-names></name>; <name><surname>Giebel</surname><given-names>B.</given-names></name>; <name><surname>Roggendorf</surname><given-names>M.</given-names></name>; <name><surname>Epple</surname><given-names>M.</given-names></name>; <name><surname>Krawczyk</surname><given-names>A.</given-names></name>
<article-title>Induction of Herpes Simplex Virus Type 1 Cell-To-Cell Spread Inhibiting
Antibodies by a Calcium Phosphate Nanoparticle-Based Vaccine</article-title>. <source>Nanomedicine</source>
<year>2019</year>, <volume>16</volume>, <fpage>138</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2018.12.002</pub-id>.<pub-id pub-id-type="pmid">30594660</pub-id></mixed-citation></ref><ref id="ref154"><mixed-citation publication-type="journal" id="cit154"><name><surname>Ventola</surname><given-names>C. L.</given-names></name>
<article-title>Progress in Nanomedicine: Approved and Investigational
Nanodrugs</article-title>. <source>P T.</source>
<year>2017</year>, <volume>42</volume>, <fpage>742</fpage>&#x02013;<lpage>755</lpage>.<pub-id pub-id-type="pmid">29234213</pub-id></mixed-citation></ref><ref id="ref155"><mixed-citation publication-type="journal" id="cit155"><name><surname>Rastinehad</surname><given-names>A. R.</given-names></name>; <name><surname>Anastos</surname><given-names>H.</given-names></name>; <name><surname>Wajswol</surname><given-names>E.</given-names></name>; <name><surname>Winoker</surname><given-names>J. S.</given-names></name>; <name><surname>Sfakianos</surname><given-names>J. P.</given-names></name>; <name><surname>Doppalapudi</surname><given-names>S. K.</given-names></name>; <name><surname>Carrick</surname><given-names>M. R.</given-names></name>; <name><surname>Knauer</surname><given-names>C. J.</given-names></name>; <name><surname>Taouli</surname><given-names>B.</given-names></name>; <name><surname>Lewis</surname><given-names>S. C.</given-names></name>; <name><surname>Tewari</surname><given-names>A. K.</given-names></name>; <name><surname>Schwartz</surname><given-names>J. A.</given-names></name>; <name><surname>Canfield</surname><given-names>S. E.</given-names></name>; <name><surname>George</surname><given-names>A. K.</given-names></name>; <name><surname>West</surname><given-names>J. L.</given-names></name>; <name><surname>Halas</surname><given-names>N. J.</given-names></name>
<article-title>Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a
Clinical Pilot Device Study</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source>
<year>2019</year>, <volume>116</volume>, <fpage>18590</fpage>&#x02013;<lpage>18596</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1906929116</pub-id>.<pub-id pub-id-type="pmid">31451630</pub-id></mixed-citation></ref><ref id="ref156"><mixed-citation publication-type="journal" id="cit156"><name><surname>Alsaleh</surname><given-names>N. B.</given-names></name>; <name><surname>Brown</surname><given-names>J. M.</given-names></name>
<article-title>Engineered Nanomaterials and Type I Allergic Hypersensitivity
Reactions</article-title>. <source>Front. Immunol.</source>
<year>2020</year>, <volume>11</volume>, <fpage>222</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00222</pub-id>.<pub-id pub-id-type="pmid">32117324</pub-id></mixed-citation></ref></ref-list></back></article>